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Cryptococcus neoformans is a fungus that can be biotyped as variety (var.) gattii or
var. neoformans. Four primary serotypes, A,B,C, and D have been described.
Cryptococcus neoformans var. gattii is predominant in the tropics and subtropics.
Environmental investigations have established the association of Cryptococcus
neoformans var. gattii with Eucalyptus camaldulensis, E. tereticornis, E.
gomphcephala, E. rudis and most recently E. blaykeli. Worldwide, C. neoformans
var. neoformans has been associated with avian sources. This thesis examines C.
neoformans and the meningitis it causes, based predominantly in Papua New Guinea
(PNG).
Investigations of possible plant, mammal and avian associations in PNG, revealed
that few E. camaldulensis survive experimental planting, while E. tereticornis is
endemic. In Port Moresby, E. confertiflora, E. papuana and E. alba are common.
Examination of 1130 specimens from plant, bird and animal sources, failed to
identify the ecological niche of C. neoformans in PNG.
Epidemiological studies of 96 patients presenting with cryptococcal meningitis to
Port Moresby General Hospital (PMGH) from 1972-1993 showed an annual
incidence of 33 cases per million population of Central Province and the National
Capital District. Twenty one of these are infected with C. neoformans var. gattii
and 12 with C. neoformans var. neoformans. On average 11 cases present annually
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to PMGH. Geographical clustering occurred amongst those from some parts of Gulf
and Central Provinces, with a male predominance. Possible seasonal variation was
found, with increased presentation rates in May/June and September/October. This
could reflect seasonal exposure to Cryptococcus neoformans var. gattii. The pattern
of childhood infection may result from varying exposure or susceptibility.
Eleven sequential patients with cryptococcal meningitis were diagnosed and isolates
biotyped. Seven were var. gattii (one patient with diabetes mellitus) and four were
var. neoformans. The latter came from adult patients with HIV 1 infection,
tuberculosis or Plasmodium vivax malaria. Significant clinical findings were
headache, fever, meningism, vomiting, photophobia, papilledema and cranial
nerve lesions. Five patients (45.5%) died; the 2 var. neoformans HIV 1 infected
men and 3 adult var. gattii patients. In PNG where var. gattii has been predominant
in the immunocompetent, var. neoformans is emerging as the predominant biotype
amongst immunosuppressed patients, notably those with HIV1 infection.
Laboratory comparison in Edinburgh confirmed that var. gattii were usually more
mucoid than var. neoformans colonies and that this was correlated with capsule size.
A neutrophil-monolayer assay was unable to demonstrate a clear difference in
varietal binding.
Cerebrospinal fluid examination by microscopy and cryptococcal latex antigen
failed to detect an apparently acapsulate cryptococcal isolate in an HIV infected
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patient in Edinburgh. The isolate was detected by culture on malt extract agar. The
human neutrophil-cryptococcal assay subsequently confirmed the presence of
capsule.
These studies confirm the high prevalence in PNG of meningitis caused by C.
neoformans variety gattii in immunocompetent individuals, and the presence of
potential mammal and plant sources similar to those found in Australia. Although
cases are clustered geographically, the source(s) of C. neoformans remain elusive.
Alone, the small series of prospectively studied patients cannot indicate whether the
course of meningitis caused by the two varieties of C. neoformans differs in the
immunocompetent. Laboratory studies investigated the intriguing differences in
pathogenesis between the two varieties and emphasise the importance of culture in
clinical diagnosis.
The work described here has formed a foundation for further clinical,
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There are 19 known species of Cryptococcus (Rippon, 1988), but the aetiological
agent in virtually all cases of cryptococcosis is Cryptococcus neoformans. Just over
one hundred years ago it was first described in nature, being isolated from peach
juice in Sardinia by Sanfelice in 1894 (Sanfelice, 1894) and described in a tibial
lesion of a woman in Germany by Busse and Buschke (Busse, 1894; Buschke,
1894). Sanfelice confirmed its pathogenicity in animal experiments, calling it
Saccharomyces (Vuillemin, 1901). Sanfelice isolated a similar yeast from the
lymph node of an ox lymph with primary liver carcinoma (Sanfelice, 1895) and then
in 1902 in Massachusetts, Frothingham identified such a yeast in a pulmonary lesion
of a horse (Frothingham, 1902). These findings together confirmed this yeast as the
cause of both human and animal disease.
Vuillemin reclassified the fungi identified by Busse and Sanfelice to the genus
Cryptococcus as C. hominis and C. neoformans as they neither fermented carbon nor
formed ascospores, unlike the Saccharomyces genus (Vuillemin, 1901). In 1905
Von Hansemann described a case of meningitis with gelatinous cysts present (von
Hanseman, 1905) and in the same year Stoddard and Cutler recorded two cases,
interpreting the surrounding capsule as an area of tissue destroyed by the histolytic
action of the fungus and naming the causative organism Torula histolytica (Stoddard
and Cutler, 1916). From this misinterpretation the disease was named torulosis, a
term which was used for many years. Nomenclature proved a divisive issue, but this
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seems to have been settled in 1950 by Benham (Benham, 1950). Up to that point
several names had been used including Saccharomyces neoformans, Blastomyces
neoformans, Cryptococcus hominis and Torula histolytica. Derived from these were
a number of terms for cryptococcosis such as torulosis, European blastomycosis and
torula meningitis. A new variety based on the observation of an atypical isolate
forming elongated cells as well as round cells in mouse brain was described in 1970
(Vanbreuseghem and Takashio, 1970). This variety was called C. neoformans
variety (var.) gattii after its original description by Gattii and Eeckels that year.
Taxonomy became further complicated when the sexual, teleomorph, state of C.
neoformans was described in 1975 in the basideomycemorph genus Filobasidiella
(Kwon-Chung, 1975). After considerable and complex debate, reviewed by Kwon
Chung, she concluded that Filobasidiella neoformans var. neoformans and
Filobasidiella neoformans var. gattii should be considered as varieties of the same
species (Kwon-Chung et al. 1982a). The anamorpic states of these are C.
neoformans var. neoformans and C. neoformans var. gattii respectively.
Reviews of reported patients with central nervous system torulosis carried out by
Freeman and Levin showed that two thirds of the sixty patients were aged between
30 and 60, with a male to female ratio of two to one (Freeman, 1931; Levin, 1937).
Those afflicted were not clustered in place nor had any particular occupation. The
onset of illness was slow, occurring over several weeks or months with
papilledema a common finding. Cerebrospinal (CSF) pressure was often raised
with lymphocyte predominance and yeasts visible on microscopy which could be
cultured on Sabouraud's media. After a variable course all patients died of
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respiratory failure after becoming comatose and half had evidence of
extrameningeal involvement, particularly in the lung but also in kidneys, spleen,
adrenals and skin. Histopathologic examination showed a granulomatous meningitis
with cerebral cystic and granulomatous lesions.
1.1.2 Host predisposition
It was highlighted in 1954 that patients with cryptococcosis commonly had an
association with malignant disease of the reticuloendothelial system and
subsequently other predispositions have been clearly linked such as those with
sarcoidosis and corticosteroid therapy (Zimmerman and Rappaport, 1954). These
findings were identified in patients predominantly in the United States but in
tropical and sub tropical regions this association did not seem to hold true. Cox and
Tolhurst reviewed thirteen cases in 1946 that had presented in Australia, dating back
to 1914 (Cox and Tolhurst, 1946). They described how four of six autopsied cases
had large torulae collections in the brain and five of six had such torulae in the
lungs, unlike the findings in the United States series. They also suggested that the
incidence was higher than in the United States. A review of experience between
1957 and 1975 of cryptococcosis in the Northern Territory of Australia found that
no cases had been treated with corticosteroids or had malignant disease prior to
admission (Schupbach et al. 1976). Previously healthy individuals have similarly
been predominant amongst those presenting with cryptococcosis elsewhere in
Queensland, Australia, Singapore, Malaysia and Zimbabwe (De Wytt et al. 1982;
Tjia et al. 1985; Pathmanathan and Soo-Hoo Tuck Soon, 1982; Gould and Gould,
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1985). These reports have predated the AIDS epidemic and C. neoformans isolates
have generally not been biotyped.
1.2 Mycology of Cryptococcus neoformans
1.2.1 Introduction
The origins of mycology are botanical, because fungi were initially thought to be
part of the plant kingdom and so studied and classified in ways appropriate to plants.
'Mykes' is derived from the Greek for mushrooms. Fungi are absorptive eukaryotes
as defined in the Whittaker scheme of classification (Whittaker, 1969). This means
that they absorb nutrients from their surroundings, as opposed to using chlorophyll
and being photosynthetic (Plantae), or ingestive (Animalia). They have a true
nucleus and are characterized by discrete chromosomes bounded by a nuclear
membrane, organelles and a cell membrane, typically comprised of ergosterol.
Taxonomy is somewhat complex and controversial, at times being complicated by
the separate discovery of sexual and asexual forms of the same species. Asexual
forms, also known as the anamorphs, reproduce by budding or hyphal extension,
whereas the sexual (teleomorph) fonns require two mating forms to contribute
gametes before reproduction occurs.
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1.2.2 Cryptococcus neoformans
The teleomorph, sexual form of C. neoformans is called Filobasidiella neoformans.
C. neoformans is often referred to as a basidiomycetous yeast-like fungus. The
Basidiomycetes are those fungi in which the sexual process involves the production
of haploid basidiospores borne on a basidium in which a diploid nucleus undergoes
meiosis. Thus for the sexual, teleomorph form F. neoformans the sexual propagule
is known as a basidiospore. If a fungal isolate does not produce a sexual phase then
it is assigned on the more limited information available from asexual sporulation.
The form of reproduction by the spores (and their type) dictates the genera into
which a fungus is classified. Yeasts, many of which do not spore, have been
classified on the basis of the vegatative cell and fermentation tests as well as on the
sporulation process. Indeed, in most cases the haploid anamorph (yeast) is isolated
from natural or clinical samples.
Over 95% of the fertile natural teleomorph isolates belong to the a mating type of F.
neoformans. The asexual yeast forms, C. neoformans, typically develop a
polysaccharide capsule following budding. While the majority of fungi are
filamentous with hyphae enabling them to colonise substrata that are nutrient rich,
but otherwise difficult to attack, yeasts are fungi that lack or rarely produce hyphae,
are unicellular and multiply by budding. Yeasts are abundant in habitats such as the
surface of plants and animals. It is likely that yeast forms are superior to hyphae in
resisting hydrostatic pressures generated by the fluctuating ambient water potentials
or osmotic conditions on such surfaces.
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1.2.3 Basidiospore production and the infectious propagule
How often, if at all, sexual reproduction by F. neoformans happens in nature is
uncertain. The basidiospores are small and dry which would allow them to
penetrate the lung to the alveoli, taking on the role of the infectious propagule (Ellis
and Pfeiffer, 1990a; Ellis and Pfeiffer, 1992). Clinical isolates C. neoformans are
generally haploid and virtually always one of the two mating types, the a type
(Madrenys et al. 1993; Takeo et al. 1993). During sexual reproduction equal
numbers of each mating type are produced. Patients would be expected to have both
a and a mating types, but all clinical isolates and most found in nature have the a
allele. This information suggests that either the natural infectious propagule is the
asexual, yeast form (in this case derived from the a mating type), or that the a
mating type does not survive as well in the environment as the a mating type.
Recently Wickes et al showed haploid fruiting of C. neoformans in 'starvation
conditions' associated with the a mating type locus, independant of serotype
(Wickes et al. 1996). Basidiospore production in these circumstances may explain
the preponderance of this a mating type in the environment and the nature of the
infectious propagule of C. neoformans.
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1.2.4 Culture
Culture of Cryptococcus neoformans on Sabaoraud's dextrose agar or malt extract
agar from clinical specimens is optimal at 25-30°C, colonies developing within 36-
72 hours. They appear white/cream coloured and have a degree of mucosity
reflecting the degree of encapsulation. Microscopy of such colonies shows rounded
budding yeasts which are also seen in tissue specimens (Erke and Schneidau, Jr.
1973). Single or multiple buds may be seen which detach easily from the parent
form. Examination of a wet preparation gives the impression of a capsule, which is
seen more clearly by staining with India ink or phase contrast microscopy.
1.3 Identification, growth and physiology
C. neoformans requires simple carbon and nitrogen sources for growth, but may not
need vitamin supplementaion with thiamine (Bruatto et al. 1992). Doubling times at
37°C vary between strains from 2.5 to 6 hours (Miller et al. 1990), which is not as
quick as other yeasts such as Candida albicans and Saccharomyces cerevisiae given
similar conditions. The use of low-molecular-weight nitrogenous compounds such
as creatinine may partially explain the ecological niche of C. neoformans var.
neoformans in avian guano.
Most other species of Cryptococcus are unable to grow at 37° C and are not
pathogenic whereas C. neoformans does grow at this temperature, but is generally
killed after 24 hours at 40° C. The ability of most strains to secrete urease is used in
identification of C. neoformans (Zimmer and Roberts, 1979). Another feature is
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phenol oxidase production, perhaps acting as an antioxidant so enhancing survival
of the yeast in the host (Jacobson et al. 1994; Jacobson and Tinnell, 1993). The
presence of this enzyme which results in the production of melanin from
catecholamine precursors is used in identification. Pigmented colonies are produced
when grown on catechol enriched media such as bird seed agar which can be picked
out on plates where other microorganisms are present, for instance in
environmental or respiratory specimens (Staib et al. 1987). These features along
with resistance to antimicrobial agents such as penicillin, gentamicin and
streptomycin are used in isolation and identification from contaminated clinical or
environmental specimens (Kwon-Chung and Bennett, 1992; Warren and Hazen,
1995; Staib et al. 1989a). Phenol oxidase activity may account for the predilection
of C. neoformans for the central nervous system, which is catechol rich, allowing
melanin production and protection from host defences (Rhodes et al. 1982).
1.4 Capsule
1.4.1 Serology
Polysaccharide capsular antigen determinants form the basis for serotyping. Initially
in 1949 Evans identified differences in rabbit sera following inoculation with
different clinical isolates (Evans, 1949). Three serotypes were identified, A, B and
C. Almost 20 years later Vogel identified a fourth serotype, D (Vogel, 1966). There
are now four recognised serotypes, A,B,C and D. Type-specific antiserum is
prepared by immunising rabbits with formalin killed yeast of known serotype, and
adsorbing the antiserum with yeast of heterologous serotypes (Wilson et al. 1968).
Some capsulate isolates are untypeable on this basis and some react with antisera to
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the types A and D and so are called AD (both A and D determinants present). A few
isolates are acapsulate and so cannot be typed in this way.
1.4.2 Biochemistry
Capsular polysaccharide from C. neoformans grown in vitro or during infection in
vivo is soluble and can be precipitated from culture supernatant or detected in
bodily fluids such as blood, urine and cerebrospinal fluid (CSF). Culture filtrates
contain at least three antigens which have been well defined, glucoronoxylomannan
(GXM), galactoxylomannan (GalXM) and a mannoprotein (Murphy et al. 1988).
The main capsule constituent is GXM. Small variations in this constituent, in
particular the degree of O-acetylation of hydroxyl groups and the number of xylose
residues, forms the basis for the current serotyping scheme (Turner and Cherniak,
1991; Wilson et al. 1968). The recent application of 13C nuclear resonance
spectrophotometry has lead to the realisation that a simple structural relationship
between the GXMs of the four serotypes is an oversimplification. Certain
structures, considered typical of one serotype have been identified in heterologous
serotypes by this method (Turner and Cherniak, 1991). Also, structural differences
have been reported among strains of the same serotype (Cherniak et al. 1991;
Cherniak et al. 1993; Small et al. 1986; Turner et al. 1992), and antigenic
differences have been identified by monoclonal antibodies (Belay et al. 1993;
Dromer et al. 1993; Spiropulu et al. 1989; Todaro-Luck et al. 1989). GXM is poorly
immunogenic alone, but if conjugated to a protein carrier induces a strong antibody
reponse, as then the whole cell is the immunogen (Casadevall et al. 1992; Devi et al.
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1991; Goren and Middlebrook, 1967). GXM has been shown to be anti¬
inflammatory, antiphagocytic and immunosuppressive. Mouse studies have shown
that GXM induces specific tolerance both in a low-dose T-cell- dependant and high-
dose T-cell-independant manner (Cherniak and Sundstrom, 1994; Sundstrom and
Cherniak, 1993). For some time GXM has been known to be an activator of the
alternative complement pathway, resulting in opsonization of encapsulated yeast
cells with C3 (Bolanos and Mitchell, 1989). Recently Kozel et al have linked the
activation of the alternative pathway with GXM and quantified the deposition of
C3b and iC3b (Kozel, 1993; Pfrommer et al. 1993; Young and Kozel, 1993).
In addition to GXM, two further minor carbohydrate antigens, GalXM and
mannoprotein form the capsule and can be obtained from culture filtrates of C.
neoformans (Cherniak et al. 1982; Turner et al. 1984). Mannoprotein is the
immunodominant antigen responsible for evoking cell mediated immunity (CMI)
(Cherniak and Sundstrom, 1994). GXM and mannoprotein appear to have separate
effects on the immune system (Murphy et al. 1988), while at present the role of
GalXM is unknown (Cherniak and Sundstrom, 1994).
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1.4.3 Influences on capsule size.
Capsule formation is a major feature of C. neoformans. Clinical specimens virtually
always demonstrate this finding, but on repeated subculture the size of the capsule
may be diminished, although optimisation for a given strain can be achieved by
manipulating the environmental conditions in which it is grown. The capsular size
can be markedly influenced by the environmental conditions. At physiological
pCC>2 concentrations capsular size is increased, whereas at environmental
concentrations it is diminished (Granger et al. 1985). As the growth rate is slowed
so the size of capsule is increased. Culture with 1% glucose, <1.0 |u.g/ml thiamine,
>1.0 mg/ml glutamate, neutral pH, elevated carbon dioxide or decreased iron
concentration maximises formation of the capsule (Dykstra et al. 1977; Granger et
al. 1985; Littman, 1958; Vartivarian et al. 1993). Reduction of capsule formation
can be achieved by cultivation at high osmolarity (16% glucose or 2.9% NaCl) or
acid pH, or storage in soil (Dykstra et al. 1977; Ishaq et al. 1968). When grown
under identical conditions different strains produce capsules of differing
thicknesses, demonstrating the phenotypic variation of C. neoformans.
The availability of ferric iron also affects growth and capsule size. With reduced
ferric iron it increases (Vartivarian et al. 1993) and it has been suggested that C.
neoformans has specific iron receptors for iron acquistion (Jacobson and
Vartivarian, 1992). Such stimuli may influence adaptation to survival in the host.
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1.5 Cryptococcus neoformatis varieties gattii and neoformans
The varieties of C. neoformans have been defined on the basis of genetic and
biochemical studies. C. neoformans var. neoformans includes serotypes A, D and
AD, whereas C. neoformans var. gattii includes serotypes B and C only. The two
varieties can easily be separated on the basis of colour changes on solid media, such
as canavinine-glycine-bromothymol blue (CGBB) agar (Plate 1.1), which turns from
green/yellow to cobalt blue with var. gattii, but not with var. neoformans. (Kwon-
Chungetal. 1982b).
This method is sensitive, specific and easy, without recourse to sophisticated or
expensive equipment, and so is practicable to use in a tropical setting. C.
neoformans var. gattii is resistant to L-canavanine, whereas all serotypes D and 28%
of A serotypes are sensitive at concentrations of 5 p/ml or less (Polacheck and
Kwon-Chung, 1986; Kwon-Chung et al. 1982a). The resistant C. neoformans var.
neoformans isolates do not assimilate glycine. A colour change results from the
rising pH as C. neoformans var. gattii assimilates glycine. In addition C.
neoformans var. gattii assimilates maleate and is relatively temperature sensitive
(Rippon, 1988; Kwon-Chung et al. 1982a). It seems that the ecology, epidemiology
and pattern of disease caused by the two varieties differs.
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Canavanine glycine bromothymol blue agar used for biotyping.
Cryptococcus neoformans var. gattii turns the agar blue while with
var. neoformans it remains light green
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1.6 Molecular aspects of typing
Molecular methodology is being increasingly applied to cryptococci, and at least 23
C. neoformans genes have been cloned, (Mitchell and Perfect, 1995). Pulsed field
gel electrophoresis (PFGE) has been used to identify the chromosome size and
number (electrophoretic karyotyping) in a number of eukaryotes, and differentiates
between the two biotypes of C. neoformans (Wickes et al. 1994). The smallest
chromosome of var. gattii is 400-700 kB in size and that for var. neoformans
consistently larger about 770 kB (Wickes et al. 1994). Var. gattii isolates average
13 chromosomes, and var. neoformans average 12. Typing has also been carried out
by random amplification of polymorphic DNA (RAPD), by the polymerase chain
reaction (Crampin et al. 1993; Haynes et al. 1995) and DNA finger printing of
restriction endonuclease digested DNA with dispersed repetitive DNA sequences
cloned from C. neoformans (Spitzer and Spitzer, 1992; Varma and Kwon-Chung,
1992; Haynes et al. 1995). Restriction fragment length polymorphism analysis in
mitochondrial DNA has also been used to differentiate strains and demonstrate
varietal-specific patterns of homology (Varma and Kwon-Chung, 1989).
These typing methods seem to be reproducible and discriminatory and hold out
promise in helping to define better the ecology and epidemiology of cryptococcosis.
It has been suggested that on the basis of biochemical and genetic differences the
two varieties of C. neoformans may be diverging into separate species. Mating of
intervarietal crosses was only successful in so far as serotypes B and D produced




From the information currently available it seems likely that the two varieties of C.
neoformans occupy different environmental niches. These are summarised in Table
1.1.
Table 1.1 Cryptococcus neoformans isolates from natural sources
Variety Avian guano other sources
Cryptococcus neoformans pigeons rotting vegetables
variety neoformans*









*includes isolates where type not stated.
Adapted from (Kwon-Chung et al. 1990). References: Emmons, 1955; Pal and Mehrotra,
1985; Pal, 1989; Ellis and Pfeiffer, 1990b, Ellis and Pfeiffer, 1990a; Sanfelice, 1894;
Cobcroft et al. 1978; Klein, 1901; Swinne et al. 1986a; Lazera et al. 1993
39
For many years it has been recognised that var. neoformans can be found in soil and
weathered avian guano, particularly that of pigeons (Columbia livia), which is
enriched with a high content of low-molecular weight nitrogenous compounds such
as creatinine (Emmons, 1955; Emmons, 1951). Staib showed that C. neoformans
utilises creatinine as a nitrogen source, unlike other species of Cryptococcus.
Therefore the droppings can serve as a selective medium in nature for C.
neoformans. Despite the association with avian sources, birds do not become
infected, perhaps because of their high body temperature, yet they may distribute the
yeasts. In such nesting areas the cells have minimal capsules, are dry (dessicated)
and can easily be aerosolized (Bulmer, 1990; Neilson et al. 1977; Ruiz and Bulmer,
1981). These smaller yeast cells could then be inhaled to the alveolus (Neilson et al.
1977; Powell et al. 1972). C. neoformans var. neoformans has been isolated from
droppings of other birds including canaries (Staib, 1962a; Swinne-Desgain, 1975),
parrots (Bauwens et al. 1986), munia birds (Pal, 1989), buderigars and other birds
(Staib and Eleissenhuber, 1989; Wegener and Staib, 1983), swallow's nest, dairy
products, soil (Ajello, 1958; Currie et al. 1990), wood, rotting vegetables fruits and
in a bagpipe (Cobcroft et al. 1978).
Until relatively recently the natural source of C. neoformans var. gattii has remained
elusive. In 1989 Ellis and Pfeiffer reported the environmental isolation of var. gattii
in South Australia, New South Wales and subsequently California (Ellis and
Pfeiffer, 1990b; Pfeiffer and Ellis, 1991). The organism was isolated from debris
(bark, wood and leaves) under the canopies of Eucalyptus camaldulensis (red river
gum) during and for some months after flowering (Plate 1.2).
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Airborne sampling detected fungus around flowering, but not non-flowering trees.
Electrophoretic karyotyping of eucalypt and human derived C. neoformans var.
gattii confirm that they are the same organism (Kwon-Chung et al. 1992b). It
should be noted that var. gattii serotype B but not serotype C has been isolated from
environmental sources. E. camaldulensis is concentrated in the subtropics and
tropics, having been planted widely for commercial purposes. These regions in
general correlate with areas of the world where clinically apparent human C.
neoformans var. gattii infections occur (Ellis and Pfeiffer, 1990b). Ellis and Pfeiffer
have also reported var. gattii carriage in koalas (Ellis and Pfeiffer, 1990a) as well as
E. tereticomis, (forest red gum), closely related to E. camaldulensis, with a similar
distribution. This ties in with previously reported cryptococcosis in koalas, which
feed on eucalypts (Bollinger and Finckh, 1962). In Brazil, Lazera on one occasion
found var. gattii in bat guano, and proposed that these mammals may have a role in




C. neoformans in nature is saprophytic, and its natural niche has been widely sought.
It may be that the findings of var. gattii in association with Eucalypt sources
indicates such a niche. C. neoformans has been isolated from wood in an aviary in
the Antwerp zoological garden (Bauwens et al. 1986), but examination of 477
samples of tropical wood was negative (Swinne and Ed: Torres-Rodriguez, 1988). It
is possible that the telomorphic (sexual) phase is related to a natural niche with
wood in the environment. Recently the isolation of var. neoformans from decaying
wood on the inner surface of hollows in living trees in urban Rio de Janiero, Brazil,
has been reported. The trees involved were the Pink shower tree (Cassia grandis),
November shower {Senna multijuga), Fig tree (Ficus meciocarpa), Java plum
(Syzgium jambolan), Munguba {Bombax munguba), Coconut palm (Cocos nucifera)
and mango tree {Mangifera indica). Homogenized wood suspension was streaked
onto niger seed agar in all instances resulting in positive isolates. All but one of 113
air samplings were negative. Decaying wood is discoloured suggesting partial lignin
and xilan degradation. The wood debris from eucalypts contains very high
concentrations of lignin and polyphenols suggesting that phenol oxidase activity of
C. neoformans may be an adaptation to its natural habitat (Ellis et al. 1996).
1.8 Epidemiology - clinical isolates
Kwon-Chung and Bennett have described varieties and serotypes of 725 clinical
isolates from patients without the Acquired Immunodeficiency Syndrome (AIDS)
(Kwon-Chung and Bennett, 1984). Those isolates from the tropics and subtropics
such as Central Africa, Brazil, South East Asia, Australia and Southern California
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show a high frequency (35-100%) of C. neoformans var. gattii (serotypes B and C).
In contrast the isolates from temperate climates such as the United States (exluding
California and Hawaii), Europe and Japan were virtually all C. neoformans var.
neoformans (serotypes A and D). Of these isolates, 16% were serotype A, 16% D or
AD, 11% serotype B and 2% serotype C, and 1% untypeable. Four serotype B
isolates came from the United Kingdom, but the details of patient origin were not
available, whilst 88% of type C isolates came from Southern California. Dromer et
al have found that C. neoformans serotype D is relatively more common in France,
comprising 21% of clinical isolates. Serotype D seems to be more frequent in the
more humid and colder regions amongst patients over 60 years of age, born in
Europe, receiving corticosteroid treatment and those who had skin lesions (Dromer
et al. 1996).
With the advent of AIDS the geographical distribution of serotypes has not changed,
but the relative frequencies of isolates is altering dramatically, particularly in the
tropics and subtropics. For example in California, initial reports have suggested that
where a large number of clinical isolates were var. gattii, all infections in AIDS
patients were due to var. neoformans (Rinaldi et al. 1986). In Central Africa 92%
of isolates collected between 1951 and 1969 were var. gattii (Kwon-Chung and
Bennett, 1984; Swinne-Desgain, 1976), but only var. neoformans was found
amongst isolates from Zairean patients between 1970 and 1987 (Kapend'a et al.
1987; Kwon-Chung et al. 1990). Over these years cases of cryptococcosis increased
rapidly, with all isoates since 1980 coming from patients with probable or definite
AIDS. Var. gattii infection in AIDS has been infrequently described, despite the
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previous predominance of these infections in the tropical and subtropical areas
where now AIDS and var. neoformans infections are dominant.
1.9 Epidemiology - patients
In temperate climates cryptococcal meningitis has tended to occur in
immunocompromised patients, even before the spread of AIDS. In a UK series of
61 cases, 85% had predisposing disease, and in American studies up to 69% of
patients had concurrent conditions associated with immunosuppression, particularly
lymphoma, sarcoidosis and corticosteroid treatment (Diamond and Bennett, 1974;
Hay et al. 1980; Lewis and Rabinovich, 1972). In such patients the predominant
abnormality is an impairment of cell mediated immunity. There has been a
suggestion that some apparently immunocompetent patients had minor defects in
their T cell response to cryptococcal antigens (Graybill and Alford, 1974; Schimpff
and Bennett, 1975; Lalloo et al. 1994). It appears that neither neutropenia nor
immunoglobulin deficiency increase susceptibility to cryptococcosis. In contrast to
the studies mentioned above, those reported from the Northern Territory of
Australia, Zimbabwe, Papua New Guinea (PNG) and Singapore only reported up to
12% of patients with a condition associated with immunosuppression (Lo, 1976;
Gould and Gould, 1985; Lalloo et al. 1994; Tay et al. 1972; Tjia et al. 1985). In
both tropical and temperate areas men appear to be infected more frequently than
women and the incidence of cryptococcosis in prepubescent patients is low. This
could be linked to variation in exposure or possible protective effects of oestrogens
against cryptococci. Tropical studies do however demonstrate a less marked male
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preponderance and younger age group, with a peak incidence in the third decade of
life, rather than over the age of 30 as found in temperate series.
With the advent of AIDS the incidence of cryptococcosis has risen dramatically. In
the UK 4% of patients with AIDS have developed cryptococcosis while in the
United States 6-10% of such patients are infected with C. neoformans. (Knight et
al. 1993; Chuck and Sande, 1989). In the tropics the number of patients with
cryptococcosis may be as high as 30% of all patients with AIDS in some regions
(Taelman et al. 1991). This is having massive social and economic repercussions.
Virtually all the isolates from these patients, with a few exceptions, have been var.
neoformans, even where previously var. gattii predominated. These variations
suggest a difference in the pathogenicity of the two varieties of C. neoformans.
In PNG and Victoria, Australia var. gattii was not found in immunosuppressed
hosts, whereas 87-90% of var. neoformans infections occurred in
immunosuppressed hosts in the Victorian and another recent Australian study
(Naraqi et al. 1979; Lalloo et al. 1994; Speed and Dunt, 1995; Mitchell et al. 1995).
A summary of differences between the two varieties of C. neoformans, including
epidemiological differences, is given in Table 1.2.
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Table 1.2 Probable and possible major differences* between
Cryptococcus neoformans varieties gattii and neoformans and
resultant central nervous system disease
Feature/Variety gattii neoformans












Rate of capsular C3
deposition
slower faster
glycine assimilation 100% 10-20%
canavanine susceptibility no yes
malate assimilation yes no
Distribution Tropics/subtropics Worldwide
Predominant patient group Immunocompetent Immunocompromised.






Length of treatment ?longer ?shorter






* These are generalisations; some exceptions exist.
** Xyl = xylose, Man = mannose, GlcA = glucoronic aid
References: (Wickes et al. 1994; Bhattacharjee et al. 1984; Young and Kozel, 1993;
Kwon-Chung and Bennett, 1984; Speed and Dunt, 1995; Polacheck and Kwon-
Chung, 1986; Sabetta and Andriole, 1985; Mitchell et al. 1995; Speed, 1990;
Henderson et al. 1981)
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1.10 Virulence
Although it is not known to produce any exotoxins, there are a number of factors
that contribute to the virulence of C. neoformans. These include the ability to grow
at body temperature, 37°C, as well as at the lower temperatures found in the
environment unlike other cryptococcal species, the production of a polysaccharide
capsule, superoxide dismutase activity, melanin production and possibly a mating
type, as shown in Table 1.3.
Table 1.3 Factors that may play a role in the virulence of
Cryptococcus neoformans
Virulence Factor Mechanism Enhancing Virulence
Growth at 37°C Ability to survive and grow in deep tissue
at body temperature.
Polysaccharide capsule Antiphagocytic; inhibits
lymphoproliferation; T-cell activation
and cytokine release; depletes
complement levels; potentiates HIV
infection.
Superoxide dismutase activity Confers resistance against microbicidal
oxidants.
Melanin production by phenol oxidase Confers resistance against microbicidal
oxidants.
Mating Type (a) Mechanism undefined.
Mannitol production Scavenges free radicals, increases heat
and osmotic tolerance
Phospholipase production Uncertain
References: (Bulmer and Sans, 1968; Macher et al. 1978; Truelsen et al. 1992;
Mody and Syme, 1993; Wagner et al. 1992; Jacobson et al. 1994; Wang and
Casadevall, 1994; Kwon-Chung and Rhodes, 1986; Jacobson and Tinnell, 1993;
Kwon-Chung et al. 1992a; Rhodes et al. 1982; Chaturvedi et al. 1996a; Chaturvedi
et al. 1996b; Chen et al. 1997)
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1.10.1 Capsule in virulence
Encapsulated yeast activates complement solely by the alternative pathway, and
once opsonized can be phagocytosed by macrophages, neutrophils and monocytes
(Mitchell and Perfect, 1995). Phagocytosis of encapsulated yeasts is reduced in
strains with large capsules (Bulmer and Sans, 1968). Differences in the structure of
the capsules may influence this activation, impeding clearance, and may contribute
to difference in pathogenesis of different serotypes, as C3-binding rates to serotypes
B and C are slower than to serotypes A and D (Young and Kozel, 1993). A large
load of organisms may cause depletion of complement and opsonin (Macher et al.
1978). The antiphagocytic properties of the capsule may be overcome in vitro by
mouse macrophages activated by tumour necrosis factor (TNF) and granulocyte
macrophage colony stimulating factor (GM-CSF) (Collins and Bancroft, 1992).
Capsular glucoronxylomannan (GXM) has been shown to promote pro and anti
inflammatory cytokine release from peripheral mononuclear cells and neutrophils
respectively (Vecchiarelli et al. 1996; Retini et al. 1996). Although in vitro
interactions therefore occur, the net effect in vivo has yet to be elucidated.
Molecular evidence of the importance of the capsule in cryptococcal virulence has
been demonstrated by deletion of the CAP59 gene, resulting in acapsulate strains of
reduced virulence in mice (Chang and Kwon-Chung, 1994). In this series of




The ability to produce melanin-like pigment from catecholamine precursors via a
phenoloxidase system is thought to play a role in virulence as mutants deficient in
melanin have been shown to be less virulent in mice (Kwon-Chung and Rhodes,
1986). The central nervous system is rich in these precursors, which may account
for the predilection of C. neoformans for this site, allowing production of melanin
and protection from host defences. Melanin can also act as an antioxidant,
confering resistance to microbiocidal oxidants such as hypochlorite and
permanganate ions. The CNLAC-1 gene, which is responsible for melanin
production by encoding laccase enzyme in C. neoformans has been isolated and
cloned (Williamson, 1994). Mice infected with C. neoformans with disrupted
CNLAC-1 were not killed, whereas complementation of melanin negative mutants
with CNLAC-1 increased virulence to mice (Salas et al. 1996). Recent studies by
Huffnagle and colleagues suggest that melanin may act by down regulating the
afferent phase of T cell-mediated immunity rather than protecting the organism
from intracellular killing (Huffnagle et al. 1995). At 37°C melanin is supplemented
by superoxide dismutase activity, which has a similar though narrower spectrum of
activity (Jacobson et al. 1994)
1.10.3 Mating type
The mating type must differ for the sexual process to occur, which prevents mating
between genetically identical cells. It is also thought to be associated with
virulence. The a-type of C. neoformans var. neoformans is 30-40 times more
common in environmental and clinical isolates than the a-type, and has been shown
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to be more virulent in mice (Kwon-Chung et al. 1992a). The molecular basis for
these findings has not as yet been clarified.
1.10.4 Mannitol production
C. neoformans isolates produce the acyclic hexitol, D-mannitol in vitro which may
be found extracellularly (Wong et al. 1990). It has been suggested that cerebral
tonicity and oedema may be caused by accumulated mannitol and that it scavenges
free radicals, interfering with cryptococcal killing by phagocytes (Chaturvedi et al.
1996b). Mannitol production also influences C. neoformans tolerance to heat and
osmotic stresses and its pathogenicity in mice (Chaturvedi et al. 1996a).
1.10.5 Other candidates
In addition to mating type there has been a report of secreted proteinases which may
contribute to the breakdown of host tissue or humoral proteins (Brueske, 1986).
Further extracellular proteins have recently been found which result in an antibody
response (Chen et al. 1997). Extracellular phospholipase activity has now been
correlated with virulence in a mouse model resulting in the suggestion that
phospholipases may have a role to play in human virulence (Chen et al. 1997).
Other non-capsular antigens have recently been reported by Hamilton et al
(Hamilton and Goodley, 1993). The first of these was purified from culture filtrate
material and found to be an acidic glycoprotein containing mannose with a size of
115 kDa. This binds a monoclonal antibody that reacts only weakly with the
mannoprotein (Hamilton and Goodley, 1993). On immunoblots patient sera reacted
strongly to this antigen. The second is a cytoplasmic antigen which reacts to sera
from HIV positive patients and immunocompetent var. gattii patients. A 19kDa
band was identified as a superoxide dismutase purified and characterized from both
varieties of C. neoformans. This enzyme is a further candidate as a determinant of
virulence in C. neoformans.
1.11 Host response
1.11.1 Exposure to Cryptococcus neoformans
Where C. neoformans is common in the environment, exposure is most likely to be
frequent. Surveys using cryptococconin (antigenic extract of C. neoformans) for
skin testing are difficult to interpret as skin testing has not been standardised, and so
comparisons are difficult to make. They do however demonstrate skin reactivity in
laboratory personnel who have worked with C. neoformans and pigeon handlers
(Atkinson, Jr. and Bennett, 1968; Newberry, Jr. et al. 1967). This implies exposure,
although there is no evidence of occupationally acquired cryptococcosis other than
by direct skin inoculation of blood infected with C. neoformans (Glaser and Garden,
1985). Pigeon handlers have a high frequency of cryptococcal antibody in serum.
Outbreaks of cryptococcosis have not been described, although there are anecdotal
reports of cases asssociated with a particular source (Procknow et al. 1965). While
these studies show that exposure to Cryptococcus neoformans is common among
certain groups, there is no evidence of increased incidence of disease in such groups.
Molecular typing techniques have not yet shown exposure to a specific source to be
linked with a case of cryptococcosis. However, it is interesting to note that some
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clinical and environmental isolates are indistinguishable as determined by restriction
fragment length polymorphism analysis (Currie et al. 1994). There is also
concordance of clinical and environmental isolates of C. neoformans by RAPD
analysis (Sorrell et al. 1996).
1.11.2 Pathogenesis
Of crucial importance as to whether any organism invades and causes infection are
the virulence of the organism, size of inoculum and the host defences. Integrity of
the host defences would seem to be the key to repulsion of C. neoformans. This
assumption would seem reasonable because of the ubiquity of this yeast in the.
environment, yet low incidence of symptomatic infection. The implication being
that most people, other than those with compromised defences, are probably
resistant to such infection. This does not explain the occurrence of disease in those
with apparently intact host defences. One suggestion has been that such individuals
are exposed to a large inoculum as happens with histoplasmosis and
coccidiomycosis (Bulmer and Tacker, 1975). Another explanation may be that
different strains and indeed serotypes differ in virulence such that the strain inhaled
determines whether infection occurs. Both these concepts may be valid, but there is
evidence from experimental and clinical studies that intact cell mediated immunity
is of crucial importance in resistance to cryptococcosis.
It is thought that cryptococcosis in humans beings is most likely to be acquired by
inhalation of infectious airborne particles. The incubation period is unknown and
could be weeks, months or even years; it is uncertain whether latency occurs.
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Whether the infectious propagules are desiccated yeast cells (less than 2 microns)
(Staib, 1987; Staib and Heissenhuber, 1989) or basidiospores (less than 3 microns)
of the sexual state (F.neoformans) is unclear (Cohen, 1982; Cohen et al. 1982), but
it is thought that the encapsulated yeast cells are too large (4-20 microns) to
penetrate the defences of the upper respiratory tract. It seems likely that following
inhalation of the infectious propagule, significant clinical illness usually does not
occur, but in some cases there is progression to clinical disease.
1.11.3 Cellular immunity
Cellular defences are paramount in containing cryptococci. Mouse studies have
shown that neutrophils initially play a significant role in containing pulmonary
cryptococcal infection, followed later by monocytes (Gadebusch, 1972). Providing
cryptococci are opsonized by complement, phagocytosis by neutrophils may occur,
and is more efficient than by monocyte phagocytosis (Miller and Mitchell, 1991).
AIDS patients often have chemotactic and phagocytic defects in their neutrophils
and monocytes, which could partly explain their greater susceptibility to
cryptococcal infection. However, in general patients with neutropenia are not at
greatly increased risk. A number of lymphocytic cells are involved in controlling
cryptococci. In mice, CD4+ T-cells have been shown to be important in containing
central nervous system infection (Hill and Aguirre, 1994). AIDS patients are
deficient in CD4+ T cells, and this probably plays an important role in disease
caused by C. neoformans as shown by the occurrence of cryptococcal infection in
patients with idiopathic CD4+ lymphocytopenia (Smith et al. 1993; Duncan et al.
1993). It has been found that the gpl20 (the HIV-envelope protein) inhibits alveolar
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macrophage ingestion and growth inhibition of cryptococci (Wagner et al. 1992).
This may contribute to the infection of AIDS patients by cryptococci. Monocyte
interleukin 6 (IL-6) production has been stimulated by C. neoformans capsular
components (Delfino et al. 1997). IL-6 may play a role in upregulating HIV
replication in monocyte cell lines and act synergistically with GM CSF and tumour
necrosis factor alpha (TNF-a) in the induction of latent HIV infection (Poli et al.
1990).
In the presence of complement the cytokines TNF-a and GM-CSF have been shown
to upregulate cytokine-dependent phagocytosis of encapsulated cryptococci by
murine macrophages (Collins and Bancroft, 1992). Inhibiting these cytokines with
monoclonal antibodies leads to increased mortality in infected mice. Macrophages
incubated with interferon gamma (IFN-y) and macrophage colony stimulating factor
(M-CSF) have increased antifungal activity, which is not due to increased
phagocytosis. Monocytes exposed to purified GXM secrete reduced amounts of
IL1-P and TNF-a (Vecchiarelli et al. 1995b). However, capsular polysaccharide has
been reported to induce proinflammatory cytokine from human PMNs (Retini et al.
1996). Growth inhibition by a nitric oxide (NO)-related mechanism has recently
been reported to inhibit cryptococcal growth in human fetal astrocytes, suggesting
that NO may be an effector molecule (Lee et al. 1994). Following treatment for
cryptococcosis, apparently immunocompetent individuals showed some
abnormalitites in delayed skin testing to cryptococconin and other antigens, and
leukocyte migration inhibition (Schimpff and Bennett, 1975; Graybill and Alford,
1974; Henderson et al. 1982). There have been early reports of striking
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anticryptococcal defects in Natural Killer cells (NK cells) both from HIV-infected
patients and apparently non-immunocompromised individuals with cured
cryptococcosis (Horn and Washburn, 1995; Washburn, 1996). Unlike the pattern in
NK cells from HIV infected patients, the activity of those NK cells from apparently
immunocompetent individuals with past cryptococcosis could not be restored by
interleukin 12 (IL-12) in vitro. It should be noted that these defects in CMI have
been detected following cryptococcal infection, so it is not strictly possible to be
certain as to whether they are the result of infection, or predate it. These studies
have been carried out in patients infected with C. neoformans var. neoformans.
1.11.4 Humoral immunity
Antibody and complement are important elements in enhancing cellular host
anticryptococcal defences (Mukherjee et al. 1995; Diamond et al. 1972; Levitz et al.
1991; Diamond and Erickson, 1982; Kozel et al. 1984; Miller et al. 1990; Wilson
and Kozel, 1992; Levitz and Tabuni, 1991). Patients with cryptococcosis often have
low levels of opsonins as activation by the capsule results in depletion of
complement (Macher et al. 1978; Truelsen et al. 1992). Despite being used in
serotyping, the capsule is also poorly immunogenic (Murphy and Cozad, 1972) but it
powerfully activates the alternative complement pathway (Kozel et al. 1991).
Acapsular strains also activate the classical pathway, which suggests that the capsule
blocks the cell wall components involved in this pathway (Kozel et al. 1991). C3
binds to cryptococci, apparently at a slower rate for C. neoformans var. gattii than
var. neoformans (Young and Kozel, 1993). This may be the result of differing
capsular structure and contribute to differing pathogenensis. It may be that in
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acapsulate strains C3b is the most important opsonic ligand, while in encapsulated
strains rapid conversion to iC3b is found, suggesting that it is the more significant
ligand (Pfrommer et al. 1993). C5a is able to induce chemotaxis in neutrophils and
monocytes and is triggered by both the capsule and cell wall production via the
alternative pathway (Diamond and Erickson, 1982). In addition to these soluble
anticryptococcal factors it is thought that normal human serum may contain
globulins and a high molecular-weight component that inhibits binding to alveolar
macrophages (Reiss et al. 1975; Igel and Bolande, 1966; Levitz et al. 1992). There
may also be a fungicidal substance present in saliva (Igel and Bolande, 1966).
1.11.5 Central nervous system localization
The apparent predilection of cryptococci for the CNS may be linked to several
factors, including the lack of detectable complement activity in CSF, absent or
delayed inflammatory response to cryptococci in the brain, CNS presence of
catecholamine precursors (dopamine) and D-mannitol production by cryptococci
which may contribute to cerebral oedema and interfere with killing by host
phagocytes (Wong et al. 1990). Although the inflammatory responses seen
elsewhere in the body may not occur in the CNS, endogenous cells such as
astrocytes can produce cytokines and nitric oxide and may play a role in controlling
cryptococcal invasion (Lee et al. 1994).
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1.12 Clinical features
It seems likely that following inhalation, significant clinical illness usually does not
occur, but in some cases there is progression to disease, the most serious form of
which is meningitis or meningoencephalitis, which is fatal if untreated. The
incubation period is unknown and could be weeks, months or even years; it is
uncertain whether latency occurs. Virtually any organ may be infected, including
bone and soft tissue, generally via haematogenous spread from the lungs.
The clinical features of symptomatic C. neoformans infection overlap in different
patient groups and patient areas, but significant differences do exist. Many reviews
compare findings between those patients with AIDS and without AIDS (Mitchell
and Perfect, 1995). These differences tend to reflect the degree and type of
immunodeficiency in the bulk of patients without AIDS who are in some way
predisposed to significant infection with C. neoformans. In general, AIDS patients
have a greater burden of yeasts at the sites of infection and relatively few
inflammatory cells. There is a high frequency in such patients of positive blood and
urine cultures, extraneural sites of infection, many yeast cells yet few inflammatory
cells in the CSF and a higher incidence of clinical disease and relapse (Dismukes,
1988; Eng et al. 1986; Kovacs et al. 1985; Zuger et al. 1986). In patients with
marked immunosuppression generalized infection occurs including adrenals, heart,
liver, lymph nodes, joints and kidneys (Perfect, 1989). The main sites important for
diagnosis and management are the lungs, CNS, skin, prostate and eye.
58
1.12.1 Lungs
It is thought that the normal route of infection is via the lungs, but the form of the
infectious propagule is uncertain.
Pulmonary crytpococcosis has been well described; one review indicates well the
features that may be found (Campbell, 1966). One third of cases merely have an
abnormal chest X-ray. Most patients though present with symptoms. Cough (54%),
chest pain (46%), sputum production (32%), weight loss (26%), fever (26%) and
haemoptysis (18%) are typical clinical findings (Campbell, 1966). Other rare
manifestations are dyspnoea, night sweats and superior vena cava obstruction
(Lehmann et al. 1984; Menon and Rajamani, 1976). Presentation may be similar to
that of tuberculosis and histoplasmosis, and it is important to investigate
appropriately, as co-infection with Mycobacterium tuberculosis has been described
as has concurrent hydatid disease (Long, Jr. et al. 1980; Riley and Cahan, 1972;
Dalgleish, 1981). In immunocompetent hosts the diagnosis of pulmonary
cryptococcosis can be made by examination of sputum or lung biopsy material, and
antigen detection in conjunction with chest radiography. Often asymptomatic
respiratory tract colonization is found in patients with pre-existing lung conditions,
such as chronic obstructive airways disease (Hammerman et al. 1973; Subramanian
et al. 1982; Tynes et al. 1968). In the immunocompetent host, such colonization
does not spread elsewhere and treatment may not be required. It is important to
exclude CNS involvement in patients with pulmonary colonization/infection
(Kerkering et al. 1981; Lehmann et al. 1984). Pulmonary involvement was found in
57% of cases with meningitis caused by C. neoformans var. gattii in Northern
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Australia (Fisher et al. 1993). Chest X-ray appearances in pulmonary
cryptococcosis are variable and the true aetiology of an X-ray abnormality may only
become evident when investigations of possible malignancy yield cryptococci
(Khoury et al. 1984). Serum cryptococcal antigen, which should routinely be
checked in such instances, may not be positive. A positive result could indicate a
higher fungal burden and so suggest increased likelihood of dissemination,
encouraging antifungal therapy in such cases.
Immunosuppressed pulmonary cryptococcosis
In a review of pulmonary cryptococcosis in the pre AIDS era, 34 of 41 patients had
an immunocompromising condition. (Kerkering et al. 1981). In 29 patients the
disease disseminated and in all but one of these the patient was
immunocompromised. Eighty three percent of immunosuppressed patients had
generalised symptoms such as fever (63%), malaise (61%), chest pain (44%), weight
loss (37%), dyspnoea (27%), night sweats (24%), cough (17%), haemoptysis (7%)
and headache (7%). All patients had abnormalities on pulmonary radiography such
as alveolar or interstitial infiltrates, coin lesions, masses, cavitary lesions and pleural
effusions. Meningeal spread occurred in 25 patients within 20 weeks of diagnosis,
supporting the recommendation that specific treatment should be instituted in
immunocompromised patients. In AIDS, virtually every patient has symptoms such
as fever (81%), cough (63%), dyspnoea (50%), loss of weight (47%), headache
(41%) and sometimes pleuritic chest pain and haemoptysis (Cameron et al. 1991;
Clark et al. 1990b). Some patients may present with the adult respiratory distress
syndrome (Stern et al. 1988; Perla et al. 1985; Similowski et al. 1989). Chest X-rays
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rarely show nodular and alveolar infiltrates, large masses or pleural effusions, but
most frequently reveal focal or diffuse infiltrates and lymphadenopathy (Cameron et
al. 1991; Clark et al. 1990b; Miller, Jr. et al. 1990). These appearances are also
consistent with those of Pneumocystis carinii pneumonia, the most common cause
of such findings in AIDS, requiring appropriate investigation (Loerinc et al. 1988).
Concurrent oral candidiasis is also a frequent finding highlighting the association
with a CD4 count of <200 cells per pi (Crowe et al. 1991). Dissemination to the
CNS or blood occurs in about 94% of AIDS patients and so thorough evaluation of a
patient with pulmonary cryptococcosis is warranted (Cameron et al. 1991).
1.12.2 Meningoencephalitis
The onset and course of CNS disease are those of a subacute meningitis or
meningoencephalitis with headache, fever, lethargy, coma, personality changes and
memory loss over a few weeks. There is considerable variation in how patients
present; for instance there may be severe headaches of a few days duration,
intermittent headaches over months or no headaches. Headache may lead to an
earlier diagnosis and so better prognosis (Dismukes et al. 1987).
In tropical series of cryptococcosis, cryptococcal meningitis is the best described
form of this infection, probably because it is the most severe manifestation and
relatively clear-cut to diagnose. The pattern of disease in tropical and sub-tropical
regions and temperate regions varies, probably reflecting the differences in biotype
and immunocompetence in the series reported. In Europe and much of the US, even
before AIDS, disease tended to occur in immunocompromised patients. In tropical
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series the mean time to presentation from onset of symptoms varies from 4-10
weeks, whereas in 'Western' societies presentation is more rapid and disseminates
more often, probably related to the higher proportion of immunocompromised
patients (Lalloo et al. 1994; Hay et al. 1980; Lo, 1976; Gould and Gould, 1985;
Kerkering et al. 1981). In Zimbabwe the mean time from onset to presentation of
symptoms was 10 weeks and most Australian patients presented after over a month
of symptoms (Lo, 1976; Gould and Gould, 1985) In Western societies disease
presents more rapidly and disseminates more often (Hay et al. 1980; Kerkering et al.
1981). Despite these differences, most clinical features are similar in both
temperate and tropical regions. Common symptoms and signs of meningitis
including headache, nausea, vomiting, fever, photophobia and meningism are
accompanied by anorexia, weight loss, visual disturbances and cranial nerve
abnormalities, particularly papilledema or papillitis, which occur in up to 88% of
patients (Richardson et al. 1976). The clinical features and outcome of var. gattii
infections may differ from those caused by var. neoformans (Speed and Dunt, 1995;
Mitchell et al. 1995; Speed, 1990; Henderson et al. 1981). In two studies patients of
similar immunological status were compared (Mitchell et al. 1995; Henderson et al.
1981). In a retrospective comparison of immunocompetent hosts Mitchell et al
found that a higher incidence of cryptococcal meningitis in males, and cerebral mass
lesions, hydrocephalus, pulmonary-mass lesions and worse outcome were associated
with var. gattii infection (Speed, 1990). This series reported that a good outcome
was statistically more likely in immunocompetent patients with C. neoformans var.
neoformans than var. gattii infections, although two of the deaths in the latter group
were not directly related to cryptococcosis. In a retrospective series of 133 patients
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from the state of Victoria in Australia, there were 71 biotyped isolates (Speed and
Dunt, 1995). There were 5 immunocompetent patients infected with C. neoformans
var. neoformans, and all 20 patients infected with C. neoformans var. gattii were
immunocompetent. None of the 20 immunocompetent patients with var. gattii died
and there was a higher incidence of CNS cryptococcoma (cryptococcal mass focus
of infection) and non-fatal complications than in the patients with var. neoformans
infections (Speed and Dunt, 1995). An update on this second study suggests that
while the host preferences of var. gattii and var. neoformans contrast, the clinical
findings in hosts of similar immunological status is not so distinct (Speed, 1996).
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1.12.3 Ocular involvement
C. neoformans infection with eye involvement is not infrequent. Prior to the HIV
epidemic 45% of all patients with meningitis had ocular signs and symptoms (Okun
and Butler, 1964). Ocular palsies devlop as well as retinal involvement, sometimes
with concurrent infection with HIV and Cytomegalovirus (Doft and Curtin, 1982).
Catastrophic visual loss in patients without endophthalmitis is now well recognised
in patients with either normal retinas or papilledema on fundoscopy (Johnston et
al. 1992; Rex et al. 1993). Two major pathogenic processes have been implicated.
These are direct involvement of the optic nerve infiltrated by cryptococci and the
effects of raised intracranial pressure, however optic nerve arachnoiditis leading to
nerve infarction may also occur (Okun and Butler, 1964; Cheong et al. 1988; Rex et
al. 1993; Lipson et al. 1989; Kupfer and McCrane, 1974). The distinction betweeen
acute and slow visual loss has been made (Rex et al. 1993). Acute visual loss has
been attributed to direct optic nerve involvement, and the slow visual loss to the
effects of raised intracranial pressure. If the latter is the case, then early intervention
to lower intracranial pressure may reduce the outcome in some patients. Lowering
of intracranial pressure can be achieved by manoeuvres such as performing
sequential lumbar punctures and ventriculoperitoneal shunting, which have been
reported to improve visual function, and acetazolamide which has been used in two
patients with AIDS and cryptococcal meningitis (Cheong et al. 1988; Denning et al.
1991b; Johnston et al. 1992)
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1.12.4 Other sites
Sites beyond the CNS are frequently also involved in cryptococcosis. The protean
skin manifestations include acneform lesions, purpura, papules, superficial
granulomas, and more recent reports in high risk immunosuppressed patients of
molluscum contagiosum-like lesions and cellulitis. (Sarosi et al. 1971; Schupbach et
al. 1976; Pema et al. 1994) It is important to biopsy material from new skin lesions
in high risk patients, especially as the lesions may herald the onset of systemic
disease. Direct inoculation in clinical and laboratory accidents have occurred,
producing a papule with or without a local immune reaction (Glaser and Garden,
1985). In males the prostate gland is well recognised as a focus of infection
(Braman, 1981), but its greatest significance may be in AIDS patients who
frequently have evidence of viable cryptococci in seminal fluid and urine at the end
of therapy (Larsen et al. 1989; Staib et al. 1989b). It may be that this site acts as a
reservoir of infection and contributes to relapse in some patients. In non AIDS
patients this source has been less well studied.
1.13 Diagnosis
1.13.1 Introduction
The diagnosis of cryptococcosis is made by isolation of C. neoformans in
conjunction with the clinical setting and detection of serum and cerebrospinal fluid
capsular antigen by latex agglutination or enzyme immunoassay (Bennett and
Bailey, 1971; Horgan et al. 1990; Frank et al. 1993). Routine laboratory tests such
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as haematocrit, peripheral white blood cell count and erythrocyte sedimentation rate
are often normal.
1.13.2 Antigen and Antibody detection
Latex agglutination detection of cryptococcal capsular polysaccharide was first
described in 1963 by Bloomfield and colleagues (Bloomfield et al. 1963).
Interference in sera containing rheumatoid factors leading to false positives was
abolished by treatment of sera with dithiothreitol or a protease (Stockman and
Roberts, 1983). Rarely false positives may occur in the presence of Stomatococcus
mucilaginosis or Trichosporon beigelii (Chanock et al. 1993; McManus and Jones,
1985). Antigen detection is positive in at least 90% of cases with cryptococcal
meningoencephalitis, although infection at other sites less frequently results in a
positive antigen test (Powderly et al. 1992; Chuck and Sande, 1989; Saag et al.
1992; Bennett and Bailey, 1971). In one study 9% of AIDS patients had culture
positive cryptococcal meningitis but negative CSF antigen detection tests although
serum was negative in only 1% of patients (Chuck and Sande, 1989). Low levels of
antigen, presence of immune complexes (in non-protease treated serum samples),
high titres (due to a prozone effect - high concentrations of bound antibody antigen
complex inhibit antigen detection, but antigen can be detected at higher dilutions) or
poorly/non-encapsulated strains may contribute to such negative antigen tests
(Currie et al. 1993; Sadamoto et al. 1993). There are a number of commercial kits
available to detect cryptococcal capsular antigen by latex agglutination and enzyme
immunoassay, although there is some variation in performance (Tanner et al. 1994).
In one study, 4 kits were compared with CSF culture in patients with cryptococcal
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meningitis. The sensitivity in CSF ranged from 93-100% and specificity from 93-
98% while in serum sensitivity ranges were 83-97% and specificity 95-100%
(Tanner et al. 1994). It should be noted that meningitis cannot be excluded simply
on the basis of negative (even repeatedly so) CSF and serum antigen tests or India
ink stain.
Even when testing is available, antibody levels are not usually raised in patients with
cryptococcosis and can be detected in some healthy people, probably as a result of
previous exposure (Mitchell and Perfect, 1995). It is possible to detect antibody in
convalescent patients.
1.13.3 Microscopy
Rapid and presumptive identification can be made by using the India ink stain on
body fluids which highlights the cryptococcal capsule. This should be preceded by
gram stain to exclude bacterial pathogens and confirm yeast morphology. The yeast
cells are typically spherical and 5-7 pm in diameter. They may have a bud,
attached by a thin connection to the body of the yeast. If available, aspirates and
similar specimens can be effectively treated with a solution of calcofluor white and
examined under a fluorescent microscope (Hageage and Harrington, 1984). In
tissue sections methenamine silver and periodic acid-schiff help identify the yeast,
although it may appear collapsed and distorted. The capsule can be identified by
staining with Mayer's mucicarmine (Mitchell and Perfect, 1995) which colours it
rose red while as a further adjunct the Masson Fontana silver stain can be used for
melanin, confirming a diagnosis of cryptococcosis (Kwon-Chung et al. 1981).
67
1.13.4 Isolation
Acapsular mutants will not be identified using this stain, nor by methods which
depend on detection of capsular antigen, so extended culture at 30^C is crucial in
establishing the diagnosis in this instance. Isolation is possible on most routine
bacteriological or mycological media such as blood, Sabouraud's dextrose and malt
extract agars. For nonsterile specimens media containing cycloheximide should not
be used because the organism is susceptible to this agent. Niger seed (bird seed)
agar is useful for primary isolation from sputum and urine specimens (Denning et al.
1990). Biochemical testing can be used to confirm the identity of any yeast grown.
1.13.5 Cerebrospinal fluid findings
The CSF opening pressure is often raised, as is the protein concentration,
accompanied by a depressed glucose level and an abnormal leukocyte count with a
lymphocyte predominance. The CSF may sometimes be acellular in
immunosuppressed patients, such as those with AIDS (Powderly et al. 1992; Chuck
and Sande, 1989; Clark et al. 1990a). Skin testing does not have a role in diagnosis.
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1.13.6 Recovery from distant sites
Culture of C. neoformans from any site such as skin, bone marrow and urine
requires a search for infection elsewhere. It is sometimes necessary to culture
sediments repeatedly to obtain a positive culture, as there may be a few cryptococci
in the CSF itself. Blood culture is best done by lysis centrifugation (Tarrand et al.
1991), if available, but other techniques do detect yeasts, and can be optimized by
venting, extended incubation and terminal subculture. In the future genetic probes
may have a role in enabling rapid direct detection of fungal infection (Meyer et al.
1993; Polacheck et al. 1992).
1.13.7 Radiology
Usually chest -Xray is performed as part of the clinical workup in patients with CNS
symptoms and may identify another focus of possible cryptococcal infection as well
as other pathologies. If there is a reduced level of consciousness or focal
neurological findings computed tomography (CT) or magnetic resonance imaging
(MRI) is indicated. These are suitable for defining the ventricular system and
identifying hydrocephalus, which may need active management.
1.14 Differential Diagnosis
Other conditions that present with symptoms and signs of subacute meningitis may
mimic CNS cryptococcosis. These include both infectious and non-infectious
causes such as tuberculosis, other deep mycoses, syphilis, brucellosis, sarcoidosis
and neoplasm (primary or metastatic). Investigations such as treponemal serology
and neuroradiological imaging may help clarify the diagnosis in some instances, but
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often positive exclusion and diagnosis by appropriate sampling and culture is the
only way to be reasonably sure of the aetiology, and to exclude other pathologies.
1.15 Treatment
1.15.1 Early days
Prior to the discovery of amphotericin B and its commercial availability,
cryptococcal meningitis was always fatal. Now after over 35 years experience with
amphotericin B it is a curable infection (Sarosi et al. 1969). Previously, various
remedies were tried without notable success. These included iodides, penicillin,
sulphanilamides, X-ray therapy, hyperthermia and acriflavine but all were
unsuccessful. These are reviewed by Cox and Tolhurst (Cox and Tolhurst, 1946)
who included an account of immune rabbit serum delivered intraspinally (Shapiro
and Beal, 1925). This treatment was discontinued after a possible allergic reaction
to the serum. In 1946 Cox and Tolhurst described 12 cases of torula meningitis
from southern Australia. Four of these were treated with parenteral autogenous
torula vaccine and in two patients it is possible that a temporary remission was
induced. Recently this mode of therapy has been revisited by an account of two
patients treated with serum therapy in 1963 (Gordon and Casadevall, 1995). This
account has highlighted the possibilities of immunotherapy and we now are at a
point where vaccine and cytokine therapy are becoming feasible. A recent trial
using GM-CSF as adjunctive therapy to amphotericin B in AIDS has suggested that
CSF sterilisation is accelerated in the presence of GM-CSF (Torres, C. et al. 1993).
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As knowledge and technology advance these cytokines may become real options in
therapy.
Before the advent of AIDS, treatment of cryptococcal meningitis with amphotericin
B alone was successful in 60-70% of cases (Bennett et al. 1979; Dismukes et al.
1987; Sarosi et al. 1969; Utz et al. 1975). Once flucytosine became available and
was given concurrently, success rates rose even further (Bennett et al. 1979). In
recent years the triazoles fluconazole and itraconazole have become available and
been successfully used in therapy for cryptococcal meningitis. Their relatively low
host toxicity, oral bioavailability and attractive pharmakocinetics have lead to
popularity with clinicans and their patients, although amphotericin B with
flucytosine remains the gold standard treatment. The optimal conditions for triazole
administration remain to be defined. Lipid associated formulations of amphotericin
B may have a place given their low toxicity. Finally there are intriguing reports of
the clinical use of garlic treatment and recently echinocandins and pneumocandins
in fungal disease, but their role remains to be defined for cryptococcal meningitis.
Possible regimens are discussed in 1.15.5 below.
71
1.15.2 The antifungal agents
1.15.2.1 Amphotericin B
Derived from Streptomyces nodosus, this antifungal is lipophilic and rodlike, acting
by insertion into the fungal cytoplasmic membrane (Balakrishnan and Easwaran,
1993). It binds to sterols in the membrane such as ergosterol, increasing membrane
permeability resulting in loss of intracellular potassium (Hsu and Burnett, 1993).
This and other molecules are lost and fungal viability is impaired. Amphotericin B
deoxycholate is administered to patients in 5% dextrose over 2-4 hours. In serum
the deoxycholate separates from the amphotericin B, 95% of which binds to serum
proteins, presumably bound to cholesterol in such proteins. Degradation occurs in
situ, with a small percentage of the drug being excreted in bile and urine. (Block et
al. 1974; Craven et al. 1979). Levels are not influenced by hepatic or renal failure.
It has been found that with either normal or inflammed meninges penetration is
poor.
The glomerular filtration rate is decreased by amphotericin B in a dose dependant
fashion caused by a vasoconstrictive effect on afferent renal arterioles, which
reduces glomerular and renal blood flow (Sawaya et al. 1991) Other renal effects
are potassium and bicarbonate wasting and reduction in erythropoetin synthesis.
Permanent destruction of renal tubular cells and loss of nephron units is related to
the total dose of amphotericin B. Some clinicians give a litre of normal saline daily
which may reduce nephrotoxicity in some patients (Branch, 1988). Due to the
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marked potassium losses oral or intravenous replacement is required to prevent
hypokalaemia.
As amphotericin B is infused patients may experience chills, fever and tachypnoea
which wane over 2-4 hours. Such reactions do not constitute anaphylaxis and are
not contraindications for further administration, as they become milder with further
infusions. The reactions are less frequent in children and patients on adrenal
corticosteroids and may be reduced by premedication with oral paracetemol or 25-
50mg hydrocortisone (Bennett, 1995).
There are three lipid associated formulations of amphotericin B licensed in the
United Kingdom. Amphotericin B colloidal dispersion (Amphocil) contains
cholesterol sulfate, amphotericin B lipid complex (ABLC, Abelcet) is a complex
with lipid and liposomal amphotericin B (Ambisome) is a unilamellar liposome
containing lipid. These have all been used in the treatment of cryptococcal
meningitis (Begue and Lindo-Soriano, 1991; Hostetler et al. 1992; Leenders et al.
1997). In addition to these formulations some hospitals have mixed amphotericin B
with Intralipid (Pharmcia and Upjohn), a parenteral fat emulsion (Joly et al. 1996).
These new formulations have rarely been compared directly with amphotericin B.
One recent randomised trial in patients with AIDS and cryptococcal meningitis
suggested that initial treatment with Ambisome 4mg /d was as effective and less
toxic than with amphotericin B 0.7mg/d (Leenders et al. 1997). Lipid associated
preparations are generally accepted to be less toxic, allowing tolerance of higher
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doses, however their efficacy over amphotericin B has not been proven. There is
considerable uncertainty over their place and little doubt of their higher cost.
1.15.2.2 Flucytosine
Flucytosine is also known as 5-fluorocytosine (5-FC) and acts as a pyrimidine
antagonist. It was originally synthesized as an antitumour agent, but was
unsuccessful in this role. Screening revealed that it had antifungal effects which is
now its only clinical indication. The fluorine analogue of cytosine, a normal body
constituent, it is thought to be deaminated to 5-fluorouracil (5-FU) and then
converted to a noncompetitive inhibitor of thymidylate synthetase, which interferes
with DNA synthesis (Diasio et al. 1978). It is well absorbed orally, with 90% being
exceted in the urine with minimal protein binding (Block et al. 1974). CSF
concentrations are about 74% of those in the serum, while peritoneal and
haemodialysis remove flucytosine from the body. Hepatic dysfunction does not
influence half life, but in renal impairment this may be considerably prolonged.
Toxicity is relatively rare, and includes rashes, diarrhoea and in up to 5% hepatic
dysfunction in patients with otherwise previously normal gastrointestinal, renal and
haematological function. In patients who have renal failure or are receiving
concurrent amphotericin B, marrow suppression and enterocolitis may occur,
especially if flucytosine levels in blood exceed 100-125 p/ml (Stamm et al. 1987).
Those experiencing marrow or gastrointestinal toxicity often tolerate lower doses.
In rats flucytosine is teratogenic and should not normally be used in pregnancy in
humans.
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The use of flucytosine alone usually leads to secondary drug resistance with
associated clinical failure, so use in combination with amphotericin B is the norm.
These two agents are at least additive in vitro and in mice infected with Candida
and Cryptococcus sp. (Medoff et al. 1971; Polak, 1978). Using them together
prevents the emergence of flucytosine resistance and permits the effective use of
lower and less toxic doses of amphotericin B These benefits and the combined
efficacy have been confirmed in large multicentre trials of cryptococcal meningitis
treatment (Dismukes et al. 1987).
1.15.2.3 Triazoles
A number of organic compounds have acquired antifungal activity with the addition
of an imidazole ring. N-substitution of such imidazoles generates the family of
triazoles, which have less effect on human sterol metabolism. They inhibit the 14-a
-methylation of lanosterol in fungi by binding to a cytochrome P-450 enzyme. This
results in reduced production of ergosterol, essential for normal fungal cytoplasmic
membrane. P-450 enzyme inhibition can lead to disruption of Cortisol and
testosterone in mammals and so selection of antifungals which affect fungal sterol
synthesis at much lower concentrations than mammals is an important aspect of
triazole drug development. Miconazole was used for treatment of cryptococcosis
but its role has been taken over by the newer triazoles. Ketoconzole was initially
used for deep fungal infection. Standard doses alone have not been effective in
treating cryptococcal meningitis although it may have a role in non meningeal
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cryptococcosis (Dismukes et al. 1983). It has largely been superceded by
fluconazole and itraconazole.
1.15.2.3.1 Fluconazole
This triazole is well absorbed form the gastrointesinal tract, with over 80%
bioavailability (Zervos and Meunier, 1993). Some 60-75% of the oral dose is
excreted in the urine and 8-10% in the faeces. Eleven percent of the serum
fluconazole is protein bound with the CSF concentration being 70% of that found in
serum, whether or not the meninges are inflamed. Penetration into other body fluids
is also excellent (Zervos and Meunier, 1993). The levels of phenytoin, glypizide,
tolbutamide and cyclosporin are increased by fluconazole, while rifampicin lowers
the fluconazole blood levels by a quarter (Weinroth and Tuazon, 1993b). Rarely are
there side-effects. These occur in less than 5% of cases and may include nausea,
abdominal pain, diarrhoea, vomiting and rash (Perfect et al. 1992). There is
uncertainty whether hepatic necrosis may have occurred in patients on fluconazole
and alopecia has been reported in those on doses of 400mg daily or higher
(Weinroth and Tuazon, 1993). There is no evidence of teratogenicity in rabbits.
Oral and intravenous preparations are available for use in fungal infections.
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1.15.2.3.2 Itraconazole
At present only oral formulations are available, a suspension has recently been
licensed in the United Kingdom with a higher bioavailability than the capsule. Oral
absorption is increased in the presence of food (Barone et al. 1993) giving a
bioavailability of 55% following breakfast. In the presence of a raised gastric pH as
with antacids, IT> blockers and proton pump inhibitors absorption is substantially
impaired (Lim et al. 1993). It is 99% bound to serum proteins, metabolized in the
liver and excreted in faeces as metabolites, with no active drug present in the urine.
Plasma concentrations are unaffected in renal impairment and dialysis. In tissue
itraconazole concentrations are generally higher than in plasma, but in CSF they are
generally unmeasureable.
Dose related nausea and abdominal discomfort rarely are severe enough to require
stopping therapy and may be reduced by dividing the daily dose. At doses of 400mg
daily hypokalaemia and oedema may become evident and an allergic rash is seen
occasionally. There does not appear to be hepatotoxicity, but itraconazole is
contraindicated during pregnancy and lactation.
Aside from the gastric interactions mentioned above, itraconazole has a number of
other clincially significant drug interactions. Levels of itraconazole may be
decreased by rifampicin, phenytoin and carbamazepine, while rifampicin levels are
themselves reduced by itraconazole. The antifungal can increase levels of
cyclosporin, digoxin, terfenadine, astemizole and loratidine. The latter three are
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new non sedative antihistamines; accumulation of these may result in life-
threatening torsades de pointes (Crane and Shih, 1993).
Itraconazole has a role in treatment of blastomycosis and histoplasmosis (Dismukes
et al. 1992), and has been given for indolent cases of invasive aspergillosis (Jennings
and Hardin, 1993) and cryptococcal meningitis in AIDS patients (Cleary et al.
1992), but controlled comparisons with amphotericin B have not been carried out.
1.15.2.4 Others
1.15.2.4.1 Garlic
There are clinical reports of garlic (Allium sativum) use in the treatment of
cryptococcal meningitis, both alone (Anonymous, 1980) and in conjunction with
amphotericin B (Tjia et al. 1985; Yu et al. 1988; Davis et al. 1990). There are
though no trials reported of garlic treatment in humans. Low concentrations of
Allium sativum extract are inhibitory and lethal to numerous strains of (untyped) C.
neoformans (Fromtling and Bulmer, 1978). In vitro combination of amphotericin B
and diallyl trisulphide (a Chinese commercial garlic preparation) demonstrated
synergistic activity against C. neoformans (Shen et al. 1996). Used alone in mice
oral garlic reduced brain cryptococcal burden, but did not achieve complete
eradication (Louria et al. 1989). In humans commercial Allium sativum extract
given intravenously to 5 patients with cryptococcal meningitis lead to a doubling of
plasma anti C. neoformans activity and detectable activity in 4 of 5 CSF samples
(Davis et al. 1990). There was no activity in pooled normal CSF.
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1.15.2.4.2 Echinocandins and pneumocandins
Echinocandins and pneumocandins, new classes that target the fungal cell wall, are
in clinical development. Recently in an in vitro study of activity against fungi,
echinocandins were found to be inactive against C. neoformans (Zhanel et al. 1997).
1.15.2.4.3 Cytokine therapy
In paediatric AIDS human recombinant GM-CSF has been used inconjunction with
liposomal amphotericin B to good effect and neutrophils from patients with AIDS
exhibit increased in vitro C. neoformans killing (Manfredi et al. 1997a; Vecchiarelli
et al. 1995a). Therefore in some circumstances cytokine therapy may be a useful
adjunct to treatment.
1.15.3 Susceptibility testing
Initial isolates of C. neoformans generally have low minimum inhibitory
concentrations (MICs) to amphotericin B, flucytosine and the azoles (Ghannoum et
al. 1992). Various methods of sensitivity testing have been proposed, with problems
in reproducibility of results even between laboratories using identical methods. In
the United States a method using broth macrodilution for yeast testing using
standardized media, inocula, and endpoint determinations has been proposed
(Espinel-Ingroff et al. 1992; National Committee for Clinical Laboratory Standards.
1992). In RPMI, some strains of C. neoformans do not grow well and require 48-72
hours incubation before final MIC determination can be made. Microtitre methods
have also been developed using BYNB-7 medium (Ghannoum et al. 1992). It is
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hoped that as experience grows with MIC testing in vitro for C. neoformans, it will
become useful in guiding clinical decisions.
Less than 2% of C. neoformans strains are resistant to flucytosine and a rising MIC
in isolates correlated with clinical relapse in early studies where flucytosine was
used alone for treatment of cryptococcal meningitis and pulmonary cryptococcosis
(Utz et al. 1972; Kerkering et al. 1981).
The MICs of amphotericin B to clinical isolates are low and show little variation.
Rare cases have been resistant in vitro (Bodenhoff, 1968). It appears that with
current treatment regimens failure has not been linked to polyene resistance even in
heavily immunosuppressed patients.
The use of azoles in treatment of fungal infections has accelerated with the AIDS
epidemic. In vitro activity against primary isolates is usual. With widespread use of
azoles in such patients, isolation of resistant Candida species have predicted clinical
failure. Clinical relapses of patients on cryptococcal therapy have not generally
been linked to more resistant isolates (Casadevall et al. 1993). In this study
sequential isolates from patients with relapsed cryptococcal meningitis were no
more resistant than the initial isolates. Molecular typing of the sequential isolates
has indicated that these were relapses rather than reinfections (Spitzer et al. 1993).
Often the waning immunity of the AIDS cases has been the most important factor in
relapse, although in some instances difficulties in compliance may play a role.
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Recent case reports correlating clinical relapse with a rising MIC of fluconazole in
AIDS associated cryptococcal meningitis describe rises in MIC from 4 to >64mg/ml,
16 to 128mg/ml and <0.25 to 16 mg/ml (Paugam et al. 1994; Birley et al. 1995). It
has been suggested that the reason why this clinical failure linked to resistant
isolates occurs infrequently is because the azole resistant strains may be less virulent
than the wild-type strains (Iwata et al. 1990).
It would appear that virtually all primary isolates of C. neoformans are susceptible
to the antifungals used in clinical practice. However it is probably worth storing
such isolates so that they can be compared with any future isolate in case of relapse
(Mitchell and Perfect, 1995). In such cases an increase of MIC >4 fold would
suggest that relapse is related to drug resistance and so a new drug regimen
indicated (Mitchell and Perfect, 1995).
Combination testing of antifungal drugs in vitro is even less well standardized for C.
neoformans than for single agents. Overall it is suggested from in vitro and in vivo
studies that a beneficial interaction occurs with flucytosine and azole, amphotericin
B with flucytosine, azole, rifampicin, and triple combination of amphotericin-
flucytosine -azole. (Borgers and Van de Ven, 1987; Polak et al. 1982). Antagonism
has not often been found in vitro in such combinations.
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1.15.4 Animal Models
Most of the above observations on sensitivity testing have been made in vitro, but
animal models form an important bridge between drug screening and use in human
trials. The mouse model has been widely used as mice are genetically stable, their
immunology has been well described and most strains are extremely susceptible to
disemminated infection as are immunocompromised patients. Infection has been
introduced by intrarespiratory, intravenous and intracerebral routes allowing
antifungal agents to be tested and compared. Immune based treatments can also be
tested in such models, such as TNF-a and GM-CSF (Collins and Bancroft, 1992).
Rabbits have been used as a model of cryptococcal meningitis which closely
parallels infection in humans (Perfect et al. 1980). In the sphere of antifungal
treatment low levels of CSF amphotericin B and itraconazole have been found in
both rabbits and human cryptococcal meningitis, yet clinical success has followed
treatment using both agents (Perfect and Durack, 1985; Denning et al. 1989). These
findings suggest that the action of these drugs is similar in both rabbits and humans
and gives confidence in the rabbit as an appropriate model.
1.15.5 Antimicrobial treatment of cryptococcal meningitis in humans
The aim of treatment is to treat symptoms and signs and suppress or eradicate
infection. In the immunosuppressed patient the outcome depends on the underlying
immunosuppression. If immunosuppression cannot be reduced patients must remain
on lifetime prophylactic therapy, while in the immunocompetent the aim is to
eradicate infection and allow survival off therapy. Based on studies carried out in
areas where C. neoformans var. gattii is rare, the initial treatment of choice in
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immunocompetent patients has been a 6 week course of amphotericin B
(0.3mg/kg/day) and flucytosine (150mg/kg/day) (Bennett et al. 1979). The study on
which this regime is based was carried out in the pre AIDS era and with the advent
of AIDS, therapy has evolved further.
In AIDS patients in the United States a randomised trial of higher dose amphotericin
B (0.7 mg/kg/d with or without flucytosine (100 mg/kg/d) over 2 weeks followed by
fluconazole (400 mg/d) or itraconazole (400 mg/d) concluded that amphotericin B
and flucytosine is associated with an increased rate of cerebrospinal fluid
sterilization compared with earlier studies (van der Horst et al. 1997). A subsequent
trial to evaluate the role of these two azoles in maintenance therapy using 200 mg/d
after successful acute treatment was stopped due to significantly more relapses in
the itraconazole arm. Analysis of the data showed that lack of flucytosine during the
initial two weeks of therapy was more predictive of relapse than any other factor,
including itraconazole maintenance therapy. Many investigators suspected that
initial better clearance of the organism is achieved when flucytosine is used during
the first two weeks (van der Horst et al. 1997). Currently amphotericin B in
combination with flucytosine for 2 weeks, followed by fluconazole 400 mg/d for 8
weeks (reduced to 200 mg/d thereafter) is considered the treatment of choice.
Itraconazole is an acceptable alternative treatment for those intolerant of
fluconazole, followed by maintenance dose of 400 mg/d. Attention must also be
given to reducing raised intracranial pressure, which is associated with a poor
outcome (van der Horst et al. 1997). In AIDS patients without poor prognostic
indicators, fluconazole 200-400 mg/day has been shown to be as effective as
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amphotericin B 0.4-0.6 mg/kg/day (Saag et al. 1992). Fluconazole combined with
flucytosine for oral treatment of cryptococcal meningitis in AIDS has given
promising results and triple therapy with these two agents and amphotericin B is
also reported to have a good outcome when compared with amphotericin B and
flucytosine (Larsen et al. 1994; Just-Nubling, 1996).
In patients with features associated with a good prognosis at presentation (headache,
normal mental status, CSF leukocyte count of >20/mm3, pretreatment serum
cryptococcal antigen titres of <1:32 and post treatment serum and CSF cryptococcal
antigen titres of <1:8) up to 88% of patients without immunosuppression will
respond to four weeks of therapy (Dismukes et al. 1987). Where possible,
flucytosine levels should be monitored.
In immunocompetent and var. gattii cryptococcosis there are no trials comparing
treatments. In vitro studies comparing susceptibilities of the two varieties to
different antifungals have shown largely similar sensitivities, although one showed
diminished var. gattii sensitivity to flucytosine (Ellis and Pfeiffer, 1992; Shadomy et
al. 1987; Fromtling et al. 1986). It has been suggested that in immunocompetent
patients with C. neoformans var. gattii infection, cerebral cryptococcomas or dilated
ventricles, a longer course of amphotericin B with flucytosine therapy was required
than in immunosuppressed patients (Mitchell et al. 1995). The role of azoles
especially in immunocompetent patients is uncertain.
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Liposome associated amphotericin B preparations with reduced toxicity have been
reported to be efficacious in doses of 3-5 mg kg/day and may have a role where
nephrotoxicity is problematical (Schurmann et al. 1991). If host
immunosupppression cannot be significantly reduced, life-long maintenance therapy
is required to prevent relapse, as in those patients with AIDS.
In practice, treatment and maintenance must be carefully tailored to each individual,
depending on severity of disease and underlying host status, with aggressive
management of raised intracranial pressure (van der Horst et al. 1997).
Reports of garlic use in the tropics and China are intriguing. There is a report of
oral and intravenous garlic preparations alone curing 6 of 21 patients of central
nervous system cryptococcosis in China, and of concurrent use of garlic tablets with
amphotericin B and flucytosine in 13 patients in Singapore (Anonymous, 1980; Tjia
et al. 1985). In another study of two patients with cryptococcal meningitis
anticryptococcal activity rose following an infusion with commercial allium sativum
(garlic) extract (Davis et al. 1990). The biotypes of the Chinese strains are
unknown, whilst in tropical centres where garlic has been used it is likely that var.
gattii predominates. Perhaps this biotype is particularly sensitive to garlic, or garlic
enhances immunity explaining its apparent therapeutic success. Garlic is both cheap
and readily available even in less wealthy countries so exploration of its role in
treatment of cryptococcosis an attractive avenue of research.
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Cytokine therapy may also prove to have a role - there is a preliminary report of
clinical use of GM-CSF in conjunction with amphotericin B that has given
encouraging results (Torres, C. et al. 1993).
1.15.6 Adjunctive measures
Apart from antifungal drug therapy, adjunctive measures may also be appropriate.
Wherever possible early treatment of raised intracranial pressure (ICP) is probably
important. This can be achieved by repeated lumbar puncture, use of
acetazolamide, shunting and nerve sheath fenestration as available, and may prevent
blindness (Lipson et al. 1989; Denning et al. 1991a; Johnston et al. 1992). It has
been suggested that the low mortality rate in one study (5.5% in the first two weeks
and 3.9% in the next eight weeks), as compared with other large, randomized trials,
was helped by such careful management of elevated intracranial pressure (van der
Horst et al. 1997). This serious complication of cryptococcal meningitis occurs not
only in patients with AIDS, but also in immunocompetent individuals. The place of
short-term steroid therapy in reducing ICP, inflammation and oedema is uncertain
(Rex et al. 1993; Denning et al. 1991b). There is no clear evidence that surgical
removal of cerebral cryptococcal mass lesions is required.
For infection outside the central nervous system there is no standardised therapy,
although depending on site and degree of immunosuppression, amphotericin B is
usually included in the regime prescribed, except in patients with pulmonary
cryptococcosis alone, where in the immunocompetent careful observation is a
reasonable course to follow.
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1.15.7 Outcome
The outcome of infection reflects the ease with which any underlying disease can be
controlled. In a retrospective study of patients with AIDS and neoplastic disease
there was a median survivial of 9 months and 2 months respectively (White et al.
1992). In all areas the mortality of cryptococcal meningoencephalitis is high,
ranging from 9.4 to 60% (Diamond and Bennett, 1974; Slobodniuk and Naraqi,
1980; Fisher et al. 1993; Gould and Gould, 1985; Tay et al. 1972; Tjia et al. 1985;
Spickard et al. 1963; Kerkering et al. 1981; van der Horst et al. 1997) perhaps higher
in the tropics due to later presentation, lack of resources for optimal management or
possibly more common var. gattii infection. Hydrocephalus contributes to this
mortality, with the reported incidence varying from 6.6% to 74% (Diamond and
Bennett, 1974; Diamond, 1995; Gould and Gould, 1985; Tjia et al. 1985; De Wytt et
al. 1982). Even amongst survivors the morbidity is considerable with visual loss,
chronic brain syndrome, motor impairment and unresolved cranial nerve palsies (De
Wytt et al. 1982; Diamond and Bennett, 1974).
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1.15.8 Prevention
There is no evidence that occupational exposure to a particular potential source
leads to infection, though similar isolates have been found in both patients and the
environment (Currie et al. 1994). It would seem reasonable that immunosuppressed
patients in particular should avoid undue exposure to avian dropppings, but given
the apparent rarity of var. gattii infection in AIDS and other immunosuppressed
patients, there is no evidence to support a particular recommendation for these
patients to avoid eucalyptus trees. It might be that if var. gattii is found consistently
in the environment during flowering of such trees, it would generally be advisable to
avoid exposure at such certain times of the year.
Human immunisation with C. neoformans GXM conjugated to tetanus toxoid has
produced antibody that improved survival in mouse cryptococcosis when used for
passive immunization (Devi et al. 1991; Williamson et al. 1993). In the future it
may be possible to develop a vaccine to protect those with HIV infection in
particular. As antifungals are used in AIDS patients for other indications, the
incidence of cryptococcal meningitis may fall, as has been found in patients treated
with fluconazole for mucocutaneous candidiasis (Powderly et al. 1995; Manfredi et
al. 1997b).
88
1.16 Papua New Guinea
1.16.1 Introduction
Papua New Guinea (PNG) is comprised of a diverse group of islands lying between
1 and 12 degrees south of the Equator, lying at its closest point some 160km north of
Australia across the Torres Strait. The main land mass of New Guinea is divided
into Irian Jaya (under Indonesian control) and PNG. The country is spread over an
area 1000 kms by 1500 kms, much of which is water, being bounded on the north by
the Bismarck Sea, on the west by the Solomon Sea and on the south by the Coral
Sea (Plate 1.3)
The main islands rise to 2,000 metres whilst on the main land mass of PNG there is
a massive central spine of mountains, the Owen Stanley Ranges, which rise to 4,509
m at their highest point within PNG, Mount Wilhem, which at times is snow capped.
The geographical situation of the county, with the variations in altitude, contribute
to a wide range of climatic conditions, which allow a diverse flora and fauna to
flourish. Included in this are thirty eight species of bird of paradise and two thirds
of the world's orchids.
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Plate 1.3 Map of Papua New Guinea
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The population is 3,529,538 growing at a rate of 2.4% per year (1990 Census),
which speaks over 700 languages, 45% of all the languages in the world
(Anonymous, 1993a). The principle lingua franca is Pidgin English, with English
being in use in the urban centres and for international communications. There are
strong ties between those from the same village who therefore speak the same
language and are known as 'wantoks' ("one talk!"). Owing to the difficulty of travel
and communication, many villages have only had contact with the outside world for
a few decades; there are still occasional reports of a 'new' group being discovered by
those 'on patrol'. The people are of Melanesian origin, and traditionally subsist by
hunting, fishing and gardening with some local and coastal trade. In some fertile
valleys in the mountainous areas there have been attempts to introduce cash crops
such as coffee and in the recent past coastal areas exported copra. There is now a
burgeoning bureaucracy in the main centres and exploitation of natural resources
such as timber, gas, gold, copper and platinum, which is resulting in literally
explosive changes.
Port Moresby is the Capital of PNG and lies within the National Capital District
(NCD), bounded by the Coral Sea and Central Province (CP) in the southern,
Papuan region of the country. PNG became independant in 1974, having been an
Australian protectorate. It has a democratically elected parliament in Port Moresby,
with local governments in each Province. The head of state is Queen Elizabeth II of
Great Britain ('Missis Kwin') who is highly regarded. Rather impractically for a
capital, Port Moresby has no road links outwith NCD and CP, requiring travel by air
or sea to reach other provinces with any ease. Within the Capital, crime flourishes,
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related to unemployed migrants in search of cash earnings and the excesses of
alcohol. This is relatively unencumbered by effective policing. Many 'expatriates',
especially those in High Commissions and Embassies are fenced within mini-
fortresses guarded by alarms, dogs and barbed wire. Some of the 'rural migrants'
live in settlements in and around Port Moresby without access to adequate housing
and water facilities. As a result communicable disease such as tuberculosis, typhoid
and diarrhoeal disease are endemic in these areas.
The University of Papua New Guinea (UPNG) is based in Port Moresby and
includes a Faculty of Medicine at the teaching hospital, Port Moresby General
Hospital (PMGH). Students from all over PNG and the western Pacific attend this
Faculty which has National Papua New Guinean and expatriate staff. PMGH is a
tertiary referral hospital for PNG with 600 beds serving local populations of 193,242
in the NCD and 140,584 in CP. There are 12,000 admissions per annum, with
microbiological, haematology and pathology laboratories on site. In addition to
communicable diseases, conditions such as cardiovascular disease and diabetes
mellitus are becoming more prominent reflecting changing life-styles, particularly in
the urban centres. Most health care in PNG is provided by Aid Post workers and
Health Extension Officers with doctors in the major centres and mission/volunteer
hospitals. Traditional healers are also frequently consulted as many afflictions are
thought to have social and spiritual roots. Occasionally patients 'abscond' from
hospital or default from clinics to attend these healers.
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1.16.2 Cryptococcal meningitis in Papua New Guinea
The pattern of cryptococcosis in PNG is largely consistent with that already
outlined. The first recognition of cryptococcosis in PNG was by Backhouse,
described by Cox and Tolhurst (Cox and Tolhurst, 1946). Here a "torula collection"
in the lung is mentioned at post mortem in a New Guinean patient. Meningitis was
first reported in a Melanesian male from Morobe Province, but who had been
working in East New Britain (Champness and Clezy, 1962). His initial complaints
were respiratory, but he then developed signs of meningitis and was found to have a
lymphocytic CSF with low sugar levels. Despite subsequent anti-tuberculous
therapy he died and brain sections examined at the School of Tropical Medicine,
Sydney, showed cryptococcal forms with mucicarmine staining capsules, consistent
with Cryptococcus neoformans. At Port Moresby General Hospital two patients
with cryptococcal meningitis were reported out of 2000 consecutive admissions in
1965 and then in a review of deep mycoses in Australia and New Guinea in 1970, a
case reported by Hickie and Walker in 1964 is mentioned (Campbell and Arthur,
1964; Frey and Durie, 1970). The next report in the literature is of a 30 year old
male from Madang Province also working in East New Britain (Kariks, 1967). He
presented with chronic headache, papilledema and a solitary chest Xray lesion.
Lumbar puncture showed a raised CSF pressure of 30cm and lymphocytosis, but
Gram and Ziehl-Neelsen stains were negative. He was treated for tuberculosis but
died shortly afterwards. Autopsy demonstrated cryptoccoci in the brain and lung
(Kariks, 1967).
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In 1980 Slobodnuik and Naraqi described the first series from Papua New Guinea of
13 adult cases occurring between 1972 and 1978 (Slobodniuk and Naraqi, 1980).
These patients with cryptococcal meningitis were mainly young adults all of whom
were apparently immunocompetent. This study showed that cryptococcal
meningitis was the commonest form of chronic meningitis in adults, tuberculous
meningitis being second. Mortality was 60% and attributed to frequent
misdiagnosis of tuberculous meningitis in an area with a high incidence of
tuberculosis.
A report on neuropsychiatric aspects of cryptococcal meningitis in PNG was made
in 1980 indicating its presentation as an acute organic psychosis (Andrew and
Burton-Bradley, 1980). In 1987 129 cases diagnosed as having cryptococcal
meningitis between 1978-87 were noted (Temu et al. 1987). This was largely on the
basis of laboratory data, including results of antigen testing on sera received from
other hospitals in PNG. The apparent increase in incidence of cryptococcosis
probably reflects an increasing awareness of the disease, and the availability of
cryptococcal latex antigen testing of CSF, serum and urine. Up to this point no CSF
isolates from PNG had been biotyped but by 1984 it was recognised that the
distribution of the two biotypes of C. neoformans varied, with var. gattii
predominating in tropical and subtropical regions and var. neoformans being found
in all regions (Kwon-Chung and Bennett, 1984). When six biotyped isolates from
apparently immunocompetent individuals presenting at PMGH were reported in
1990, five were shown to be var. gattii and one var. neoformans, suggesting that this
geographical distribution holds true for PNG (Currie et al. 1990).
94
There is also evidence for non human sources of cryptococci in PNG. C.
neoformans has been reported as the cause of mastitis in cattle (Anonymous, 1965).
Then in 1984 pulmonary cryptococcois in a rat in Rabaul, East New Britain was
described (Scrimgeour and Purohit, 1984). Mucicarmine and immunofluorsence
stains confirmed the cause of cystic pulmonary lesions to be C. neoformans. They
sugggested that the rat may have a role in transmission of cryptococcosis to humans
as it sometimes nests in the rooves of houses. The only confirmed isolation from the
environment was again in Rabaul when a soil suspension was injected
intraperitoneally into a mouse and the C. neoformans identified in the mouse (Frey
and Durie, 1964). This was prior to the differentiation of the two varieties of C.
neoformans.
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Since the studies cited above, further work to be described in this thesis has been
carried out in PNG as well as Edinburgh. The aims of the studies described in this
thesis were to:
1) Identify potential environmental sources of C. neoformans in PNG.
2) Attempt to isolate the yeast from such sources.
3) Investigate the epidemiology of C. neoformans meningitis in PNG.
4) Describe the clinical features of a prospectively observed series of cryptococcal
meningitis cases in PNG.
5) Study human-neutrophil cryptococcal interactions.
6) Highlight the need for appropriate culture in addition to microscopy and latex
antigen testing of CSF in order to diagnose cryptococcoal meningitis. An apparently
acapsulate isolate was studied in part using the human neutrophil-cryptococcal
assay.
These studies were carried out in PNG and Edinburgh and are described in this
thesis. They have formed the basis for further observations in PNG subsequently
made by Seaton and other colleagues, which will be alluded to in the discussions.
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CHAPTER 2
Potential environmental sources of
Cryptococcus neoformans in PNG:




The flora and fauna of PNG are diverse. The dominant influences come from
Australia, although much has not been assessed by systematic specialists. As
discussed by Slater, there are no large mammal predators and the largest indigenous
mammals are marsupials (Slater, 1959). Differences from related species
elsewhere have arisen over long periods of geographical isolation. For example the
flying phalanger (.Petaurus breviceps papuana), a type of possum, agile wallaby
(.Protemnodon agitis papuana) and tree kangaroo (Dendrologus goodfellowi
shanmayeriari) are endemic to PNG, whereas the airborne spectacled fruit bat
(Pteropus conspici/latus) is found both in Australia and New Guinea.
The scope of birds is less constrained than that of land-based animals, but there are
none-the-less unique adaptations in those with reduced range extension imposed by
exacting environmental limitations. These limitations include tolerance to climatic
conditions, altitude and vegetation and the degree of efficiency and power of flight.
Within such constraints the flightless Cassowaries (Casuarius spp), and spectacular
crowned pigeons (Goura spp) have evolved.
The reptilian populations again reflect the proximity to Australia in the sub-specific
variations including the taipan (Oxyranus scutellanus canni), death adder
(Acanthopis antarticus), New Guinea Crocodile (Crocodilus novaeguineae) and
Estuarine Crocodile (C. porosus). The range of the Viperidae family stops west of
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New Guinea, which is the 'citadel' of the front fanged venomous snakes of the
family Elapidae.
The vegetation of the island of New Guinea is also complex and varied. In lowland
areas there is tropical jungle, inundated with large quantities of water, and adjacent
well drained areas with lower rainfall, resulting in savannah with sparse trees and
shrubs. At higher altitudes, from 1000 to 2200 metres there is sub tropical forest,
with temperate and then alpine areas in the highest ranges. The genus Eucalyptus
can thrive from sea-level to temperate areas, depending on the species, soil, position
and amount of precipitation. Typical savannah near Port Moresby is shown in Plate
2.1.
2.1.2 Ecology of Cryptococcus neoformans
C. neoformans var. neoformans has been found in close association with avian,
particularly pigeon, droppings and soil associated with such droppings, since
Emmons first report in 1951 (Emmons, 1951; Emmons, 1955). Since this time a
similar link has been confirmed in many parts of the world. Staib showed that C.
neoformans utilised creatinine as a nitrogen source, but other species of
Cryptococcus did not (Staib, 1962b). Var. gattii, which does not occur in pigeon
droppings actually utilises creatinine better as a nitrogen source than var.
neoformans (Bennett et al. 1978), so it would seem unlikely that creatinine use is
important in determining the ecological differences between the two varieties.
99
Plate 2.1 Typical savannah outside Port Moresby
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Whether the infectious propagule of C. neoformans is the asexual or sexual form is
uncertain. The basidiospores of Filobasidiella neoformans are dry, may be present
in air and are small enough (1.8 - 3jam diameter) to be deposited in the alveoli.
Desiccated yeasts may also be small enough to reach the alveoli following
inhalation. Perhaps the reservoir for this form is on plant matter rather than in avian
droppings. This was suggested by Ellis and Pfeiffer following their discovery of var.
gattii in association with flowering Eucalyptus camaldulensis (Ellis and Pfeiffer,
1990a; Ellis and Pfeiffer, 1990b). They proposed that the distribution of var. gattii
disease reflects that of the natural host of this fungus, initially suggesting that the
countries to which E. camaldulensis had been exported were those in which C.
neoformans var. gattii could be found causing human meningitis. They pointed out
that the koala, which feeds on eucalypts develops cryptococcosis (Bollinger and
Finckh, 1962) and they were able to isolate this variety from koalas (Ellis and
Pfeiffer, 1990a). Currie et al. suggested that E. camaldulensis was not the source of
var. gattii in PNG as it is not indigenous here (Currie et al. 1990). As discussed
already, cryptococci had previously been found causing bovine mastitis, rat
pulmonary infection and in soil within PNG.
Against this background investigation of potential environmental sources of C.
neoformans was begun. The aim was to identify potential sources of C. neoformans,
particularly var. gattii in the environment in PNG. Specifically the hypothesis that
Eucalyptus camaldulensis or a similar plant source is associated with C. neoformans
var. gattii in PNG was considered. Birds and mammals would also be identified that
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There are University and National Libraries, both in Port Moresby. These were
helpful sources of reference books on flora and fauna of PNG. In addition at the
main UPNG campus, Waigani, there is a Herbarium adjacent to the Department of
Biology. This contains plant material and documents with species identification,
date and location gathered over many years. The staff in these departments were
interested and helpful in guiding me, particularly Dr Ian Burrows Head of Biology,
Dr Simon Saulei and Mr Max Kuduk. They suggested further discussions with Mr
Neville Howcroft of the Forestry Research Institute who had carried out fieldwork in
many parts of PNG. He was able to give me details of Eucalyptus species derived
samples held at the Forestry Research Institute Herbarium in Lae, Morobe Province.
A further source of information was identified in the library of the Department of
Forests in Port Moresby. Latterly information has been obtained from purchased
published texts and those in the Darwin Library of Edinburgh University.
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2.3 Results
2.3.1 The Genus Eucalyptus
This genus was first described and named by the French botanist L'Heritier in 1788.
He studied specimens probably collected in Tasmania on Cook's third voyage in
1777. Evidence from fossil pollen suggests that ancestral eucalypts existed thirty
million years ago (Costermans, 1994).
Now over 600 species are recognised (authorities vary in their interpretation of
'species'). The genus Eucalyptus is the largest in the family Myrtacae and
indigenous species are largely limited to Australia and nearby islands. Like other
members of Myrtacae they have hard-textured leaves with oil glands and woody
fruit capsules. Most are trees, though some, mainly the mallees, are more shrub
like. They are more common in coastal areas with regular rainfall, but inland are
associated with periodic watercourses and subsoil moisture. Some species, notably
the River Red Gum {Eucalyptus camaldulensis) and Blue Gum (Eucalyptus
tereticornis) have been widely exported (Jacobs, 1979).
In common with other plant groups originating in Australia eucalpyts have an
evolutionary relationship with fire (Jacobs, 1979; Costermans, 1994). They
constantly drop dry leaves and bark flakes, have volatile, flammable oils in the
leaves and combustable wood. Their mechanisms of surviving the effects of fire
vary between species. This depends on insulating properties of the bark, the ability
to produce emergency epicormic buds under the bark, which become new branches
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after the crown of the tree has been burnt out. Also the mallees in particular have
lignotubers which are swellings at the base of the trunk with food reserves and
dormant growth buds which can produce new stems from ground level. Some
species are killed by fire, but the heat causes fruit capsules to open and drop seeds
onto burnt ground, allowing regeneration.
2.3.1.2 Classification and Identification
The genus Eucalyptus can be divided into seven subgenera Blakella, Corymbia
(bloodwoods), Eudesmia, Gaubaea, Idiogenes, Monoclyptus (peppermints, sallees,
stringybarks, ashes), and Symphomyrtus (mahoganies, boxwoods, mallees, gums
ironwoods) (Pryor and Johnson, 1971). These are subdivided into sections, series,
subseries, superspecies, species and subspecies. The 'red gums', section Exsertaria,
are part of the subgenus Symphomyrtus (Pryor and Johnson, 1971). These cannot
survive where ground freezes in winter. Species are distinguished on the basis of
numerous characteristics, notably bark type, leaves (juvenile and adult), buds,
anthers, flowers and fruits. The size of growth, location and geographical
distribution can also give an indication as to the species. Hybridisation may occur
where both parents are or have been in the same area with overlapping flowering
periods and are in the same subgenus. This complicates species idenfication
considerably, even for experts.
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2.3.1.3 Eucalypts occurring naturally in PNG
There are at least 6 indigenous Eucalyptus species in PNG as shown in Table 2.1.
(Jacobs, 1979; Boland, 1957; Saulei and Howcroft personal communication). In the
National Capital District and Central Province, the predominant species are E.
papuana, E. confertiflora and E. alba (Heyligers, 1982). These are shown in Plates
2.2 and 2.3. These species dominate the open grassy woodlands in Central
Province, as well as thriving in Port Moresby itself. The canopy may be up to 16
metres in height. The soils in this region are neutral or mildly acidic; eucalypts are
sparser on alkaline soils. E. alba and E. confertiflora exhibit facultative
deciduousness, with the severity of the dry season determining how much foliage is
shed. They do not regenerate under forest conditions and need fire such as may
occur as a result of thunderstorms to trigger rapid regeneration.
E. tereticornis occurs at altitudes up to 6,000 feet in the Sogeri Plateau, in the
Astrolabe Range and Hombrum's Bluff, inland from Port Moresby, as well as being
present at sea level, particularly south eastwards in Rigo and Abau in Central
Province. Elsewhere in PNG it is found in Northern Province, Western Province
around Daru and the Transfly areas and in eastern Australia from Queensland to
Victoria (Boland, 1957). This species can be wind pollinated, unlike many others.
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Table 2.1 Eucalyptus species indigenous to PNG
Species/Sites Common Name Province Sources of
data
E. confertiflora cabbage gum NCD, Central, Western IFL, FAO,
FRI, Hey,
UPNG
E. papuana ghost gum NCD, Central, Western IFL, FAO,
Hey, UPNG
E. alba white gum NCD, Central IFL, FAO,
Hey, UPNG












E. brassiana Western FRI, FAO
IFL - own observations, FAO - (Jacobs, 1979), FRI - Forestry Research Institute
Herbarium, Lae, Hey - (Heyligers, 1982), UPNG -University of Papua New Guinea




E. deglupta is also found in the eastern parts of Central Province, but is more
commonly found in indigenous sites in the Northern Province, around Oro Bay,
Popondetta. Reliable observers have reported this species at several other sites in
PNG namely Vanimo Sepik, Morobe, Northern and Milne Bay New Britain
(Documents at UPNG Herbarium).
There are many herbarium specimens of E. brassiana at the Forestry Research
Instutue in Lae collected at Daru in Western Province.
It is of interest to note that there are indigenous species of the red gum group
exsertaria, closely related to E. camaldulensis. These are E. tereticornis, E.
brassiana, E. alba and E. papuana.
There is considerable uncertainty over identification or indigeneity of further
species, E. polycarpa (bloodwood) in Western Province, and E. platyphylla to the
east and west ofPort Morsby (UPNG Herbarium documents).
2.3.1.4 Introduced eucalypts and plantations
Skelton, who summarised information from many sources, including the verbal
history of experienced foresters, states that there was little 'serious reforestation'
prior to 1950 in PNG (Skelton, 1981). The earliest plantation documented is of teak
in Madang, which is of doubtful quality and may now be 'contaminated' by
shrapnel. In the early 1950's the natural state of forestry was estimated by aerial
photography and sampling by ground surveyors. Local and national government
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forestry departments tried to establish a number of plantations for experimental and
commercial exploitation. PNG is a 'new' country in developmental and geological
tenns leading to high rates of soil erosion because of steep slopes and ridges. As a
result the rivers carry high silt loads. The upshot of this and periodic fires is that
there are fewer large trees than are seen in Africa and Asia.
Skelton's observations (relating to both government and privately owned plantations
and records) and information from the First Papua New Guinea Silvicultural
Research Conference in 1968 are summarised in Table 2.2. I found no information
on any similar subsequent conference.
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1951 alba acmenoides camaldulensis citriodora
deglupta gigantea grandis micorocorys
muelleriana pilularis robusta saligna scabra








1955 citriodora deglupta grandis camaldulensis
microtheca miniata nisophila paniculata










1976 stjohnii robusta saligna regnans rubida
dalrympleana nitens goniocalyx obliqua





1959 alba camaldulensis citriodora cladocalyx
cloewiana dalrypmleana decasiana
(urophylla) fastigantea globulus grandis
goniocalyx leucoxylon maculata maidenii
marginata mulleriana nitens obliqua
pnalicuate paucijlora pilularis frensns
resinfiera robusta rubida saligna scabia






1958 alba camaldulensis citriodora cladocalyx
cloeziana gigantea globulus grandis
maculata maidenii microcorys ornata







1972 robusta grandis yes, but land
problems




East Sepik 1964 tereticornis grandis deglupta no





1982 grandis robusta stjohnii unknown






Northern (Oro) 1975 tereticornis deglupta not stated
Data summarisec from (Skelton, 1981; Anonymous, 1968).
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There have been additional commerical schemes, but information on these is not
available in any collated form. Since 1950 E. camaldulensis has been planted in
trials at Brown River, Central Province, Lapego and Mount Hagen, Western
Highlands Province, Goroka, Eastern Highlands Province, Bulolo, Morobe
Province) (Skelton, 1981), and at sites in East and West Sepik and Madang
Provinces (Saulei, personal communication). Virtually all the known plantations of
E. camaldulensis have failed, with poor tree growth and death in many instances
(Saulei and Howcroft, personal communication). Occasional trees do survive - for
example, there are a few specimens on the Bulolo golf course in Morobe Province.
The main reason for failure of many plantations has been land ownership disputes
between local villagers and government and plantation companies, leading to
prevention of further forestry access and poor maintenance of plantations.
Government funding of forestry has dwindled since the early days of Australian
administration, contributing to plantation failure. Fire too has destroyed other
plantations. Thus the success rate has been low for reasons other than those of
purely climatic or geographical origin.
2.3.2 Mammals
2.3.2.1 Introduction
Flannery's monograph 'Mammals of New Guinea' provides the most up to date
overview of this topic, drawing together many communications and personal
observations with a review of the literature (Flannery, 1990).
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Knowledge of the mammals of New Guinea has been accumulated only over the
past 100 years or so, important initial contributors being Luigi D'Albertis, Michael
Thomas and George Tate. The former was an explorer and field scientist who lead
expeditions in the 1870's, collecting for the Museo Civico di Storia Naturale in
Genoa, Italy. Based at the British Museum, Thomas described material collected by
others, including D'Albertis, but never visited his subjects' countries of origin. Tate
was both an active systematist and field worker, employed by the American
Museum of Natural History during the 1920's. Since the work of these men,
museums in Hawai, Leyden, Berlin, Paris, Canberra, Sydney and Port Morseby have
all researched and collected New Guinean mammals.
2.3.2.2 Indigenous Mammals
Today at least 187 indigenous, 13 introduced and 11 extinct species of mammal
have been identified from the island of New Guinea (Flannery, 1990). A summary
of indigenous mammals is given in Table 2.3 and examples illustrated in Plates 2.5
and 2.6. Those mammal species where mention in the literature of feeding on
eucalypts or related species is made are particularly highlighted. In many instances
little is known of their diet, natural history and range, even by the local peoples.
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Plate 2.4 Goodfellow's tree kangaroo
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Plate 2.5 Spotted cuscus ( maculatus)
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Table 2.3 Indigenous mammals o New Guinea
FAMILY Genera Species COMMENTS
Tachygloissidae 2 2 Both echidna species are edentulous large-brained
spiny insectvorous monotremes.
Dasyuridae 8 14 Includes Phascalosorex dorsalis (narrow striped
dasyure)
Peroyctidae 3 8 Bandicoots and echmiperas
Peramelidae 1 1 Isoodon macrourus (Northern brown bandicoot)
Macropodidae 5 15 Includes tree-kangaroos (Dendrolagus dorianus, D.
goodfelloM'i, D, matschiei, D. spadix and D. urisnus)
which eat fruit and figs, wallabies (Dorcopsulus spp)
and agile wallaby (Macropus agilis) feed on
Eucalyptus sp. leaves and figs, found near Port
Moresby (Merchant, 1983).
Phalangeridae 3 8 Includes Phalanger carmeliiae (mountain cuscus) -
eats casuarina leaves and pandanus fruits, P. sericeus
(silky cuscus) - eats young foliage of myrtaceous
plants, including Eucalyptus sp.
Acrobatideae 1 1 Disoechurus pennatus (feather tailed possum) eats
fruit and insects.
Burramyeliae 1 1 Cerartetus caudus (long tailed pygmy possum).
Petauridae 2 5 Oposum layang biasa (sugar glider) known to eat
eucalypt sap in Australia (Henry and Suckling, 1985).
Pseudocheiridae 2 8 Pseudocheirus forbesi (painted ringtail) found in
montane forests.
Muridae 22 57 Rats and mice.
Pteropodidae 7 19 Bats including 'flying foxes'. Pteropus scapulatus
(little red flying fox) main food Eucalyptus sp.
blossoms. P. alecto (black flying fox) preferred food
includes Eucalyptus sp. blossom (Hall, 1983). P.
neohibernicus (greater flying fox) largest New
Guinean bat feeds on fruits; -widespread below
1000m. Also 'blossom bats': Syconycteris hoggit, S.
australis, Macroglossus minimus.
Emballonuridae 3 9 Mainly cave roosting bats. Many spread to Moluccas,
Asia and Australia
Hipposideridae 2 10 Mainly cave roosting bats
Rhinophidae 1 4 'Horse-shoe' bats
Vespertilionidae 10 21 Obligatory cave roosting bats. Some widespread:
Japan and New Caledonia to Mediterranean eg
Miniopterus schreibersi
Molossidae 4 6 Fly above forest canopy so difficult to catch and
study. Little known.




A number of mammals have been introduced to New Guinea, generally linked to
human inhabitation (Flannery, 1990). Homo sapiens has been a component of the
fauna for at least 40,000 years (Groube et al. 1986). In the latter part of this time
there has been contact with peoples from surrounding landmasses, and possibly
several waves of imigration. The feral pig, Sus scofa is hunted widely and relied
upon to impregnate domestic sows. Pigs can damage forest understorey and so
affect the habitat of other animal and plant species. Dogs, in the form of Canis
familiaris, constitute feral populations which do not bark, yet howl! Various forms
of rat have been introduced in conjunction with Homo sapiens, including Rattus
rattus which is mainly found in the lowlands near human habitation. Another
introduced murid species is Mus musculus which is a serious pest in coastal towns
and villages as well as occurring in grasslands around Port Moresby and elsewhere.
Three species of deer have been introduced. Cervus limoriensis (Rusa) arrived in
1928 brought by the Dutch (this species is now used as a source of meat). Dama
dama (fallow deer) and Axis axis (Axis deer) were also introduced to the Madang
area of PNG. Details of their introduction are uncertain. Finally feral cats (Felis
catus) occur as a result of domestic cats 'going wild'. Little is known of their
impact on local fauna.
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2.3.3 Birds
The birds of New Guinea are also extremely diverse, there being some 570 endemic
non-marine species, including 445 forest dwellers (Beehler, 1985). This diversity
(on an island second only to Greenland in size) arises because of the large areas of
forestation, proximity to the Australian landmass, and the islands linking to Asia. A
further 40 seabird and 90 migrant species have been identified in New Guinea and
associated islands. (Beehler et al. 1986). Approximately 71% of PNG is forested;
65% of the country is undisturbed rainforest and 20% man disturbed, with
mountains climbing to 5,000m in Irian Jaya (the western half of the island of New
Guinea). As in other aspects of flora and fauna, formal documentation of the bird
species has only occurred over the last century through exploratory natural science
expeditions. Groupings and species that feed on plant nectar and fruits and or may
be found near human habitation are shown in Table 2.4. Rainbow lorikeets
(example shown in Plate 2.7) frequently flew and roosted in trees within Port
Moresby. In some villages near Port Moresby pigeons and cassowaries (Plate 2.8)
are also kept as pets and sources of eggs or meat. At Laloata Island near the capital
several species of bird and mammal are kept in captivity and birds for study are kept
at the Christensen Research Institute near Madang.
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Plate 2.6 Lorikeet ( Trichaematodus)
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46 Electus roratus (Electus parrot), common
near human habitation, Probosciger aterrimus
(Palm cockatoo), Trichoglossus haematodus




11 Chlamydera cerviniventris (Fawn-breasted
bowerbird), savannah and town habitats,




38 Macgregoria pulchra (MacGregor's Bird of
Paradise) Paradisaea rudolphi (Blue Bird of
Paradise) Epimachus fastuosus (Black
Sicklebill), Ptilris magnified (Magnificent
Riflebird) - lowland species.
Cassowaries: Casuariide 3 C. casuarius (Southern cassowary)








7 Megapodius freycinet (Common scrub fowl)
lowland forest, lays eggs in mounds of humus
Pigeons and Doves:
Columbidae
45 Columbia livia (Rock Pigeon), Goura cristata
(Common Crowned Pigeon), G. scheepmakeri
(Scheepmaker's Crowned Pigeon), G. victoria
(Victoria Crowned Pigeon), Ducula zoeae
(Zoe Capped Fruit Dove), Ptilinopus
pulchellus (Crimson Capped Fruit Dove)
(Compiled from Beehler, 1985; Beehler et al. 1986; Pryor and Johnson, 1971)
Many of the rarer species' numbers are at risk of falling due to factors such as large
size and ease of human disruption, small geographical ranges, being hunted for
human food or ceremonial plumes and being colonisers of rare habitats. The birds
of paradise are national emblems of PNG and regional emblems of Irian Jaya,
reflecting their cultural significance and hence the value of their plumes.
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2.4 Discussion
It would appear that despite the attempted importation and planting of many
Euca/pytus species, their success in plantations has not been good (Saulei and
Howcroft, personal communication; Skelton, 1981). In particular E. camaldulensis,
although imported and planted at several sites, has not in general thrived (Howcroft,
Saulei personal communication). Two cases of confirmed C. neoformans var. gattii
meningitis have originated from Goroka, one from Bulolo, where some E.
camaldulensis survive, and other non biotyped cases have originated from all the
areas mentioned above (See Chapter 4). Therefore it is possible that although a few
clinical cases of cryptococcal meningitis could be linked to this species of
Eucalyptus, it is unlikely to account for the majority of cases in PNG.
At least 2 cases of cryptococcal meningitis including one with confirmed C.
neoformans var. gattii have come from the Sogeri Plateau, as well as further cases
in the Rigo and Abau areas of Central Province. E. tereticornis is found in all these
areas. E. brassiana is prevalent in the Northern and Western Provinces of PNG as
well as being widespread in areas of Northern Australia (Boland, 1957);
cryptococcal meningitis occurs in all these areas. E. alba, E. confertiflora and E.
papuana are commonly found in and around Port Moresby and Central Province,
areas where var. gattii meningitis is prevalent.
It therefore seems possible that there are several Eucalyptus species associated with
C. neoformans var. gattii. Since this study was initiated, Ellis and Pfeiffer have
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reported associations with E. tereticornis in Queensland, E. rudis, E.
gomphocephala and blakelyi in Western Australia (Pfeiffer and Ellis, 1992; Ellis et
al. 1996; Pfeiffer and Ellis, 1997). All four of these species are related to E.
camaldulensis, being of the red gum group Exsertaria, as are E. alba and E.
brassiana, which are found in PNG (Pryor and Johnson, 1971; Boland, 1957).
C. neoformans var. neoformans is well recognised worldwide in association with
pigeon droppings. There have been cases of meningitis caused by this var. in PNG.
Pigeons such as the imperial pigeons {Ducula spp) and fruit doves (Ptilinopus spp),
occur in PNG, and could be linked with this variety. (Coates 1985). Other birds
such as rainbow lorikeets (Trichoglossus haematodus) are endemic in PNG and feed
and roost on eucalypts near human habitation (own observations; Coates, 1985). In
addition some pigeons and cassowaries were observed within villages as pets. They
could play a role in C. neoformans transmission.
Mammals could also be implicated. Cryptococcosis has been reported in a rat
(.Rattus rattus) in Rabaul, PNG, and in the koala (.Phascolarctos cinereus - a
member of the supercohort marsupialia), in Australia (Scrimgeour and Purohit,
1984; Bollinger and Finckh, 1962). C. neoformans var. gattii has been isolated from
koalas, which feed predominantly on eucalypts (Ellis and Pfeiffer, 1990b). There are
many mammals, including marsupials in PNG. These may be involved in
transmission of cryptococcosis in this country. For example fruit bats such as the
little red flying fox (Pteropus scapulatus) and black flying fox (P. alecto) feed on
sap, nectar and flowers of eucalypts (Hall, 1983).
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Whether the birds mentioned above and mammals other than the rat and koala are
infected by a host tree remains to be seen. Further investigations described in
Chapter 3 attempt to extend the understanding of the ecology of C. neoformans.
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CHAPTER 3
Sampling of potential environmental sources of
Cryptococcus neoformans in Papua New Guinea
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3.1 Introduction
The yeast like fungus Cryptococcus neoformans is distributed world wide, and can
be serotyped on the basis of its polysaccharide capsule, giving four serotypes,
A,B,C,D and some which serotype as A/D or are untypeable. Biotyping can be used
to differentiate C. neoformans varieties gattii and neoformans. Clinical isolates of
C. neoformans var. gattii occur in tropical and subtropical regions predominantly in
apparently immunocompetent rural dwellers, whereas C. neoformans var.
neoformans is found also in temperate regions, particularly in immunocompromised
urban dwellers. In 1989 C. neoformans var. gattii was consistently identified during
and after flowering in association with the red river gum tree, Eucalyptus
camaldulensis, in South Australia and in New South Wales (Ellis and Pfeiffer,
1990b). A similar association was confirmed in California (Pfeiffer and Ellis, 1991)
and more recently in Italy and India (Montagna et al. 1996; Chakrabarti et al. 1997).
In 1991 after the start of this study C. neoformans var. gattii was found in sheltered
humus debris ofE. tereticornis (Forest red gum) (Pfeiffer and Ellis, 1992).
Recognising that the distribution of E. tereticornis and camaldulensis even in
Australia does not exactly mirror that of clinical human cases, Ellis and Pfeiffer
have continued to investigate other potential eucalypt sources, reporting in 1996 that
they had now found an association with E. gomphocephala (tuart) and rudis
(flooded gum) in Western Australia (Ellis et al. 1996). Livestock had contracted
var. gattii disease and when the local environment was investigated further C.
neoformans var. gattii was isolated from wool on fencing beneath these species of
Eucalyptus. E. blakelyi (Blakey's red gum) has also just been reported in
association with var. gattii (Pfeiffer and Ellis, 1997). All these euclaypts are red
gums, related to Eucalyptus camaldulensis.
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Var. gattii has also been isolated from koalas, which feed on eucalypts, and on one
occasion from bat droppings (Ellis and Pfeiffer, 1990a; Lazera et al. 1993). C.
neoformans var. neoformans has been isolated from avian, particularly pigeon
excreta in both temperate and tropical climates. In PNG C. neoformans has been
isolated from soil near Rabaul and has caused bovine mastitis (Frey and Durie,
1964; Anonymous, 1965).
The national incidence in PNG of cryptococcal meningitis is at least 4.3 patients per
million population per year (caused predominantly by C. neoformans var. gattii) and
is estimated to be 33-42.8 patients per million population per year in the National
Capital District (NCD) and Central Province (CP) (Chapter 4 and (Seaton, 1996)).
Disease occurs predominantly in HIV negative patients with no clinical,
haematological or biochemical evidence of immunosuppression (Chapter 5 and
(Slobodniuk and Naraqi, 1980; Lalloo et al. 1994; Seaton, 1996)).
E. camaldulensis is not endemic to PNG. Since 1955 E. camaldulensis has been
planted in trials at several sites in PNG (Skelton, 1981). Some trees survive from
these trials, but in general they have not thrived, as suggested by the records and
observations of Department of Forestry, Forestry Research Institute and University
Foresters and Biologists (Chapter 2; Currie et al. 1990; Skelton, 1981). Many cases
of cryptococcal meningitis originate in areas where no E. camaldulensis have been
planted. There are no records of export of E. rudis, E. gomphcephala and E.
blakelyi to PNG, nor are they endemic to this country. The predominant and
endemic species around Port Moresby are E. alba, E. papuana and E. confertiflora,
with E. tereticornis and E. deglupta elsewhere in Central Province. Some species
hybridize which can make definite identification difficult.
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Attempts were made to determine the habitat of C. neoformans by sampling
eucalypts, other plant sources, mammal and avian droppings in a number of
provinces of PNG.
3.2 Methods
Sampling from environmental sites in Port Moresby, National Capital District,
Central Province, Western Province, Madang and Rabaul (East New Britain) was
carried out during 1991-4. In particular dust, soil and vegetation in and around
houses of patients infected with C. neoformans var. gattii were sampled. Included
were any nearby eucalypts, taking care where possible to sample from hollowed out
areas, stem junctions and sheltered areas around trees. Sampling was performed on
plants that had flowers and those that were not in flower. There is great variation in
the timing and duration of flowering of eucalypts, depending on the local
microclimate, which varies dramatically within a few kilometres. Avian and
mammalian droppings were also sampled.
Samples of 5 - 15g material were collected in sterile containers and shaken in 20
mis sterile water or 0.85% saline and allowed to stand for 10 - 15minutes. The 47
samples from mammals in Western Province were frozen at -20°C until thawed,
diluted and cultured 3 months later. Heavy loopfuls (40-80p.L) from the resulting
suspensions were streaked onto Guizotia abyssinica creatinine agar (GACA) (also
known as bird seed agar) plates and incubated at ambient temperature (24-26°C) for
7 days (Ellis and Pfeiffer, 1990b). Positive controls using clinical isolates to spike
environmental samples were set up with each batch at a concentration of
approximately 1 x 103 colony forming units per milliliter, and the brown colour
effect (BCE) and typical mucoid morphology of C. neoformans confirmed.
Approximately 1ml of 25 flowering eucalypt associated suspensions as above were
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given to Dr. D. Ellis for C. neoformans examination in Adelaide. In addition a few
slants from off-white, pink and 1 mm diameter light brown colonies were sent to
him.
3.3 Results
In total, 1130 samples collected over wet and dry seasons from the following
sources were analyzed: E. confertiflora (flowers shown in Plate 3.1), white gum (E.
alba), ghost gum (E. papuana), E. tereticornis, kamarere (E. deglupta), coconut
flowers and coconuts (Cocos nucifera), raintree flowers {Albisia saman) (Plate 3.2),
bougainvillias (Bougainvillea spp), banana plants and flowers (Musa sapientum),
legumes (Peltophorum pteocarpus), rubber trees (Willughbeia coriacea), frangipani
(Plumaria spp), mango trees (Mangifera spp), okari (Terminalia okari), breadfruit
(Artocarpus communis), Guttarda speciosa (Rubicaciaeae), casurina
(Casuarinaceae), sawdust from sawmills, pigeons (Columbia sp.), lorikeet
(Trichoglossus haematodus) and cockatoo (Cacatuiane), cuscus (Phalanger
mimicus and P. sericeus) and Goodfellow's Tree-kangaroos (Dorcopsis atrata).
Locations (National Capital District, Central Province and elsewhere), sample types
and sampling periods are shown in Tables 3.1-3.3.
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Plate 3.1 Flowers of Eucalyptusconfertiflora. One patient sat beneath such
flowers during school breaks at Gerehu High School. He is
holding the flowers.
130
Plate 3.2 Raintree flower (Albisia saman) in the grounds of PMGH
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Table 3.1 National Capital District specimens collected November 1991 -
April 1994
Source/Specimen Type Flowering3 Othersb
E. alba 24 8
E. confertiflora 55 2
E. papuana 23 4
Eucalyptus sp. 108 370
Other plants & trees 53 41
Total 724 specimens, 594 Eucalypt associated, a: debris and flowers from trees/plants in
flower, b debris from non flowering plants/trees. 67 and 11 repeated specimens from
around homes of two patients. Further specimens not tabulated: patient's house dust/soil:
13, bird faeces (pigeons/cockatoo): 11 and 1 nest, marsupial faeces ( cuscus/tree kangaroo):
11.
Table 3.2 Central Province specimens collected December 1991 -
September 1993
Source/Specimen Type Flowering3 Othersb
E. alba 8 7
E. confertiflora 8 0
E. deglupta 0 6
E. papuana 5 3
E. tereticornis 24 43
Eucalyptus sp. 125 35
Other plants & trees 35 7
Total 336 specimens, 274 Eucalypt associated, a: debris and flowers from trees/plants in
flower, b: debris from non flowering trees/plants. 47 (including some on repeated
occasions) and 2 specimens from around homes of two patients. Further specimens not
tabulated: patients' house soil: 5, sawdust: 6, bird faeces (pigeon/canary), marsupial faeces
(cuscus/tree kangaroo): 2.
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Table 3.3 Specimens taken elsewhere in Papua New Guinea
May 1992 - April 1994
Province/Details Sample type (quantity) Source
Madang (CRI) faeces (4) Goodenough kangaroo,
cockatoo, lorikeet
flowers (1) Guttarda speciosa
Morobe tree debris (3) E. camaldulensis
tree debris (1) E. tereticornis
Western* faeces (47) P. sericeus Dorcopsis sp,
P. forbesi, unidentified
marsupials




CR1: Christiansen Research Institute, Madang Province.* Frozen -20°C.
Spiked control samples generally produced 10-30 typical BCE colonies per quarter
plate. This is illustrated in Plate 3.3. These varied in size from 2-4 mm and became
evident after 3-4 days culture, growing well in the presence of moulds. In some
environmental samples there were off-white, light pink and brown yeast colonies
grown, as well as moulds, some of which would stain the medium a light brown
colour. None of these appeared similar to the BCE colonies of C. neoformans on
control plates. With care the yeast colonies could be picked off. In none of these
cases was C. neoformans identified. C. laurentii was the only Cryptococcus grown,
particularly from Eucalyptus spp. All samples were negative for C. neoformans.
One case diagnosed with var. gattii infection was born in Wau/Bulolo in Morobe
Province where there are a few E. camaldulensis surviving. One set of samples
taken from these trees was negative. Further sampling was not possible for
logistical reasons.
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Plate 3.3 Guizotia abyssinica creatinine (bird seed) agar exhibiting brown
colour effect with Cryptococcus neoformans (round mucoid
brown colonies) and lack of growth inhibition by other fungi.
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3.4 Discussion
Given the frequency of cryptococcal meningitis in PNG, it is surprising that
environmental sampling using similar methodology to that used by Ellis and Pfeiffer
has not yielded positive results for either variety. These authors shook
environmental samples in 20mls sterile water, allowed them to stand for 10-15
minutes and streaked 0.5ml aliquots onto GACA, incubating at 26°C for 7 days
(Ellis and Pfeiffer, 1990b). They made 2,100 collections before finding C.
neoformans var. gattii, but once alerted to an environmental source, were more
frequently successful. Discussion with D. Ellis and examination of literature
suggested that positive environmental samples yielded heavy and even
semiconfluent growth of typical colonies though scanty smaller pinhead size
colonies could occasionally be identified as C. neoformans (Dr.D.Ellis, personal
communication). This investigation focussed on perceived likely sources, and
hoped for more rapid success. Freezing for transport and storage of the 47
marsupial related specimens from Western Province and the use of smaller aliquots
than Ellis and Pfeiffer could contribute to negative findings. Staib and colleagues
have noted that some isolates of C. neoformans from AIDS patients and pigeon
faeces fail to exhibit the BCE on bird seed agar (Staib et al. 1987). This may be due
to the coexistent growth of other fungi leading to inhibition of the BCE by lowering
the pH of the medium (Staib and Senska, 1973). All spiked control samples,
exhibited the BCE on GACA without evidence of growth inhibition by other fungi.
The investigation of non-BCE yeast colonies (no colonies showed typical
morphology) revealed no isolates of C. neoformans. It is therefore unlikely that C.
neoformans was missed because of growth inhibition by other fungi or
misidentification of yeasts. The examination of flowering eucalypt associated
suspensions by Dr Ellis with negative findings adds weight to these conclusions.
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It would appear that E. camaldulensis is not the prime source of C. neoformans var.
gattii in PNG, as there are so few surviving trees, although it is possible that this
eucalypt could account for an occasional case (Chapter 2; Currie et al. 1990). The
close relationship of E. tereticornis and its endemicity to PNG made this a likely
source on epidemiological grounds, reinforced by the recent findings of C.
neoformans var. gattii in association with this species in Australia (Pfeiffer and
Ellis, 1992). It was not possible to confirm these associations in PNG. Since the
distribution of var. gattii infections in PNG does not mirror the distribution of
imported or endemic eucalypts it seems likely that the organism has a more
ubiquitious distribution in nature. Recently Chen et al have demonstrated that the
random amplification polymorphic deoxyribonuclear acid (RAPD) profile from
infected patients with C. neoformans var. gattii in Arnhemland, North Australia
differs from that of var. gattii isolated from Australian Eucalyptus camaldulensis
and E. tereticornis (Chen et al. 1997). These eucalypts do not occur in Arnhem
land, an area with a high incidence cryptococcal meningitis caused by C.
neoformans var. gattii. These findings also suggest the existence of an alternative
environmental source, other than known host eucalypts.
These results suggest that in PNG the environmental infectious propagules may be
transiently present. Alternatively they may exist in a form that is not readily
detected. Others too report lack of success in isolating C. neoformans var. gattii
elsewhere in the tropics (Fisher et al. 1993; Swinne et al. 1994), although there has
been a positive finding on one occasion in Brazilian bat guano (Lazera et al. 1993).
No bat associated samples were investigated in the study described here. The latter
group have also just reported persistent isolation of var. gattii from a hollow a
pottery tree (Moquilea tomentosa) in Brazil (Lazera et al., 1998). Identification of
the source(s) of C. neoformans var gattii as well as var. neoformans in tropical areas
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should continue and may allow the development of strategies to avoid infection,
particularly important where disease occurs both in healthy fit individuals as well as




of Cryptococcus neoformans meningitis
in Papua New Guinea
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4.1 Introduction
Despite the continuing interest in cryptococcosis within PNG, particularly in Port
Moresby, there had been no attempt to define clearly its epidemiology. The largest
previous study in PNG (reported in a conference abstract) showed that 129 cases of
cryptococcal meningitis were diagnosed from 1978-87 (Temu et al. 1987). There
were 75 males and 64 females with ages ranging from 1.5 to 50 years. Thirty four of
these cases were aged less than 15 years. No data on season of presentation or
geographical distribution of cases were reported. Prior to this Slobodniuk and
Naraqi presented a series of 13 cases from Central Province, of whom 5 were born
in the Rigo Subprovince (Slobodniuk and Naraqi, 1980). This study describes the
epidemiology of cryptococcal meningitis in PNG.
4.2 Methods
4.2.1 Case finding
Retrospective and prospective data was gathered from the literature, patient notes
and prospective study cases. In PNG one of the most important features in the
patient's social history is the village and region of origin. This indicates the likely
mother tongue, beliefs, social affiliations and loyalties. In most instances this is
accurately recorded in patient notes. The 'address' given by a patient at admission
often simply indicates the contact point of a wantok (relative) who lives or works in
Port Moresby. The area within the city, as opposed to a house number and street
where the patient is based may be all that is indicated. Sometimes the address was
not recorded in the inpatient notes. Patients considered prospectively at PMGH
were asked where they had lived over the 6 months prior to admission. Although
the incubation period of cryptococcal meningitis is not known, it is possible that
exposure to the C. neoformans during this period might lead to clinical disease.
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Visits, telephone calls or letters to the main hospitals in Madang, Lae and East New
Britain helped to confirm details on patients presenting to these hospitals. PMGH
laboratory cerebrospinal fluid results and Central Public Health Laboratory (CPHL)
of Port Moresby cryptococcal latex antigen results were reviewed as available to
identify and then trace records of patients identified. The CPHL receives samples
from throughout PNG for cryptococcal latex antigen testing.
4.2.2 Case definition
A case of cryptococcal meningitis was defined as a patient in whom there were
symptoms and signs of meningitis confirmed with positive cryptococcal findings on
CSF microscopy and/or culture and/or serum cryptococcal antigen test. Biotype and
serotype of C. neoformans isolates were also noted, when such information was
available.
For the purposes of this part of the study, concentrating on epidemiological aspects,
I identified cases defined in time, person and place and then tried to identify
potential trends and correlations which might indicate clues as to the source(s) of
infection.
4.2.3 Patient age
Until recently, in many hospitals and other healthcare centres, the age of an adult
patient has not been recorded, simply because many patients do not know their age.
Therefore an age recording of'adult' is not uncommon. Health care workers are now
encouraged to record an estimated age, as it is often useful to have some indication,
even if not totally precise. In the data recorded here, ages such as 'adult' are not
included in analysis.
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4.2.4 Census and rainfall
Data was obtained from the 1980 and 1990 National Censuses, to provide
denominators (Anonymous, 1982; Anonymous, 1993a). The University of Papua
New Guinea Physics Department and National Weather Centre were able to
provided rainfall data for Port Moresby.
4.2.5 Long term mortality
A retrospective group of 48 patients' virtually full records, including details of
possible contact points, were available. These patients were followed up to find the
long term mortality rate associated with cryptococcal meningitis in PNG. Wherever
possible patients were visited, relatives contacted by telephone, writing or 'bush
telegraph'. Tessi, the hospital social worker and the National Blind Association
were valuable sources of information. In analysis it was assumed that patients who
had left hospital within two weeks of presentation and diagnosis had received
incomplete therapy and were probably dead.
4.2.6 Statistics
Data was handled on Epilnfo. The Chi squared (x ) test as described by Snedcor
and Irwin, with Yates' correction was used to compare observed and expected
numbers (Snedecor and Irwin, 1933; Yates, 1934).
4.3 Results
4.3.1 Demographic characteristics of all cases and isolates
Data was gathered on 96 cases of cryptococcal meningitis. These 96 cases were not
consecutive as some sets of notes/results on further cases could not be located.
There were 55 males and 41 females ( ratio 1.3:1; PNG population 1.1:1), presenting
from 1972-1993. The difference in numbers of males and females is not
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significantly different from that anticipated from the PNG population ratio (y} =
0.55, DF=1, p>0.5). The mean age was 26.2 years (standard deviation 13.3) with
ages ranging from 6-60 years old. A total of 20 isolates were biotyped, 15 as
Cryptococcus neoformans var. gattii (all serotype B) and 5 as Cryptococcus
neoformans var. neoformans (all serotype A). Sixty two (64.6%) of the cases are
known to have died.
All but 4 cases identified were immunocompetent on clinical, haematological and
biochemical grounds. Those cases studied since September 1991, and some prior to
this date were tested for antibody to HIV 1. Two male cases in late 1991 were
identified as HIV 1 positive, and Cryptococcus neoformans var. neoformans,
serotype A was isolated from both. One female case who died with cryptococcal
meningitis in the first half of 1991 had previously had a renal transplant and was on
immunosuppressive therapy. Her isolate was not biotyped. A further male case
with var. gattii meningitis was found to have diabetes mellitus.
4.3.2 Incidence of cryptococcal meningitis
Estimates of the incidence of cryptococcal meningitis in PNG can be made from
Temu's report (Temu et al. 1987). They identified 129 cases in PNG in the 10 years
1978-87, 12.9 per year, which, based on the 1980 Population Census gives a rate of
4.3 cases/million/year (Anonymous, 1982).
Eleven patients with cryptococcal meningitis presented from September 1991 to
August 1992 to PMGH. Seven isolates were C. neoformans var. gattii and four var.
neoformans, two in HIVI positive men. This suggests that about eleven cases of
cryptococcal meningitis present per annum from those actually living in CP and the
NCD. Using Census figures from the 1990 Census, this gives an incidence of 33
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cases/million population/year (Anonymous 1993a). If HIV infected individuals are
excluded the incidence of cryptococcal meningitis is 27 cases/million
population/year, with 21 Cryptococcus neoformans var. gattii infections/million
population/year.
4.3.3 Patients' geographical distribution
4.3.3.1 Province and subprovince distribution
Many local patients spent some time in Port Moresby, and some time (e.g. at
weekends) in their village, if it was within 4-5 hours drive of the city.
Table 4.1 Province of origin of 84 cases of cryptococcal meningitis and
population distribution
Province Population (% total) Cases of CM (% total)
Chimbu 183,800 (5.1) 1(1.2)
East Sepik 248,308 (6.9) 1 (1.2)
West Sepik 135,185 (3.8) 0
Enga 238,257 (6.6) 0
Southern Highlands 302,724 (8.4) 0
Western 108,705 (3) 2 (2.4)
Western Highlands 291,090 (8.1) 0
Gulf 68,080(1.8) 14(16.7)
Eastern Highlands 299,619 (8.3) 10(11.9)
Manus 32,830 (0.1) 0
Madang 270,299 (7.5) 1(1.2)
Central 140,584 (3.9) 36 (42.9)
Morobe 363,535 (10.1) 4(4.8)
Northern 96,762 (2.7) 1(1.2)
NCD 193,242 (5.4) 8(9.5)
New Ireland 87,194 (2.4) 0
East New Britain 184,408 (5.1) 0
West New Britain 127,547 (3.5) 1(1.2)
Milne Bay 157,288 (4.4) 5(6)
North Solomons (WAR) -145,000 0
Total Population of PNG = 3,529,538, Male:Females 1.1:1 (Anonymous, 1993a).
Patients with known Province of Origin =84
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Table 4.1 shows the Province of Origin for all cases in PNG. Most cases originate
from Central (36 cases, 42.9%), Gulf (14 cases, 16.7%) and Eastern Highland (10
cases, 11.9%) Provinces, and the NCD (8 cases, 9.5%). If the Chi squared test is
applied, it is found that significantly more cases come from Gulf (x^ =9.4; DF=1;
0.01>p>0.001) and Central (x^ = 33.4; DF=1; p<0.001) Provinces, than would be
expected. The number of cases originating from the NCD {y} = 0.69; DF=1;
p>0.1) and Eastern Highlands Province (x^ = 0.34; DF=1, p>0.5) are not statistically
different from that expected, although Southern Highlands Province has
significantly fewer cases (0 cases, y} = 9.9; DF=1; 0.01<p<0.001) than expected.
Table 4.2 Population distribution and subprovince of origin of 32 cases of
cryptococcal meningitis in Central Province
Subprovince Population CM
(% of CP total) (% of CP total)
Abau 30,515 (21.7) 5(15.6)
Goilala 21,812(15.5) 5 (15.6)
Hiri 28,638 (20.4) 5(15.6)
Kairuku 29,266 (20.8) 2 (6.3)
Rigo 30,353 (21.6) 18(56.3)
CM = patients with cryptococcal meningitis. Total cases in Central Province (CP)
32. Table does not include data from the National Capital District.
Table 4.2 shows a similar breakdown for Subprovinces within Central Province.
Plate 4.1 is a map of central Papua New Guinea, including Central Province. Within
Central Province a significantly high number of cases was found in Rigo (18 cases,
56.3%. X1 =6.99; DF=T, 0.01>p>0.001), and significantly low number of cases in
Kairuku (2 cases, 6.3%. X2 =8.89;DF=1; 0.01>p>0.001), whereas elsewhere the
proportions were in keeping with the underlying population distribution shown in
Table 4.2)
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Plate 4.1 Map of central Papua New Guinea
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4.3.3.2 Province of origin and biotype
The Province of Origin of 15 known var. gattii infected patients are considered for
all of PNG. For seven patients the Province of Origin was Central Province, four
originated from Eastern Highlands Province, and one each came from Morobe and
Gulf Provinces, and the NCD. The five known var. neoformans meningitis patients
originated from Central (2), Gulf (2) and Morobe (1) Provinces.
4.3.3.3 Recent residence and biotype
In addition, for some var. gattii patients the residence over the 6 month period prior
to admission is known. These seven patients were resident in Central Province and
the National Capital District. Four cases lived entirely in one location (2 in Port
Moresby, 1 in Sogeri and 1 in Gerehu), whilst three cases spent time in both their
home village (in Rigo, Abau and 9 Mile settlement), and in Port Moresby. In the
latter three cases one cannot conclude where infection was acquired, even if it was
thought to have been within the six month time period. Origin and recent address
within Port Moresby showed no clustering. Three (including the two HIV 1 positive
individuals) var. neoformans infected patients had been living in Port Moresby and
two in remote villages within Central Province over the six months prior to
admission.
4.3.4 Age structure of infected population
The age distribution of the population within each Province is not statistically
different from that for the whole of PNG. This is compared with the age
distribution of cryptococcal meningitis patients as shown in Table 4.3.
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Table 4.3 Age distributions of PNG population and cryptococcal meningitis
patients
AGE IN YEARS <1 1-4 5-14 15-44 >44
POPULATION % 3.2 11.6 25 50 14.4
(n = 3,529,538)
CM CASES % 0 0 18.1 70.5 11.4
(n) (16) (62) (10)
Mean age 26.2, SD 13.5 and range 6-60 years for the 88 cases, is applied to numbers not
percentages. y2 = 6.9; DF=1; 0.01>p>0.001 for difference in incidence in 15-44 year old
age group, from that anticipated if cases were spread in proportion to population. %^
=1.17;DF=1; 0.5>p>0.1 if population aged 15 and over is considered separately.
No patients presented under the age of six years. Significantly (p<0.01) more
patients were found in the 15-44 year age group than expected by comparison with
the underlying population. Taking the population aged 15 and over years separately
(i.e. all adult 'cases'), this finding still holds true, with p<0.05
4.3.5 Seasonal variation
4.3.5.1 All patients
Patient admission dates were well recorded, so the seasonal pattern of presentation
can be described, as shown in Figure 4.1 for all cases that presented to PMGH.
Patients presenting elsewhere in PNG are not included. An apparent peak occurs in
May/June, with a second later in September/October. Neither of these peaks are
significant if the Chi squared test is applied (for the June peak of Figure 4.1, =
0.38; DF=1; p>0.5). If var. gattii meningitis is associated with a specific seasonal
environmental source then seasonality may be masked by confounding var.
neoformans data. Removing the five known recent Cryptococcus neoformans var.




Figure 4.1. Month of presentation of 90 patients with cryptococcal
meningitis at PMGH.
Years ranging from 1972-93. 36 females (■) and 54 males (■).
Breaking down the data into smaller groups reduces the numbers being analysed and
only highly significant trends will be revealed. There is the possible benefit of
uncovering significant correlations, which may otherwise be obscured by the mass
of data. In an attempt to find such trends other subgroups were analysed.
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4.3.5.2 Variety gattii infections
There were a total of 15 Cryptococcus neoformans var. gattii infected patients, 12
male and 3 female (ratio 4:1). Their mean age was 20.9 years (SD 12.6), with a
range from 6 to 42 years old. Fourteen of these cases presented at PMGH. The
month of presentation for these cases is shown on Figure 4.2. The seasonal
distribution of cases suggests a 'peak' in March to May, with possibly another in
September to October, consistent with the pattern shown in Figure 4.1. The
numbers are too small to be conclusive.
month
Figure 4.2 Presenting month with neoformans var. gattii meningitis.
Mean age 20 years, SD 12.5,3 females(W), 11 ma!es(B).
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4.3.5.3 Sex ratio and age grouping
The age and sex distribution in the under 15 year old age group is shown in Figure
4.3. There were no patients aged less than 6 years. The female : male ratio is 1.7:1,
in reversal of the ratio of all the cryptococcal patients (F:M 1:1.1). In this group of
patients there was seasonal variation in the presentation at PMGH. All female cases
presented from December to March, and all males from April to September, with no
overlap.
6 7 8 9 10 11 12 13 14
age (years)
Figure 4.3 Age and sex distribution of patients aged under 15 years. 17
cases, 10 female(B), 7 male(B). Mean age 9.7, SD 2.5. 6 isolates
biotyped and serotyped; all were var. gattii, serotype B.
This data suggests a possible difference in the age of presentation between the
sexes, with males generally presenting aged 8 or under, and females from 8 years
onwards.
Older age groups' seasonal, age and sex distributions reflected those of the total
cryptococcal meningitis population. In the 15-30 age group 8 patients out of 40
presented in September, although this is not statistically significant (p>0.05).
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4.3.6 Rainfall and month of presentation
Port Moresby and much of Central Province lies in the rain shadow of the
mountainous Owen Stanley Ranges, and so precipitation is not high, with a mean
annual rainfall of 1145mm annually between 1945 and 1985. This allows savannah
to predominate along the southern part of the Papuan Region. Data from the
Department of Physics UPNG as well as personal experience shows that there is
considerable variation in rainfall, even within Port Moresby itself.
Figure 4.4 Month of presentation of all cases (♦) at PMGH compared with
mean monthly rainfall (mm) (■) in Port Moresby 1945-85
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As illustrated in Figure 4.4 the cases' presentation seems to peak in the dry season,
rising from the end of the wet season, falling in July and August, which are dry, and
then peaks again in September, before falling again as the rain arrives in November.
4.3.7 Long term follow-up
Follow up of past patients proved difficult, despite extensive efforts to locate them.
Villages do not have regular formal communications with the outside world; street
postal addresses are vague and difficult to trace. Travel, apart from natural hazards
of flooding rivers, dirt (or no) roads, rough seas and dangerous flying, becomes
increasingly awkward as one tries to avoid armed hold ups by 'rascals'.
The median age at presentation of the 48 adult cases presenting from 1979 to 1990,
was 26 years, with a range from 12-60 years, male:female ratio 1.7:1 and duration
of symptoms 1 day to 7 months. At follow up by August 1992, 15 (31.3%) were
alive, 18 (37.5%) dead and 15 (31.3%) could not be traced. Considering the group
in whom outcome was confirmed, five year survival of patients is shown in Table
4.4.
Table 4.4 Survival over 5 years in patients with known outcome
Years 0.5 (n=35) 1 (n=34) 2(n=32) 5 (n=20)
Dead/Alive 15/20 15/19 15/17 11/9
% Alive 57 56 53 45
The causes of death were usually unknown and Standard Mortality Rate was not




The figures derived from Temu et al.'s data suggests an incidence rate of
cryptococcal meningitis for the whole of PNG to be 4.3 cases/million
population/year (Temu et al. 1987). During the years 1978-87 the annual incidence
appeared to rise (Temu et al. 1987). This was probably due to the increased clinical
awareness and introduction of cryptococcal latex antigen testing. There had been no
known cases of HIV infection. The figure of 4.3 cases/million population/year may
well be an underestimate, as the diagnoses of cases were all confirmed at PMGH,
CSF, serum and urine samples being sent from all over PNG. It is possible that
some cases in remote regions and those without laboratories may remain
undiagnosed, although in cases with gradual progression of symptoms and signs,
there is time to reach more 'sophisticated' centres.
The rate of 4.3 cases/million population/year compares with rates of 2.5-5.0
cases/million/year in Victoria, Australia, 1.2 cases /million /year in Auckland, New
Zealand, and 140 cases/million/year in the Aboriginal population of the Northern
Territory of Australia (Speed, 1990; Speed and Dunt, 1995; Hutchinson et al. 1991;
Fisher et al. 1993). The latter population is probably the most comparable to that in
PNG, as there are similarities in both ethnic origins and environment. Amongst this
Aboriginal population, the predominant variety of Cryptococcus neoformans is
gattii (Fisher et al. 1993). Other series described from the tropics in the
predominantly pre AIDS era from Singapore, Zimbabwe and Malaysia do not give
overall comparable rates, but the rates deduced suggest that they are considerably
lower than those in PNG (Tjia et al. 1985; Gould and Gould, 1985; Pathmanathan
and Soo-Hoo Tuck Soon, 1982).
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If it is thought that most of the cryptococcal meningitis seen at PMGH is acquired in
or around Port Moresby, then the rate suggested by the current study is much higher
at 33 cases/million population/year in Central Province and the National Capital
District (27 cases excluding the recently diagnosed HIV1 patients), including 21
cases of Cryptococcus neoformans var. gattii. This level is most likely to be nearest
to the actual rate during the study period, and is high when compared with most of
the other rates mentioned above.
A subsequent 30 month study reported nationwide and Central Province incidences
of 8 and 42.8 cases/million/year respectively (Seaton, 1996). This study included 4
HIV positive patients and may reflect the increasing incidence of HIV in PNG.
Whether these high rates in PNG and Northern Australia are due to increased
virulence of C. neoformans var. gattii, occult immunocompromise on the part of the
local Melanesian population or high levels of exposure is not known.
4.4.2 Geographical clustering
The number of cases originating in Central (36) and Gulf (14) Provinces is
significantly higher than those in Southern Highlands (0). The latter is lower than
might be expected (Table 4.1). The Eastern part of Gulf Province is fairly accessible
to Central Province and Port Moresby. The high number of cases originating from
these areas could be explained by the fact that, despite movement of the population
within PNG, by far the greatest proportion of people actually living in the NCD,
Central and Gulf Provinces originate from these areas, and so they are more likely
to present to PMGH. There are no Census or Hospital statistics available to confirm
or refute this fact. Equally, they may also have had greater life time exposure if
there is an environmental focus in these Provinces. They would be more likely to
have acquired infection which then reactivated than individuals who have lived
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some of their life elsewhere in PNG. In fact, one might expect more cases
presenting from the NCD itself, if residence here conferred a greater risk of
acquiring cryptococcal infection, but this is not the case. The increased incidence in
those originating from Gulf and Central Provinces may reflect greater exposure or
predisposition in these areas as well as access to PMGH.
There are no road links between the highlands and southern areas of PNG, including
Central Province and the National Capital District. Eastern Highlands Province
(EHP) has the best internal and external communications by road and air. There is a
major hospital at Goroka, EHP, as well as road links to Lae and Madang hospitals.
The low number of patients presenting from distant Provinces such as Southern
Highlands Province could reflect logistical factors or those related to exposure.
Prior to this study, anecdotal suggestions have been made that a predominance of
cases of cryptococcal meningitis seem to come from the Rigo Subprovince of
Central Province. The numbers of patients with cryptococcal meningitis in the
current study originating from Rigo (32) and Kairuku (2) subprovinces are
significantly higher and lower respectively than expected (4.4.2.1.). Whether this is
solely due to differing exposure to the source(s) of infection or not is not clear. A
potentially confounding factor is the accessibility of these populations to PMGH,
and the local availability of health care facilities to these populations. Northwest of
Port Moresby, Hiri and Kairuku Subprovinces, which have a combined population
of 57,900, (36.4% of CP population), together contribute only 7 (21.9%) cases,
lower than expected when their population is taken into consideration. They have
comparable air, road and healthcare facilities to those of Rigo, southwest of Port
Moresby. The number of cases is disproportionately low when compared with Rigo,
southwest of Port Moresby with comparable communication links. There is
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therefore no evidence to suggest that the high number of cases originating from Rigo
in particular can simply be attributed to ease of access to Port Moresby. A further
way to ascertain the proportion of overall admissions originating from a particular
region would be from hospital admission records, but such detail is not available.
The distribution of the Cryptococcus neoformans varieties gattii and neoformans
infected patients by Province of Origin is consistent with the overall distribution of
cases, as are the addresses of residence of these patients over the 6 months prior to
admission. It should be noted that one C. neoformans var. gattii isolate came from a
man originating from the village of Kuru who presented at Goroka Base Hospital
Eastern Highlands Province. Other non-biotyped cases are known to have presented
there, so it seem likely that there is a source in that vicinity. Trial plots of E.
camaldulensis were planted near Goroka, and in the Whagi Valley (Chimbu
Province), although they are reported to have fared poorly (Currie et al. 1990).
4.4.3 Age, sex distribution and exposure to Cryptococcus neoformans
The age distribution of cases may partly reflect the focus of attention on adult cases
at PMGH. Although local clinicians are aware that paediatric cases occur in
Madang, Lae and Port Moresby, they have not been previously described. The more
detailed retrospective data available, including 13 cases from Slobodnuik and
Naraqi's paper and the cases related to the 6 biotypes identified by Currie and
colleagues in 1989, has focused on adult cases, and so the paediatric cohort may be
under represented (Slobodniuk and Naraqi, 1980; Currie et al. 1990). This bias does
not account for the possible excess of females in the under 15 year age group, nor
the lack of documented cases aged less than 6 years. The latter is very much against
the trend of infections in children which are often commonest in the very young.
For example tuberculous meningitis is commoner than cryptococcal meningitis in
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the PNG paediatric population, and certainly does occur in much younger patients
(Professor J.Vince, personal communication). In a Malaysian series, the youngest
patient with cryptococcal meningitis was 9 months old, but the biotype of the isolate
not reported (Pathmanathan and Soo-Hoo Tuck Soon, 1982). The data presented
here suggests that first exposure in PNG may occur at the age of 5 - 6 years, possibly
related to some activity outside the home. There is no evidence for direct person to
person spread of cryptococcosis (there are no close spacial or temporal clusters).
The different ages of presentation in boys and girls under 15 (Figure 4.3.) suggests
varying susceptibility or exposure, although the number of cases is too small to
provide conclusive evidence.
The fact that all six isolates biotyped from the under 15 year old age group were
Cryptococcus neoformans var. gattii is of interest suggesting that most infections in
this group were with this variety. If this was the case, then their distribution and
pattern may be of particular significance. It was not possible to identify any specific
activity/exposure carried out by one sex but not the other at a particular age.
Hormonal changes at puberty could be deleterious (males) or protective (females) as
the apparent sex distribution of cryptococcal meningitis in the under 15 year age
group (Figure 4.3.) reversed with female predominance, when compared with the
overall study population. This is consistent with the earlier suggestion of the
protective effect of oestrogens (De Wytt et al. 1982).
The study population's large over representation in the 15-44 cohort could be due
to the adult bias in previous interest in cryptococcal meningitis in PNG.
Considering the adult population only there is still a significant excess of cases
occurring in the 15 - 44 year age group. However, this previous bias may not
account for all of this predominance. A follow on study of 60 patients of all age
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groups identified a cryptococcal meningitis incidence of 8 and 42.8 cases/million
population/year in PNG and Central Province respectively with fewer cases in
children under 12 years old and most in men (male:female sex ratio 2.2:1) (Seaton,
1996). Elsewhere in the tropics cryptococcal infection is reported to be commonest
in the third decade of life, with male predominance, but infection rates are not
compared with denominator populations (Lo, 1976; Gould and Gould, 1985; Tjia et
al. 1985).
4.4.4 Seasonal variation of cryptococcal meningitis presentation and rainfall
The month of presentation of cases may reflect supposed (Eucalypt-associated) or
other environmental exposure to Cryptococcus neoformans var. gattii, even though
the incubation period is not known.
It was thought that by considering specific age groups, significant seasonal trends
might be revealed. The main observation found was possible variation between the
sexes in the season of presentation in children, females presenting from December
to March, and males from April to September (4.3.5.3). No behavioural difference
between sexes was identified that might explain such variation.
4.4.5 Season and eucalypt flowering
Initial discussions about Eucalypts raised the possibility of there being two
flowering periods, one in the wet, and one during the dry season. Eucalypt
flowering was documented in several locations. Within Port Moresby Eucalyptus
papuana flowered in January, E. confertiflora in December to February and E. alba
from March to June and again in November. Personal observations were not
complete enough to definitely confirm biannual flowering, as a full year of informed
observation was not quite possible. The dry season commences about April and
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rainfall increases dramatically in November (Figure 4.4). Flowering seems to occur
mainly during the wet season.
It is feasible that if there were a 2-3 month incubation period of cryptococcal
meningitis following exposure, the seasonal variation documented here could be a
reflection of release into the environment of Cryptococcus neoformans variety gattii
associated with the flowering of one or more species of eucalypt, for example. This
would support Ellis and Pfeiffer's hypothesis that this is an endophytic fungus
associated with eucalypts (Ellis and Pfeiffer, 1990a). Further local longitudinal
study of flowering and clinical correlation would be required to clarify any possible
relationship between these two occurrences. The data on month of presentation
with cryptococcal meningitis and rainfall does not suggest a clear link. Local
microclimate varies dramatically within a few kilometers. Any potential effect of a
particular tree's flowering on incidence of cryptococcal meningitis is difficult to
discern.
4.4.6 Follow up and mortality
In those patients followed up the mortality rate of 43% in the first six months
following diagnosis probably reflects deaths directly related to cryptococcal
meningitis. The 55% 5 year mortality rate is difficult to assess without a suitable
control group or even standard mortality rate for comparison. The high mortality
rate may reflect later presentation than occurs in other healthcare settings or the
pathogenicity of Cryptococcus neoformans var. gattii.
159
Overall these epidemiological studies confirm the magnitude of the problem of
cryptococcal meningitis in PNG, and suggest clustering in one area and so a
potential source of C. neoformans var. gattii. Possible seasonal peaks of
presentation at PMGH were not associated with rainfall, while childhood infection
patterns suggest that exposure or susceptibility to C. neoformans var. gattii varies
with sex and age.
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CHAPTER 5
Clinical studies of cryptococcal meningitis
in Papua New Guinea
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5.1 Introduction
Before the emergence of AIDS, cryptococcal meningitis in the tropics and sub
tropics often occurred in apparently immunocompetent individuals, in contrast to
those presenting in temperate climates, where infection was typically associated
with immunosuppression (Lewis and Rabinovich, 1972; Lalloo et al. 1994). In both
regions the meningitis was usually chronic and uniformly fatal if untreated.
Survivors suffered a high morbidity often with permanent neurological damage.
Biotyping of isolates of this yeast like fungus showed that Cryptococcus neoformans
var. gattii (serotypes B and C) was commonly found in tropical areas, whereas C.
neoformans var. neoformans (serotypes A,D and A/D) was found in temperate areas
(Kwon-Chung and Bennett, 1984). In Papua New Guinea cryptococcosis was first
diagnosed in 1946, since when it has been documented in animals and in apparently
immunocompetent humans (Cox and Tolhurst, 1946; Champness and Clezy, 1962;
Slobodniuk and Naraqi, 1980; Temu et al. 1987; Lalloo et al. 1994). Clinical
isolates have been predominantly var. gattii, as elsewhere in the tropics and
subtropics (Currie et al. 1990; Chapters 4 and 5).
This study reports the clinical findings and outcome in consecutive patients infected
with Cryptococcus neoformans.
5.2 Methods
5.2.1 Patients and Setting
Port Moresby General Hospital (PMGH) is a 600 bed university teaching hospital,
serving the local populations of the National Capital District (NCD - population
193,242, 1990 Census) and surrounding Central Province (CP - population 140,584)
as well as acting as a referral centre for the rest of PNG (Population 3,529,538)
(Anonymous, 1993a). All the patients described were Melanesians.
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5.2.2 Diagnosis and assessment
From September 1991 to August 1992 confirmed cases of cryptococcal meningitis
diagnosed by cerebrospinal (CSF) India ink staining (Plate 5.1), culture on
Sabouraud's agar, and latex antigen testing (Crypto-LA Test, IBL), were studied
prospectively. Patients had a full history and clinical examination. Whenever
possible, accurate demographic data were obtained. Computed tomography (CT)
and magnetic resonance imaging are not available in PNG. Regular assessment was
carried out until discharge and thereafter at outpatient follow up. All isolates were
biotyped using canavanine glycine bromothymol blue agar, then confirmed and
serotyped by David Ellis and Tania Pfeiffer in Adelaide (Kwon-Chung et al. 1982b).
5.3 Results
5.3.1 Age, sex, HIV 1 status, C.neoformans variety and survival of patients
Isolates from all 11 patients diagnosed were biotyped. Details of age, sex, human
immunodeficiency virus type 1 (HIV1) status, C. neoformans variety and survival
are shown in Table 5.1. The four var. neoformans and seven var. gattii biotypes
were serotyped as A and B respectively. One of the latter patients had previously
undiagnosed diabetes mellitus. Two of the four var. neoformans isolates were from
men who were FHV 1 positive, a third from a female with concurrent biopsy proven
tuberculosis and the fourth from a male with Plasmodium vivax parasitaemia. No
other concurrent conditions were found.
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Plate 5.1 India ink slide (x ~1000) of encapsulated Cryptococcus
neoformans in the cerebrospinal fluid of Papua New
Guinean patient. Polysaccharide capsule shows as clear
white halo around yeast cells.
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Table 5.1 Age, sex, HIV1 status, Cryptococcus neoformans variety and survival
Patient No. Age (years) Sex HIV 1 status Variety Patient's
Survival*
1 18 Male negative gattii yes
2 22 Male positive neoformans no
3 21 Male negative neoformans yes
4 35 Male positive neoformans no
5 17 Female negative gattii no
6 10.5 Male negative gattii yes
7 35 Male negative gattii no
8 18 Female negative neoformans yes
9 40 Female negative gattii yes
10 30 Male negative gattii no
11 8 Male negative gattii yes
Male:female ratio gattii = 5:2; neoformans = 3:1. Median age: gattii 24 years (range
8-40); neoformans 21.5 years (rangel8-35). *Completed treatment, discharged and
have not represented by August 1995.
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5.3.2 Initial Findings
Details of age, sex and C. neoformans variety with recent residence, birthplace and
occupation are shown in Table 5.2. One patient with var. gattii meningitis presented
and died at Goroka Base Hospital, Eastern Highlands Province; his CSF was
examined at Port Moresby General Hospital, and the diagnosis made post mortem.
The remaining 10 patients presented to PMGH and had been living within Port
Moresby, NCD or the surrounding Central Province over the six months prior to
presentation. The birthplace ranged from Eastern Highlands to Central, Gulf and
Morobe Provinces. Occupation, exposure to birds, animals and plants and
consumption of cigarettes, alcohol and betel nut were assessed, but no correlation
with disease was identified.
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Table 5.2 Age, sex, and Cryptococcus neoformans variety with recent
residence, birthplace, and occupation.
Patient Age (years) Sex Variety Residence*
past 6 months
Birthplace* Occupation


































































NCD = National Capital District, EHP = Eastern Highlands Province, CP = Central
Province, Gulf = Gulf Province. *Village, Sub Province and Province.
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Clinical findings at presentation are shown in Table 5.3.
Table 5.3 Clinical findings at presentation
var. gattii var. neoformans* Both
Number of patients 7 4 11









Fever 5 3 8 (73%)
Headache 7 4 11 (100%)
Vomiting 5 3 8 (73%)
Photophobia 2 2 4 (36%)
Neck stiffness 7 3 10(91%)








Seizures 2 0 2(18%)
Cough 0 1 1 (19%)
Pyrexia >37.5° C 2 4 6 (55%)
Altered mental status 0 2** 2(18%)
Kernig's positive 4 2 6 (55%)
Papi 11 oedema 3 3 6 (55%)
Cranial nerve lesion 2 0 2(18%)
Long tract signs 2 0 2(18%)
Data in brackets are percentages except where noted. *- one case minimal history
available. **- Glasgow coma scores 10 and 11, who died and made a full recovery
respectively.
168
Two patients had a past history of tuberculosis (not microbiologically confirmed)
and seven were on antituberculosis treatment immediately prior to diagnosis of
cryptococcal meningitis. Only one patient had concurrent tuberculosis, confirmed
on neck lymph node biopsy. No patient had haemoptysis or dyspnoea at
presentation. Systolic blood pressure was in no case over 130 mmHg. Cranial nerve
lesions were found in two var. gattii patients at diagnosis (bilateral Vlth, and Xllth
palsies in one and unilateral Vlth palsy in the other). Tunnel vision was reported in
two patients and blurred vision in one other, but no objective abnormality in acuity
could be demonstrated in those able to cooperate with assessment. Long tract signs
were found in two fatal male var. gattii infected patients. No patient had an altered
sense of smell at presentation.
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In addition to the baseline data shown in Table 5.4, CSF pressure was measured to
be > 30 cm CSF in one HIV 1 positive patient, and remarked to be "high" by the
admitting resident in 6 others.
Table 5.4 Baseline CSF, cryptococcal antigen and culture characteristics
gattii neoformans Both
CSF / no. measured
Protein > 45 mg/dl 0/0 2/3 2/3
Glucose < 2.2 mmol 2/3 3/3 5/6
White cell count > 20/ul 3/4 2/3 5/7
Polymorph count/ul 6.5 (0-30) 11 (0-20) 9(0-30)
Lymphocyte count/ul 40.5 ((0-240) 11 (0-188) 33(0-240)
pressure >20 cm CSF 0/1 1/1 1/2
Cryptococcal antigen
Serum titre 6144 (128-16348)* 1536 (64-16,384 2048 (64-16384)
CSF titre 3042 (512-16384)* 512(16-8192) 2048(16-16,384)




Blood/ no. tested 0/4 0/0 0/4
Urine/ no. tested 0/3 2/3 2/6
Nasal/ no tested 0/2 0/2 0/4
Median values with ranges in brackets are shown unless otherwise indicated. CSF-
cerebrospinal fluid. * - no data on 1 case.
Patient 6 had ventricular dilatation on cerebral ultrasonography at PMGH and CT
scanning in Australia. In all patients the CSF India Ink stain and culture were
positive. In one child (var. gattii) and one HIV 1 positive (var. neoformans) patient,
no cellular CSF reaction was seen. CSF and serum cryptococcal latex antigen tests
(Crypto-LA Test, IBL) were positive in all 10 patients tested. Urinary antigen tests
were positive in 7 of 8 patients tested. In one HIV 1 patient and one with biopsy
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proven tuberculosis, urinary culture was positive for C. neoformans var.
neoformans. Neither CSF examination and culture nor blood culture was positive for
other pathogens.
Four of six survivors had a Bacillus Calmette Guerin (BCG) vaccination scar.
Mantoux testing with 10 units purified protein derivative (PPD) was negative in 5
cases, and 5 mm in the var. neoformans infected patient 3 with malaria at diagnosis
and a past history of pulmonary tuberculosis. Patients 1 and 3 were subsequently re-
tested during or after recovery, with induration of 11 and 20 mm respectively.
Admission haematology and biochemistry results are summarised in Table 5.5.
Blood films showed no evidence of haematological malignancy.
Table 5.5 Admission haematological and biochemical parameters
Parameter range (median)
Serum sodium 129-138 (131) mmol/1
Serum potassium 2.6-4.3 (2.9) mmol/1
Serum urea 2.0-12.1 (4.0) mmol/1
Creatinine 0.06-0.16 (0.10) mmol/1
Haemoglobin 8.7-14.4 (12.4) g/dl
White blood cell count 8.7-15.5 (10.3) x 1091
Platelet count 140-504 (300) x 1091
ESR 54-65 (62) mm/hr
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No clinical, biochemical or haematological evidence of malignancy or autoimmune
disease were found. In 3 patients the CD4:CD8 lymphocyte subsets could be
measured; only in one HIV 1 positive individual (4) was the ratio decreased; the
other two adult male patients (one var. gattii and one var. neoformans with P. vivax)
had normal ratios. Immunoglobulins were normal in 2 var. gattii cases measured,
with a slightly raised IgM at 2.4g/l (normal range 0.5-2.0) and IgG at 21g/l (normal
range 6-18) in the var. neoformans case with confirmed tuberculosis. Autoantibody
screen was negative in 2/2 (1 var. gattii and 1 var. neoformans) cases. Chest
radiographs were abnormal in 2 var. gattii and 1 var. neoformans cases, with apical
lesion and right hilar reticular shadowing, left upper hilar opacity, and bilateral hilar
infiltrates respectively. Examples of radiograph changes in one patient are
illustrated in Plate 5.2.
No mycobacteria, cryptococci nor tumour cells were identified in sputum from these
patients. Electrocardiographs were normal in 3 of 4 cases, with the fourth showing
a PR interval of 0.18 seconds and left ventricular hypertrophy, which did not change
with treatment.
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Chest radiograph of a patient with cryptococcai meningitis
showing left upper zone and right hilar infiltrate at presentation
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5.3.3 Treatment and outcome (Table 5.6)
Table 5.6 Treatment and outcome of patients with cryptococcal meningitis
var. gattii var. neoformans Total
Male:Female 3:1 1:1 4:2
Amphotericin B*
Total dose mg/kg 39.8 (27.6-69.1) 40.43 (30.3-50.6) 39.8(27.6-69.1)
Steroid* at any time 3 3 6
Duration of treatment (d) 71(52-121) 89 (74-104) 82 (52-121)
Cured/no. cases (%) 4/7(57%) 2/4(50%) 6/11(56%)
Death/ no. cases (%) 3/7 (43%) 2/4 (50%) 5/11 (45%)
Early < 1 day** 3 1 4 (36)
Late > 9 weeks** 0 1 1 (9)
Cured - had not represented by August 1995. Median values with ranges in brackets
are shown. * Treatment received by the 8 patients who survived more than a day
between diagnosis and death. ** - time between diagnosis and death. No case was
treated without prior laboratory diagnosis
Survivors received between 0.3-1.0 mg/kg/day of amphotericin B parenterally, and
150 mg/kg/day flucytosine orally with the response monitored clinically and
serologically. The two paediatric var. gattii cases were treated with a mean dose of
54.5 mg/kg of amphotericin B. Flucytosine levels could not be measured.
Anorexia, nausea, vomiting, phlebitis, marrow suppression and azotaemia were
particularly common. When possible the doses of antifungals were reduced in these
cases. In six of the eight patients who received treatment, intravenous
hydrocortisone was given immediately prior to amphotericin B in an attempt to
reduce febrile reactions. Bilateral and unilateral sensorineural deafness was
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detected during treatment in 2 var. neoformans and 1 var. gattii patients; this
seemed to improve clinically after treatment. In 1 other var. gattii case bilateral
deafness was noted clinically to correlate with the dose of amphotericin B.
Five patients (45%) died; four before or within 24 hours of starting amphotericin B
and flucytosine, and a fifth patient who was HIV 1 positive, died 6 weeks after self
discharge on oral ketoconazole, after he had received 57 days of combined
flucytosine and amphotericin B treatment in hospital. Six (54.5%) patients, four
with var. gattii and two with var. neoformans, survived to complete a full course of
treatment. At discharge after completing treatment one patient with var. gattii was
blind, with bilateral Vlth and left upper Xllth motor neurone palsies, and was unable
to respond appropriately to verbal commands, or make comprehensible sounds. He
had dilated ventricles and probably had raised intracranial pressure at initial lumbar
puncture. Five patients had no clinical deficit and had not represented by August
1995.
5.4 Discussion
Cryptococcal meningitis had not been previously reported in HIV 1 patients in PNG.
In May 1991 a patient on immunosuppressive therapy following renal
transplantation did present to Port Moresby General Hospital with cryptococcal
meningitis. By December 1992 there had been 129 patients with HIV infection
reported in PNG, but the patients reported here are the first found to be infected with
C. neoformans (Anonymous, 1993b). Concurrent infection with HIV 1, tuberculosis
or P. vivax may have predisposed these patients to opportunistic infection with C.
neoformans var. neoformans, although coincidental infection is possible. One var.
gattii patient had concurrent diabetes mellitus, but none had any other feature that
might predispose to cryptococcal infections. The pattern in this series reflects that
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already recognised of var. gattii infections occurring predominantly in apparently
immunocompetent individuals in tropical areas. In central Africa in the pre AIDS
era 12 of 13 isolates between 1951 and 1968 were var. gattii, whereas later 40
isolates biotyped from Zaire between 1970 and 1985 were all var. neoformans
(Kwon-Chung and Bennett, 1984; 1955; Swinne et al. 1986b). It may be that the
previous predominance of C. neoformans var. gattii and the rarity of var.
neoformans infection in tropical areas was due to the absence of appropriately
immunosuppressed individuals. Exposure to both varieties of C. neoformans may
have occurred, but there were few hosts susceptible to infection with var.
neoformans. In PNG the increasing exposure of individuals to conditions such as
HIV infection and immunosuppressive treatment may lead to a rise in var.
neoformans infections.
Prior to this study paediatric cases of cryptococcal meningitis have not been
described in PNG. Both young patients here had var. gattii infection, and originated
from similar environments within Central Province. The youngest biotyped (var.
gattii) paediatric case of cryptococcal meningitis known in PNG is 6 years old, and
the youngest case of cryptococcal meningitis reported in the literature is 9 months
old, but the biotype is not described (Pathmanathan and Soo-Hoo Tuck Soon, 1982).
Their occurrence confirms that childhood exposure occurs, although there is no
evidence of vertical transmission.
In the tropics tuberculosis is often treated without microbiological confirmation. In
seven cases, tuberculosis featured early in the differential diagnosis and treatment
was started prior to the diagnosis of cryptococcal meningitis being made, although
tuberculosis was subsequently confirmed in only one case. In PNG and the
Northern Territory of Australia tuberculosis and lepromatous leprosy have been
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reported concurrently with cryptococcal meningitis (Lo, 1976; Lalloo et al. 1994;
Fisher et al. 1993). These experiences confirm the importance of positively
excluding both tuberculous and cryptococcal infection in paediatric and adult cases
presenting with subacute or chronic meningitis in a region where both are endemic.
The diagnosis of one does not exclude the other. Where such cases are severely ill
or do not respond to antituberculosis chemotherapy, cryptococcosis must be sought
and treated without delay.
In the cases that had repeated Mantoux tests reactivity was markedly increased in
convalescence. This suggests that cell mediated immunity in these cases improved
with treatment of initial cryptococcal infection, and reduced the likelihood of
undetected immunodeficiency.
Five cases had a lumbar puncture without ill effect despite papilledema, allowing
rapid diagnosis of cryptococcal meningitis. Earlier diagnosis and treatment may
lower the mortality and morbidity. Where there is a high clinical suspicion of
cryptococcal meningitis in countries without the facility or expertise for
neuroradiological imaging and limited access to cryptococcal antigen testing the
benefits of lumbar puncture may outweigh the risks, and indeed may be therapeutic.
Hearing loss and tinnitus are recognised as possible side effects of amphotericin B
which may explain the sensorineural hearing reduction and deafness noted in our
cases, although it might be expected to be bilateral in all such cases (Casscells,
1978; Stamm et al. 1987). Pre-existing or cryptococcal disease cannot be excluded
as causes of this finding.
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A subacute or chronic presentation was typical. Papilledema occurred in 6 (55%)
of cases. In none of the cases in this series was there clinical evidence of papillitis.
Blindness ensued in only 1 (var. gattii) of 4 survivors with papilledema at
presentation. Raised CSF pressure was documented in 1 case, although the
admitting resident commented that pressure was "high" in 6 others at lumbar
puncture.
Recently in PNG blindness occurred in 9 (18.4%) of 49 patients (Lalloo et al. 1994).
These 9 constituted 31% of patients who were fully treated. In the patient reported
here blindness occurred prior to diagnosis, the rate of onset is not known and the
CSF pressure was not recorded. It is uncertain to what extent direct optic nerve
involvement, arachnoiditis or raised intracranial pressure resulting in nerve
infarction may have been implicated. The latter aetiology may be significant in
AIDS patients, as ultrasonography and CT scanning showed dilated ventricles, and
slow visual loss seemed to be associated with intracranial hypertension (Rex et al.
1993). In such AIDS patients the rate of visual loss was 1.1%. In gradual onset
blindness in these cases of cryptococcal meningitis aggressive treatment of rising
intracranial pressure (ICP) such as shunting, nerve sheath fenestration, repeated
lumbar puncture and acetazolamide therapy should be instituted when possible (Rex
et al. 1993; Denning et al. 1991b; Garrity et al. 1993). Steroid therapy may also
have a role in reducing ICP and inflammation (Rex et al. 1993; Denning et al.
1991b).
A retrospective study including those patients reported here has shown that in those
with var. gattii meningitis patients treated at any point with corticosteroids visual
deterioration and blindness occurred significantly less frequently, and in three
patients vision improved as compared with those patients who did not receive
178
corticosteroids (Seaton et al. 1997a). In another study including these and other
patients visual loss occurred in 52.6% of survivors and was associated with optic
atrophy following optic disc swelling in 60.0%. Progression of disc swelling to
optic atrophy was predicted by the presence of an abducens (VI cranial nerve) palsy
and CSF cryptococcal antigen titres of >1:1024, but not with an opening CSF
pressure of >300mm on admission (Seaton et al. 1997b). The contrasting rates of
blindness in immunocompromised var. neoformans cases and immunocompetent
var. gattii cases could be due to immune meditated optic nerve dysfunction in var.
gattii meningitis caused by either compression due to arachnoid adhesion or oedema
and inflammatory cell-mediated damage. Corticosteroids may have a role in
preventing or halting visual loss in C. neoformans var. gattii meningitis in
immunocompetent individuals.
The optimal antifungal regimen for var. gattii cases in particular is unclear. In PNG
a lower dose of flucytosine (100 mg/kg/day) is now recommended to reduce
toxicity. Ideally flucytosine levels should be monitored. Azoles and new
amphotericin B preparations in particular are often not available. Even obtaining
amphotericin B and flucytosine has become more difficult. Garlic has been used in
the treatment of cryptococcal meningitis elsewhere in the tropics and China. Garlic
and a Chinese commercial preparation, allitridium, containing mainly diallyl
trisulphide, has been demonstrated in vitro to act synergistically with amphotericin
B, demonstrating a possible clinical role especially where it is readily available
(Shen et al. 1996).
The incidence of cryptococcal meningitis at PMGH is estimated from this study to
be 21 var. gattii and 12 var. neoformans cases per million population/year from
NCD and CP. A more recent estimate of predominantly var. gattii meningitis cases
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in Central Province is higher at 42.8/million/year (Seaton, 1996). Further cases also
regularly present at other centres throughout PNG. The incidence is lower than that
of cryptococcosis reported in the aboriginal population of Arnhemland, Australia of
140/million/year, which contrasts with other reports of 28 in Victoria, Australia,
and 1.2 in Auckland, New Zealand (Lo, 1976; Fisher et al. 1993; Speed, 1990;
Hutchinson et al. 1991). A high rate of cryptococossis is also reported in Malaysia
(Pathmanathan and Soo-Hoo Tuck Soon, 1982). The incidences may not be directly
comparable, but exposure to and infection with var. gattii may be more frequent in
tropical and subtropical areas. Whether infection is due to increased exposure,
undetected immunocompromise or greater virulence is not clear.
The overall mortality rate of 45.5% in this series is similar to others from the tropics
(Lalloo et al. 1994; Slobodniuk and Naraqi, 1980). Most deaths occurred soon after
admission. In a series of 133 cases from Victoria in Australia none of 20
immunocompetent cases of var. gattii died and there was a higher incidence of
cryptococcoma and non-fatal complications than in the var. neoformans cases
(Speed and Dunt, 1995). When infection biotype is compared within the strata of
host immunocompetence these distinctions become blurred (Speed, 1996). It may
be that where cases present earlier to health care facilities many more var. gattii
cases could be cured with fewer sequelae than is currently the case in many tropical
centres.
Although this series of patients is too small to identify prognositic indicators, a
larger series which has included these patients has now identified significant
associations in C. neoformans var. gattii meningitis (Seaton et al. 1996). Mortality
was higher in men and older patients, and associated with altered consciousness,
convulsions prior to treatment and a maximum systolic blood pressure of >150
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mmHg. This suggests that death may have been due to raised intracranial presure
and subsequent tentorial herniation. Despite this, raised CSF opening pressure in
29/36 (81%) of patients did not predict outcome, nor did discharge serum
cryptococcal antigen titres.
The source of C. neoformans infection remains uncertain in this series of cases.
Var. gattu has been associated with Eucalyptus camaldulensis in Australia and
California, and more recently with other related eucalypts. It has been suggested
that the distribution of E. camaldulensis matched that of var. gattii meningitis, but
this eucalypt is not indigenous to PNG (Chapter 2 above and (Ellis and Pfeiffer,
1990b; Pfeiffer and Ellis, 1991; Pfeiffer and Ellis, 1992; Heyligers, 1982)). All but
one of this series lived in low lying savannah areas of Central Province. Three
originated from near Goroka and Bulolo where there have been poorly growing
plantations of E. camaldulensis and four from near sea level, where exposure to E.
tereticornis may have occurred. Environmental samples around the patients' houses,
from E. papuana, E. confertiflora, E. alba and E. tereticornis in NCD and CP, and
from E. camaldulensis at Bulolo, as well as other plants, birds and animals have all
been negative for C. neoformans (Chapter 3). Elsewhere C. neoformans var.
neoformans has been most consistently associated with avian, particularly pigeon
droppings (Emmons, 1955; Swinne-Desgain, 1975; Bauwensetal. 1986).
In conclusion, cryptococcal meningitis in PNG is commonly caused by C.
neoformans var. gattii in immunocompetent children and adults. Malaria,
tuberculosis and HIV 1 have been associated with C. neoformans var. neoformans
infections, and should always be sought. Cryptococcosis and tuberculosis may
present in a similar fashion and both must be considered. The source of
cryptococcal infection in PNG has not been confirmed, but there may be some
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geographical clustering of cases. Rapid presentation, diagnosis and treatment, with
appropriate adjunctive measures, to lower raised ICP and prevent visual loss
(possibly using corticosteroids) may help to reduce the high morbidity and mortality






Following inhalation of the infectious propagule of C. neoformans into the lung,
cellular defences are crucial in containing cryptococcosis. Neutrophils, monocytes
and alveolar macophages play a major role in the host defence against Cryptococcus
neoformans (Kozel et al. 1987; Levitz and Tabuni, 1991; Gadebusch, 1972; Miller
and Mitchell, 1991; Collins and Bancroft, 1992).
Despite the presence of large amounts of C3 degradation products particularly iC3b,
phagocytosis of encapsulated cryptococci by neutrophils and macrophages is
limited. Richardson et al investigated differential binding of acapsulate and
encapsulated strains of Cryptococcus neoformans to human neutrophils using a
simple monolayer assay (Richardson et al. 1993). CR1 and CR3, the main receptors
on neutrophils that bind C3b and iC3b respectively, have been shown to be
associated with phagocyte cytoskeleton and to cluster (Detmers et al. 1987; Graham
et al. 1989; Jack et al. 1986). C3 clustering occurred in a ligand-independant
fashion and therefore to alter properties of the receptors it is possible that a second
signal is required (Detmers et al. 1987). The host cell receptors and binding with C.
neoformans are important in determining whether it will establish itself as a
pathogen. The cytoskeleton influence in neutrophil fluidity and receptor clustering
may be important in this interaction.
The clinical features of C. neoformans var. gattii and neoformans disease appear to
differ. To explore these differences further in vitro studies of human neutrophil-
cryptococcal binding were carried out, aiming to compare the neutrophil binding of
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the two varieties of C. neoformans, developing techniques based on a monolayer
assay (Richardson et al. 1993).
6.2 Methods
6.2.1 Cryptococcus neoformans isolates
Deep clinical isolates from Papua New Guinea, Vietnam and Edinburgh were
studied. All have been biotyped and serotyped at Mycology Reference Laboratories
(either Adelaide, Australia, or PHLS, England) and stored until use on Sabouraud's
dextrose agar slopes or sterile distilled water at room temperature. Table 6.1
indicates details of isolates used in the initial set of experiments using the inverted
cavity slide and Table 6.2 shows additional isolates used in Giemsa stained
comparisons. In initial studies not all isolates had been serotyped and 2 var.
neoformans were subsequently found to be serotype D (17D) or not typeable
(22N/T). So that comparisons were also between known serotypes, these isolates
were omitted from later assays.
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Table 6.1 C. neoformans isolates used in inverted coverslip measurements*
Isolate NCPF Biotype Serotype Site/Source/Country
16B 92.246 gattii B CSF/HIV-/PNG
17D neoformans D CSF/HIV+/Edinburgh
19B 3798 gattii B CSF/HIV-/PNG
21B 3790 gattii B CSF/HIV-/PNG
22N/T neoformans N/T CSF/ unknown/Vietnam
23A neoformans A CSF/unknown/Vietnam
24A neoformans A CSF/unknown/Vietnam
28B 3000 gattii B CSF/HIV-/PNG
29B 3756 gattii B CSF/HIV-/PNG
30A 3745 neoformans A CSF/HIV +/PNG
N/T - not typeable. * Some isolates used in subsequent Giemsa stained experiments
Table 6.2 Additional isolates used in subsequent Giemsa experiments
Isolate NCPF Biotype Serotype Site/Source/Country
14A 3745 neoformans A CSF/HIV+/PNG
18A 3799 neoformans A CSF/HIV-/PNG
26A 3748 neoformans A CSF/HIV+/PNG
31B 3746 gattii B CSF/HIV-/PNG
6.2.2 Preparation and standardisation of cryptococcal suspensions
Cryplococcus neoformans isolates were grown on 3% malt extract agar (Unipath) at
30°C or 37°C for 5-7 days in air or 5% C02. Morphology, in particular the degree of
mucoid appearance of colonies was noted. Yeast suspensions were prepared in
0.85% (W:V) sterile saline and vortexed for 10 seconds to ensure a single cell
suspension. This was then standardised to 1 x 103 yeasts/ml by haemocytometry and
viable count and then diluted in Hanks Balanced Salt Solution (HBSS) (Sigma), pH
7.5. In each experiment var. gattii and var. neoformans strains were examined in
parallel.
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6.2.3 Capsule size measurements
Measurements were made on isolates 16B, 17D, 19B, 2IB, 22N/T, 23A, 24A, 28B,
29B and 30A at both 30°C and 37°C. India ink was added to cryptococcal
suspensions and measurements made using an eye piece micrometer of 40 cells per
strain at x 100 magnification. Cell diameter (outer edge to outer edge of the cell
wall) and the diameter of the cell plus the capsule (outer edge to outer edge of the
capsule) were measured. The capsule thickness was calculated by subtracting the
diameter of the cell from the diameter of the cell plus the capsule and dividing the
difference by 2. The capsule volume was calculated by assuming that the shape was
spherical and subtracting the cell volume from the volume of the cell plus the
capsule.
6.2.4 Neutrophil monolayer preparation
Peripheral blood was obtained by venepuncture. Single drops of blood were placed
on untreated, dust-free 16 mm coverslips (BDH) and incubated at 37°C for 30
minutes in a humid atmosphere. Coverslips were then suspended in 37°C 0.85%
saline, blood clots removed and gently agitated, before rinsing in 0.85% saline to
wash off remaining erythrocytes. This produced a 95% neutrophil monolayer on the
coverslip, as established by Giemsa staining.
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6.2.5 Serum and serum proteins
Peripheral blood collected from a volunteer was used as the source of normal human
serum (NHS) containing opsonic complement components. This was prepared by
placing approximately 40 mis of clotted blood in ice for 3-5 hours and then
centrifuged at 2000 rpm for 15 minutes. The supernatant was removed, aliquoted
into eppendorf tubes and frozen at -70°C. Prior to use NHS was warmed to 37°C.
For experiments using absorbed serum with cryptococcal antibody removed,
preparation was as follows. A plate with five day heavy growth of each variety was
harvested and the resultant yeasts suspended in HBSS. The suspension was
centrifuged at 2,000 rpm for 15 mins to pellet the yeast cells. Supernatant was
removed, fresh centrifuged serum mixed with the pellet and left on ice for 1-2 hours.
This removes any antibody present in the serum. The chilled mixture was then
centrifuged as before and the supernatant aliquoted into eppendorf tubes and frozen
in liquid nitrogen. Serum was heated at 56°C for 30 min and re-equilibrated to 37°C
before use as the opsonin in those assays requiring heat inactivated NHS.
6.2.6 Binding assay and neutrophil binding
This was performed as previously described (Richardson et al. 1993). Briefly,
neutrophil monolayers on coverslips were placed in wells of plastic tissue culture
plates ("Repli", Sterilin) containing 1 ml of Cryptococcus suspension and 0-300 pi
of opsonin. Most experiments used 100 pi opsonin. Plates were incubated at 37°C
for 30 min, monolayers washed in fresh warm saline to remove unbound yeast and
then inverted onto a cavity slide. Ten random fields for each monolayer were
observed under oil immersion phase contrast at x 100 objective. In the inverted
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coverslip slide experiments assays were performed in triplicate, with one var. gattii.
and one var. neoformans isolate run in parallel in each assay. In binding assays
where Giemsa staining was used, incubation periods varied from 0-120 minutes and
normal human serum volumes from 0 - 300 p.1 as indicated. These assays were
performed in duplicate or triplicate, again with up to two isolates of each variety run
in parallel. At least 100 neutrophils in random fields were counted.
The total number of neutrophils, number of neutrophils with yeasts associated and
total number of neutrophil associated yeasts were counted. It is difficult to
distinguish whether the associations of neutrophils with cryptococcal cells are extra
or intracellular (Richardson et al. 1993). Attempts to make this distinction and also
deduce whether cryptococci were dead/alive and internal/external were made using
acridine orange staining followed by quenching with crystal violet and examination
by fluoresence microscopy (Goldner et al. 1983). This method has been used for
this purpose in bacteria and subsequently in the yeast Saccharomyces cerevisiae.
This did not differentiate cryptococci consistently and clearly enough and was not
explored further. The yeast eukaryote DNA staining may be different from
prokaryotes where this method has been more commonly used and so differentiation
of internalised yeasts within neutrophils less clear than in studies of prokaryote
internalisation. Therefore binding was measured rather than precise documentation
of attachment or internalisation, since the latter could be very subjective. Two
parameters were calculated:
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1. The percentage neutrophils bound (%B) = (number of neutrophils with one or
more yeasts associated)/ (total number of neutrophils) x 100. i.e. the percentage of
the neutrophil population with yeasts attached.
2. The binding index (BI) = (total number of associated yeasts)/(number of
neutrophils with one or more yeasts associated), e.g. if BI was 1, then binding was
on a ratio of 1 yeast to 1 neutrophil.
6.2.7 Giemsa staining
The initial set of experiments counting yeasts and neutrophils were studied using the
inverted coverslip slide method and the remainder of the binding experiments were
carried out as follows. After the binding assay was completed and coverslips
washed as before, they were allowed to air dry before Giemsa staining (10 minutes
in methanol to fix cells, 3 minutes in 1:6 May-Grunwald stain (Sigma) followed by 3
minutes Giemsa stain (Sigma), washing in water between stains). Coverslips were
then mounted on slides using DPX (diphenyl xylene, BDH, Poole) and the number
of at least 100 neutrophils with associated cryptococci counted, usually in 3-4 fields
at x 40 magnification. This method of staining and counting allowed handling of a
greater number of coverslips per experiment and counting on different days. The




The significance of the mean of the results obtained was assessed by carrying out
two tailed unpaired Student's t test on any results where two mean values were
being compared. P< 0.05 was considered indicative of a statistically significant
difference.
6.3 Results
6.3.1 Colonial morphology: mucoid appearance
Observation of colonies on plates showed that in general var. gattii isolates were
more mucoid than var. neoformans, probably reflecting their greater capsular
thickness. Ranking from most to least mucoid of 10 isolates grown for 5 days at
37°C in air as shown in Table 6.3. This difference is illustrated in Plate 6.1.
Table 6.3 Ranking of mucoid appearance of 10 isolates
Isolate 16B 19B=21B=12B 24A* 28B* 26A= <-r<mnII<\00;ii
Appearance mucoid » -» » non-mucoid
variety gattii (neof) fI neoformans
*24A neoformans and 28B gattii exceptions to the trend
When grown in air supplemented with 5% C02 the var. gattii colonies were more
mucoid than when grown in air. Var. neoformans showed this effect to a lesser
extent.
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Plate 6.1 Cultures of Cryptococcus neoformans var. gattii (16B) below and




Table 6.4 Mean capsule thickness pm (SD*) of 10 isolates in air at 30°C & 37°C
Thickness (pm)
30°C 37°C p value
var. neoformans 1.31 (0.5) 1.24(1.36) 0.796
var. gattii 3.07(1.36) 2.58(0.81) 0.51
p value 0.042 0.018 -
*Standard deviation
Capsule thicknesses of 10 isolates: 16B, 17D, 19B, 21B, 22N/T, 23A, 24A, 28B,
29B and 30A were measured and compared. These data in Table 6.4 show that
capsular thickness of var. gattii isolates is significantly greater than that of var.
neoformans at both 37°C and 30°C. For each isolate the capsule thickness became
smaller when grown in air with a rise in temperature from 30°C and at 37° C. This
difference was not statistically significant.
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6.3.2.2 Capsular volumes
Capsular volume of the same 10 isolates was calculated. The volume of var. gattii
was greater than var. neoformans as shown in Table 6.5, as expected from thickness
and radius measurements. This difference did not reach statistical significance. It
may been that if more isolates were compared, these capsular volume differences
would become statistically significant.
Table 6.5 Mean capsular volume pm3 (SD*) in air at 37°C
volume pm3
var. neoformans 305.05 (112.1)
var. gattii 624.81 (431.6)
p value 0.17
* Standard deviation
6.3.3 Monolayer size and neutrophil content
The mean diameter of a coverslip monolayer was 1.05 cm with an average of 1254.5
neutrophils per monolayer. Neutrophils constituted approximately 95% of all cells
remaining on the coverslips, as observed after staining with Giemsa.
6.3.4 Inverted coverslip assays
In all assays washing and counting was done after 30 minutes incubation of
neutrophils with cryptococci. In the absence of NHS, or with heat inactivated
serum, the binding of neutrophils to all isolates was very low (0.5-1%). The effect
of NHS heat inactivation suggests that the opsonins involved in binding are
complement.
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The ten isolates 16B, 17D, 19B, 2IB, 22N/T, 23A, 24B, 28B, 29B and 30A (five
var. gattii and five var. neoformans) showed binding as in the Tables 6.6 and 6.7.
Table 6.6 Mean percentage neutrophil binding (SEM*) of isolates






var. neoformans 66.97 (5.9) 72.5 (5.09) 0.48
var. gattii 73.32 (4.7) 81.5 (2.95) 0.15
p value 0.41 0.14 -
* SEM = standard error of the mean
Although the percentage binding of var. gattii was greater than that of var.
neoformans these differences were not statistically significant. Cryptococci grown
in 5% C02 appeared to have a higher percentage binding, but again this difference
was not statistically significant.







va r.neoformans 1.215(0.05) 1.05 (0.07) 0.07
var. gattii 0.76 (0.05) 0.70 (0.03) 0.29
p value < 0.0001 0.0004 -
* SEM = standard error of the mean
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The difference in binding index between varieties was significant when the varieties
were grown in both air and 5% C02. Addition of C02 to the atmosphere in this way
did cause a reduction in binding index for each variety, but this effect was not
statistically signficant. In effect, although both varieties bound approximately the
same proportion of neutrophils, greater numbers of C. neoformans var. neoformans
than var. gattii cells were associated with neutrophils. Up to five neutrophils could
be seen surrounding a single C. neoformans var. gattii cell, but fewer neutrophils
were associated with each var. neoformans. This implies that after 30 minutes
incubation var. gattii recruits more neutrophils around each cryptococcus than with
var. neoformans.
6.3.5 Experiments using Giemsa staining
Although the inverted coverlip assay seemed reproducible, it necessitated rapid wet
handling of coverslips. It was decided to try an alternative method of staining with
Giemsa. This meant that once the coverslips had been washed following incubation,
they could be dried and then fixed in methanol. Further handling and staining could
be carried out over several days if necessary and so made the timetabling of assays
and counting much easier with larger batches of coverslips. The remainder of the
experiments were therefore carried out using this method of staining. Isolates used
were grown in air. Plate 6.2 illustrates the appearance of Giemsa stained films, with
cryptococci associating with neutrophils.
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Plate 6.2 Giemsa stain of cryptococcal-neutrophil interaction
x ~ 2000 Dark neutrophils associated with lighter
spherical encapsulated cryptococci
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Apart from the strain of C. neoformans used, there were many potential variables
that could influence binding. Having established that the binding assay worked the
conditions were varied to confirm that they were appropriate and optimal. As
described in Section 6.3.6 paired var. gattii/neoformans isolates were used. The
first variable considered was the effect of differing quantities of normal human
serum used.
6.3.5.1 Normal human serum dose response (0-300 pi)
6.3.5.2 At 30 minutes
Two strains: one var. neoformans, serotype A (23A) and one var. gattii, serotype B
(2IB) were studied under the same conditions as previously, except for variation in
the amount of NHS added to the mixture. Volumes of 0, 10, 30, 100 and 300 pi
NHS were used. As shown in Figure 6.1 the percentage binding with no NHS added
was 2% for both strains and percentage binding increased sharply to reach a
maximum (45%, 47%) when 100 pi of opsonin was added. Increasing the quantity
further to 300 pi did not increase the percentage binding of yeasts to neutrophils.
For both strains the binding index was 1 with no opsonin added, and reached a
maximum at 30 pi, with no further increase at 100 pi or 300pl.
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normal human serum pi
Figure 6.1 Binding of isolates 23A (♦) and 21B (■) at varying NHS volumes
after 30 minutes incubation.
Maximal binding (percentage binding and binding index) at 30 minutes incubation
of both varieties occurred at 100 pi. No increase was obtained by using 300 pi of
serum. This suggested that at these concentrations of cryptococci and neutrophils
maximal binding was occurring and that using more than 100 pi in subsequent
assays would not alter binding.
6.3.5.3 At 120 minutes
Strains 14A, 16B, 23A and 29B were studied in 120 minute assays. Volumes of 0,
10,30, 100 and 300 pi NHS were used. The results are illustrated in Figure 6.2. The
percentage neutrophil binding increased to near maximal at 100 pi and approached
the maximum (93-96%) when 300 pi NHS was added to the cryptococcal
suspension. The binding index increased by 50% (i.e. 0.5) when increasing normal
199
human serum volume from 100 pi to 300 pi. Var. gattii appeared to have a lower
binding index than var. neoformans.
These findings suggest that although the number of neutrophils bound rose little
with an increase of NHS from 100 pi to 300 pi, more opsonisation of yeasts may
occur at higher volumes of NHS allowing more cryptococci to bind each neutrophil
in the longer, 120 minute assay.
The maximal binding found at 30 minutes does not seem to reflect maximal possible
binding. This may be because of the time required for chemotactic signals to recruit
further neutrophils to bind cryptococci. It would be anticipated that maximal
cryptococcal-neutrophil binding is sterically limited and that the binding index
would reach a maximal limit if the assay is allowed to continue over time.
As 100 pi NHS had been used in previous experiments and by Richardson et al and
the difference in percentage binding between varieties appeared steady, this volume
was used in subsequent assays (Richardson et al. 1993). In addition using larger
volumes of NHS such as 300 pi would have become practically more difficult as
much greater volumes of normal human serum would be required.
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normal human serum p.1
Figure 6.2 Binding of isolates 14A (♦) 23A (■), 29B(a) and 16B (x) at
varying NHS volumes after 120 minutes incubation.
6.3.5.4 Binding assessed at intervals with constant (100 jjlI) NHS volumes
In order to compare the rate of binding several time course assays were set up,
assessing binding at intervals. An initial study over 90 minutes with two isolates
was followed by further studies over 120 minutes.
6.3.5.5 Time course up to 90 minutes
Strains 23A and 2IB, were studied at 5, 10, 30, 60 and 90 minutes incubation.
Percentage neutrophil binding appeared to reach a maximum at 60 minutes, with a
2.5 - 3% decline at 90 minutes, whereas the binding index appeared to rise rapidly to
2 and plateau between 10 and 60 minutes. It then rose to 2.7 (isolate 21B) and 2.84
(isolate 23A) at 90 minutes, as shown in Figure 6.3.
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time minutes
Figure 6.3 Binding of isolates 23A (♦) and 21B (■) over 90 minutes.
6.3.5.6 Binding of four isolates up to 120 minutes
Further timed assays were carried out with assessment at 0, 15, 30, 60 and 120
minutes using strains 22N/T, 26A, 28B and 3IB, which comprise two var.
neoformans and two var. gattii strains. As demonstrated in Figure 6.4 the
percentage of neutrophils bound by cryptococci increased to a maximum at 60
minutes and this was maintained at the same level at 120 minutes. The var. gattii
strains' maximum binding appeared to be 13% lower than the var. neoformans
strains. This difference was consistent with, and the time to maximal binding (60
minutes) appeared similar, to that shown in the 90 minute assay.
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Figure 6.4 Binding of isolates 22N/T(*), 26A(«), 288(A) and 31B(x) over 120
minutes
The binding indices are also shown in Figure 6.4. In this experiment they increased
slightly to a maximum at 60 minutes that had changed little by 120 minutes.
Although the 90 minute time point was not assessed in the 120 minute assay the
marked rise in BI seen at 90 minutes in Figure 6.3 did not seem to occur by 120
minutes in this experiment. Overall the binding index of the var. gattii strains was
marginally, but not significantly lower than that of the neoformans strains. Over the
first 30 minutes there had been little difference between isolates, so subsequent
assays omitted assessments at these times and instead included assessment at 90
minutes.
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6.3.5.7 Binding of 8 isolates up to 120 minutes using absorbed NHS.
Two further experiments were run for additional isolates only of serotypes A and B,
studying coverslips at 30, 60, 90 and 120 minutes for a further 8 strains, 4 each var.
gattii and var. neoformans. The neutrophil donor in each experiment differed, but
NHS source remained the same. Each experiment was carried out using absorbed
NHS, as other experiments (data not shown) suggested that there are factors
(probably antibody) present in normal human serum that also influence binding. Pre
assay absorption of NHS with cultured cryptococci leaves no anti-cryptococcal
antibody, so the only opsonin remaining is complement. This may account for the
remaining low level binding seen after incubation with heat inactivated serum. The
degree of influence may not affect each variety of neoformans equally.
Results shown are for at least one coverslip at each point. In these assays the
maximum percentage of neutrophils binding yeasts as shown in Figures 6.5 and 6.6
is reached by 90 minutes and for three of four var. neoformans strains, 14A, 18A
and 26A, was then reduced by 120 minutes incubation. The percentage binding of







































Figure 6.6 Binding of isolates 14A (♦), 19B (A), 23A (■) and 29B (x) over
120 minutes
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The binding index, as shown in Figures 6.5 and 6.6, rises with time up to 90 minutes
incubation for all but two strains, 18A and 29B which decrease slightly. Three
strains, 14A, 16B and 26A, then showed a reduction in binding index by 120
minutes incubation. There is considerable variation between strains with no clear
pattern emerging.
There was no correlation between serotype/variety and binding index or percentage
of neutrophils bound in these assays.
The rise in binding index at 90 minutes seen in the intial 90 minute assay, shown in
Figure 6.3 was also found with some strains in these assays, shown in Figures 6.5
and 6.6. Isolate 23A consistently showed this rise in binding index in both the 90
and 120 minute assays.
6.3.5.8 Summary of time course experiments
Flaving found that the percentage binding was maximal at 90 minutes, yet binding
index appeared to be still rising (Figure 6.3), further time course experiments with
100 pi absorbed normal human serum were carried out over 120 minutes,
comparing varietal pairs of strains (Figure 6.4). These showed that the percentage
binding and binding index maximized by 60 minutes and suggested that in these
paired assays percentage binding and binding index of var. gattii was less than that
of var. neoformans. In order to ascertain whether these findings were consistent and
to increase the range of strains tested, similar experiments were set up to compare 4
serotype A and 4 serotype B strains, run in two separate assay runs (Figs. 6.5 and
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6.6). Although these assays showed near maximal or maximal percentage binding




The aim of the human neutrophil-cryptococcal experiments was to compare the
interactions of the two varieties of C. neoformans. For all strains studied the
presence of NHS was necessary for significant levels of binding to occur. If the
NHS was heated to 56°C binding was reduced to low levels, therefore complement
is the main opsonin involved. Presence of opsonising antibody could account for
low level binding. Alternatively the low levels of apparent binding in the absence of
NHS or presence of heat inactivated NHS could be explained if the washing process
was inadequate to dislodge all cryptococci from the coverslip. Such cryptococci
would then be included in counts of associated yeasts if apparently touching
neutrophils. In practice all yeasts appeared to be associated with neutrophils, none
appeared to be isolated on their own, as would be expected to occur if washing was
inadequate. Therefore it seems most likely that all cryptococci were genuinely
'associated' with neutrophils. In assays with no added NHS low level association
was observed. This could occur if some other ligand other than complement or
antibody sufficed for binding or neutrophils were able to generate low levels of
complement.
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In the 30 minutes assay the percentage binding and binding index were maximal
with 100 pi NHS (Figure 6.1), however in the 120 minutes incubation maximal
binding was not achieved with any volume of NHS up to 300 pi (Figure 6.2). The
percentage binding was maximal by 60-90 minutes of incubation in the timed
Giemsa stained assays (Figures 6.3-6.6). In all assays where the binding index was
measured over varying times it tended to increase over time (Figures 6.2-6.6).
Overall the results suggest that there may be significant differences between the
varieties of C. neoformans in their cryptococcal-human neutrophil interactions, but
further experiments would be required to prove this as the data is not entirely
consistent as it stands.
6.4.2 Colonial appearance and capsule size
The degree of colonial mucoid appearance was generally linked to the capsule size
of the isolate. Var. gattii appeared more mucoid than var. neoformans isolates, in
keeping with their larger capsule sizes (Table 6.3). Isolates grown at 37°C had
smaller capsules than at 30°C (Table 6.4).
Within varieties, it is known that capsular sizes vary considerably, demonstrating
considerable phenotypic variation. Few direct comparisons have been made of C.
neoformans var. gattii with var. neoformans isolates grown under the same
conditions, but the greater capsule sizes of C. neoformans var. gattii has been
previously noted (Young and Kozel, 1993). In that study, these differences were not
highlighted, although in 15 encapsulated strains examined (3 of serotype D and 4
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each of serotypes A,B and C), ranking of capsule sizes showed that var. gattii
isolates were usually bigger than var. neoformans. In the current studies a similar
and statistically significant difference in mean capsular size was found. Such a
difference may play a role in the differing pathogensis of the two varieties.
However, despite the fact that human cases of cryptococcosis due to minimally
encapsulated var. neoformans isolates have a stronger host response, greater
inflammation and less severe disease (Farmer and Komorowski, 1973; Levinson et
al. 1974; Milchgrub et al. 1990), cryptococcal virulence has not always been
correlated with capsule size (Dykstra et al. 1977).
Kozel et al have recently illustrated the importance of opsonization conditions on
C3 deposition and phagocyte binding of large and small-capsule Cryptococcus
neoformans serotype A cells (Kozel et al. 1996). They noted that previous studies
demonstrated that following opsonization with NHS, phagocytes bind greater
numbers of small-capsule than large-capsule C. neoformans cells. A single strain of
C. neoformans was grown under conditions to produce large or small capsules and
incubated for 30 minutes at various concentration in NHS. At low concentrations of
yeast cells (125 per pi of NHS), the deposition of C3 fragments per unit of capsule
volume and the binding of yeast cells to human monocytes was similar for yeast
cells with large and small capsules. At higher cell concentrations, large-capsule
cells exhibited suboptimal coating with C3 fragments and markedly diminished
monocyte binding compared with small-capsule cells. Therefore they suggest that
the inverse correlation between capsule size and phagocyte binding can be
overcome by conditions promoting optimal C3 deposition.
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Another way of stimulating phagocytosis of encapsulated cryptococci is by using
cytokines (Collins and Bancroft, 1992). These scientists found that stimulation of
murine peritoneal macrophages with tumour necrosis factor alpha and granulocyte-
macophage colony-stimulating factor promoted complement-dependent ingestion of
encapsulated cryptococci. These cytokines act on the phagocytes to reduce the
amount of serum required for effective opsonisation of encapsulated cryptococci.
With limited numbers of cryptococci and sufficient production of cytokines
opsonisation of encapsulated cryptococci and binding to phagocytes is effective, but
the balance is easily disrupted by an excess of yeast cells. Serum complement
depletion occurs in vivo (Macher et al. 1978), which may be an important factor
potentiating cryptococcosis in patients with widely disseminated disease, such as
patients with AIDS (Chuck and Sande, 1989).
6.4.3 Quantities of yeast cells and NHS
In the current studies the number of yeast cells/pl NHS varied from infinity when no
NHS was added, to 333 yeast cells/pl when 300 pi NHS was used. The most
frequently used ratio was 1000 yeast cells/pl as used by Richardson et al
(Richardson et al. 1993). In the current studies mean capsular volumes ranged from
132-1268 pm3. These volumes are comparable to the small volume capsules of
Kozel et al's study (Kozel et al. 1996). Their data with a single C. neoformans
strain suggests that on large volume capsules (3,400 +_ 1300 pm ) C3 binding may
be suboptimal, as compared with small volume capsules (1,200 +- 790 pm3) when
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more than 250 yeast cells/pl NHS are used (Kozel et al. 1996). At such low capsular
volumes in the presence of 1000 yeast cells/ pi NHS binding of C3 fragments is not
suboptimal at 30 minutes incubation. Therefore binding of neutrophils in the
current studies at this time is unlikely to have been limited by the amount of NHS
present. This is demonstrated in the 30 minute assays in this study.
6.4.4 Inverted coverslip assays
Initial 30 minute binding assays, counted by inverted coverslip, were carried out on
isolates grown in air and with 5% C02 supplementation. The latter conditions
mimic more closely the conditions in the lung and tissues. With heat inactivated
NHS or no NHS, binding was undetectable. Therefore in this assay complement
was required for binding to take place.
Slight, but not significant increases in binding index and percentage binding were
noted with the increase in C02 When grown under either set of atmospheric
conditions and counted using the inverted coverslip method there was a non
significant difference in percentage binding (var. gattii was greater), and significant
difference in binding index (var. neoformans being greater). Fewer neutrophils were
associated with each var. gattii cell than with each var. neoformans. In these assays
the cryptococcus:neutrophil ratio was 100:1, so the number of yeast cells should not
limit their binding to neutrophils. In this assay opsonisation with normal human
serum is not limiting either, so binding differences could reflect either limiting steric
binding, differences in complement binding or recruitment of neutrophils. These
three possibilities are considered below.
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Richardson et al found that unlike acapsulate cryptococci, opsonised encapsulated
serotype A cryptococci compete for binding to neutrophils. This requires actin,
involves neutrophil membrane ruffling and does not appear to lead to phagocytosis
of the yeast (Richardson et al. 1993). It was proposed that cryptococcal
competition, probably involving complement receptors, may limit binding, rather
than steric factors.
Young and Kozel have shown that the variations in capsular structure that
characterise each serotype have no significant influence on the maximum amount of
C3 that can bind by 80 minutes (C3max), but that the rate of C3 deposition depends
significantly on the serotype (Young and Kozel, 1993). C3 accumulates faster on
cells of serotypes A and D than on cells of serotypes B and C. They found a
significant but not linear correlation between capsular volume and C3max. It could
be that slower C3 binding on var. gattii serotypes in the 30 minute assay in this
study lead to the cryptococcal-neutrophil binding index being lower. Laxalt and
Kozel reported that incubation of encapsulated cryptococci in normal human serum
lead to release of soluble cleavage fragments that are chemotactic for neutrophils
(Laxalt and Kozel, 1979). This chemotactic factor was then shown to be blocked in
C. neoformans -activated serum by treatment with antibodies specific for C5, but not
by antibodies specific for C3 (Diamond and Erickson, 1982). This identified C5 as
the essential chemotactic factor.
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6.4.5 Giemsa assays
In the subsequent Giemsa studies, variable differences in binding between the two
varieties were found. There are several possible explanations. It may be that early
experiments showed significant differences in percentage binding and binding index
between varieties by chance. By selecting a p value of <0.05 to denote significance
will allow 1 in 20 similar comparisons to give a 'significantly different' result. A
significant difference could by chance be obscured, or the isolates used in
expriments may not be representative of the variety in general. It may be that as
experiments were carried out over a considerable period, inter and intra person
neutrophil variability lead to some of the variation between experiments, though this
should not be the cause of any differences within one assay. This could explain the
differences in binding index and percentage binding between experiments, but not
inter varietal differences within experiments, as var. gattii and var. neoformcins were
always run in parallel in each assay.
Sahu et al in a study of binding efficiency of metastable C3b to encapsulated
cryptococci of all four serotypes showed a stepwise decrease in binding efficiency
that parallels the serotype-dependent decrease in density of xylopyranosyl residues
eg., C>B>A>D (Sahu et al. 1994). This is contrasted by evaluations of C3
accumulation on encapsulated cryptococci after incubation in normal human serum
showing a greater rate of accumulation on cells of serotypes A and D than serotypes
B and C (Washburn et al. 1991; Young and Kozel, 1993) These apparently
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conflicting results illustrate the multifactorial nature of alternative pathway
activation by the cryptococcal capsule. The study by Sahu et al considered a single
component of the processs, but rate amplification is the end result of several steps of
alternative pathway activation. It is therefore suggested that serotype-dependant
variations in capsular structure may have multiple and independent effects on
initiation, amplification and regulation of the alternative pathway (Kozel, 1996).
Neutrophil-cryptococcal interactions are likely to be complex and serotype-
dependant variations difficult to interpret clearly.
The assays comparing varying amounts of NHS at 30 and 120 minutes incubation
showed that in the 30 minute assay binding was maximal when 100 pi NHS was
used. At 120 minutes, although the percentage was near maximal when 100 pi NHS
was used, the binding index rose considerably in all isolates and would appear not to
have reached a maximum by 120 minutes. This could be because cryptococcal
opsonisation was limited by the volume of available NHS, or despite optimal
opsonisation, it may take many hours to allow full cryptococcal-neutrophil
interaction to occur under the influence of secreted cytokines and altering
configurations of complement receptors.
Young and Kozel showed that maximal binding of C3 fragments to all cryptococcal
serotypes had occurred for some strains by 20 minutes and almost always by 40
minutes (Young and Kozel, 1993). Therefore the increase in percentage binding and
214
binding index with time may reflect simply a longer period following C3 binding to
allow cryptococcal attachment to occur, but may also reflect neutrophil cell surface
receptor activation and clustering, allowing more neutrophil-cryptococcal
attachment. To investigate this further assays with greater quantities of NHS over
longer neutrophil cryptococcal incubation periods could be done.
All the timed assays over 90-120 minutes showed that the percentage binding
appeared to maximise by 60-90 minutes incubation. In most assays the binding
index however had not plateaued by 120 minutes, which could reflect the ongoing
interactions and changes at the neutrophil and cryptococcal surfaces. All
neutrophils that could bind had done so by 90 minutes, but further binding with
more yeasts continued to take place up to 120 minutes. In order to find the upper
limit of the binding index longer incubation periods could be studied. The binding
index curves do not appear to be beginning to plateau, so it is not possible to
calculate from Michaelis-Menten kinetics the maximal binding, which must be
limited by physical spacial factors if not by biological factors.
Altering the method of counting/staining from inverted covers!ip to Giemsa staining
may have lead to differences between experiments. It was assumed that although
there may be a consistent difference between the two methods, this would not affect
differences between isolates within the same experiment. For each set of
experiments the same source of NHS was used, so this in itself should not lead to
variation.
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In view of earlier apparently consistent differences between the few isolates of the
two varieties when studied with the coverslip method this was surprising. In the
later Giemsa assays using a total of 4 strains at a time, handling of coverslips did
become more awkward and may have contributed to variable results.
There is considerable variation in percentage binding and binding index between the
different assays. This may be due to variations between and within the neutrophil
donors used and even variable degrees of stain uptake leading to differences in the
number of cryptococci counted as associated with each neutrophil.
In order to overcome these difficulties one could run direct comparisons of the two
counting methodologies, or run more assays over a single condensed research period
with the same neutrophil and normal human serum donors.
To differentiate better between external and internal yeasts more sophisticated
labelling using rabbit anti-C neoformans capsule antibody and goat anti-rabbit Ig-
TRITC with visualisation by fluorescence could be used (Collins and Bancroft,
1992).
Using several isolates of each variety helps to clarify whether the behaviour of
isolates of each variety is consistent, but to be able to make more valid comparisons
between different assay conditions one would need to use similar isolates
throughout.
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Studies comparing different isolates of varying capsular size may not always be
measuring the effect of capsular size. Other virulence factors such as melanin and
mannitol production may also vary between such isolates. To confirm that any
observed difference in virulence is due to capsular size differences for example, the
differing effects should be shown to related to capsular polysaccharide alone.
Another way to approach this is to measure alternative virulence factors
simultaneously and demonstrate that they do not vary, or even better have strains in
which only the gene controlling the virulence factor in question is absent and
subsequent effects correlated with virulence (Kwon-Chung and Rhodes, 1986; Salas
et al. 1996; Chang et al. 1996).
In conclusion, consistent differences in neutrophil binding to the two varieties of C.
neoformans were not demonstrated. This may be because in the conditions used
there are no differences between isolates, or perhaps because of methodological
factors. Comparisons of binding results using both methods of counting staining
would help to clarify this. It would also be of interest to look at binding at greater
volumes of NHS to see if the binding index continues to rise to a maximum amount
by 120 minutes incubation. Measurement of cytokine production in response to
varying concentrations of cryptococci and even capsular polysaccharide and their
effects on leucocyte chemotaxis, adherence and phagocytosis could also be
investigated.
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Ultimately, the definition of the gene(s) responsibe for serotype and varietal
differences and the effect of adding and deleting these in vitro and in vivo outcomes
would help elucidate the apparent differences in pathogenicity of the two varieties.
218
Chapter 7




In the UK cryptococcal meningitis caused by Cryptococcus neoformans occurs in at
least 4% of patients with AIDS, while in the USA 6-10% of cases are affected
(Dismukes, 1988; Knight et al. 1993). In Edinburgh in 1995 there were 4
immunocompromised patients diagnosed with cryptococcosis of whom 3 were
infected with HIV. In 1996 there were no new cases diagnosed, but one further HIV
infected case was diagnosed in 1997. Headache is a common presenting symptom,
but there are often no focal findings. The initial CSF findings may be virtually
normal. A patient is reported in whom the initial diagnsosis of cryptococcal
meningitis was only made after culture of CSF deposit. This highlights the
importance of appropriate culture even where CSF findings are negative.
7.2 Case report
A 17 year old Caucasian male was diagnosed as HIV positive following routine
screening during blood donation. He had previously been in a heterosexual
relationship, but denied any other risk factors. On questioning at initial presentation
he gave a 4 month history of mild intermittent headache associated with fever and
night sweats. There was no history of travel, pigeon or antifungal exposure.
Examination found him alert and orientated. His temperature was 39.8°C, he had
oral thrush and axillary lymphadenopathy without clinical hepatosplenomegaly.
There were no signs of meningitis. Negative tests included: biochemistry and
haematology profiles, repeated blood cultures, chest x-ray, induced sputum for
Pneumocystis carinii, urinary bacterial culture and computerised tomography of the
head. At presentation the CD4 lymphocyte count was 125/mm3, being 6% of the
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total peripheral white blood cell count. At lumbar puncture the cerebrospinal fluid
(CSF) protein was 474 mg/L (reference range 100 - 400 mg/L), glucose 2.8 mmol/L
with no cells or organisms present, the pressure was not recorded. The concurrent
serum glucose was 5.8 mmol/L. Gram staining of the CSF and cryptococcal antigen
testing (IMMY -Immuno-mycologics, Norman, Okla) of CSF and blood were
negative as was examination for other pathogens. After three days culture of the
spun CSF deposit on 4% malt extract agar in air at 30°C, four colonies of an
apparently non-capsulated, relatively fluconazole resistant isolate (MIC 16|ug/ml,
confirmed at the PHLS Mycology Laboratory, Bristol) of Cryptococcus neoformans
was cultured. A similar isolate was subsequently cultured from urine which then
gave a positive antigen test at a 1:4 titre. Serotyping at the PHLS Reference
Mycology Laboratory, Leeds showed the CSF isolate to be serotype A. The patient
responded rapidly to amphotericin B preparations given for 3 weeks followed by
oral itraconazole to which the isolate was sensitive in vitro. The latter was poorly
tolerated and the patient continued on fluconazole 200 mg/d. He remained well
while being prescribed fluconazole, antiretroviral therapy and pentamidine
nebulisers until 19 months later. He then relapsed complaining of headache,
vomiting and photophobia. At this stage he admitted that he had not been taking his
fluconazole for the past 2-3 weeks. On this occasion CSF examination showed
capsular cryptococci on India ink staining but was again otherwise acellular. The
CSF glucose was 2.4 mmol/L, protein 1144 mg/L and serum glucose 7.9 mmol/L.
Culture and latex antigen testing of CSF and peripheral blood were positive (antigen
CSF titre 1:512) while the CD4 count was 0/mm3. On this admission a CSF opening
pressure of 38 cm was recorded. 'Abelcet' (liposomal amphotericin) was
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commenced and he was discharged after 3 weeks improving on oral itraconazole
suspension. The isolate was reported to be more resistant to fluconazole on disc
testing than the original isolate.
The original CSF isolate was grown in air at 37°C and a neutrophil attachment assay
carried out as described in Chapter 6. This showed that normal non heat inactivated
human serum was necessary for attachment to occur. This implies that opsonisation
by complement is required for attachment and therefore that some capsule is
present. Further study of all isolates in the Regional Mycology Laboratory, Western
General Hospital, Edinburgh from this patient grown at 37°C in CSF showed
significant capsules on India ink examination.
7.3 Discussion
The capsule of the yeast like fungus Cryptococcus neoformans varies in size
depending on growth conditions (Vartivarian et al. 1993). In experimental mice the
capsule size does not seem to affect virulence (Dykstra et al. 1977), although
acapsular mutants are less virulent (Kwon-Chung and Rhodes, 1986). The capsule
inhibits phagocytosis and may impair leukocyte migration (Kozel and Hermerath,
1984; Drouhet and Segretain, 1951), as well as being immunosuppressive
(Khakpour and Murphy, 1987). Recent work suggests that capsular
glucoronoxylomannan (GXM) induces interleukin-10 (a potent down regulator of
proinflammatory cytokines) secretion by human monocytes (Vecchiarelli et al.
1996). Release of tumor necrosis factor a, interleukin-l(3 and interleukin-8,
proinflammatory cytokines, by human neutrophils has also been correlated to
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capsule size and quantity of GXM present by the same group of workers (Retini et
al. 1996). There is a report that it may enhance HIV replication (Pettoello-
Mantovani et al. 1992). Acapsular strains activate both classical and alternative
complement pathways (Kozel et al. 1992), while capsular strains only activate the
latter.
In one study 9% of AIDS patients had culture positive cryptococcal meningitis but
negative CSF antigen detection tests although serum was negative in only 1% of
patients (Chuck and Sande, 1989). Low levels of antigen, presence of immune-
complexes (in non-protease treated serum samples), high titres (prozone effect) or
poorly/non-encapsulated strains may contribute to such negative antigen tests
(Currie et al. 1993; Sadamoto et al. 1993). In cases with extraneural cryptococcosis
a much lower percentage of samples are positive. These factors and the possibility
of a false-negative antigen test may not be commonly appreciated. Urinary
screening is not always routinely carried out and urinary antigen testing not
standardised although the prostate in particular may act as a reservoir.
Commercial kits to detect cryptococcal capsular antigen by latex agglutination and
enzyme immunoassay are widely used, although there is some variation in
performance (Tanner et al. 1994). The Immy kit used here has a sensitivity and
specificity in serum of 97% and 93%, and in CSF of 93% and 93% respectively.
This can be further improved without loss of sensitivity by raising the threshold for a
positive result to 1:2 from the 1:1 indicated in the manufacturer's instructions.
Pronase treatment of serum and CSF is used with this kit to limit non-specific
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interference. All four test kits in this study were compared with culture of CSF
(Tanner et al. 1994). The sensitivity of antigen detection in the CSF was 93-100%
and specificity ranged from 93-98% while in serum sensitivity ranges were 83-97%
and specificity ranges 95-100%. It must therefore be emphasised to clinicians and
microbiologists that cryptococcal meningitis cannot be excluded simply on the basis
of negative (even repeatedly so) CSF and serum antigen tests or microscopy. In this
case the isolate was apparently acapsular on culture. It seems that this isolate could
produce capsular material as shown by its serotyping result, behaviour in the
neutrophil assay and subsequent in vitro culture in CSF. It may be that capsule
formation was stimulated by the host and that initial antigen tests were negative due
to low numbers of cryptococci present.
It is interesting to note that this patient was relatively well until 19 months after
presentation and responded to further treatment. This is considerably longer than
the median survival of 152 days in culture positive cases in the study reported by
Chuck and Sande (Chuck and Sande, 1989). Improvement in antiretroviral therapy
since that study was carried out may lead to a slower decline in immunity. Collins
and Bancroft have shown that encapsulation of C. neoformans impaires antigen-
specific T-cell responses, when compared with an acapsular mutant. (Collins and
Bancroft, 1991). Therefore it may be that the lack of apparent capsule in this case
also contributed to the longer time until relapse. Fluconazole resistance, though
rarely documented in C. neoformans, may not correlate with clinical outcome. In
this patient treatment was successful until compliance became a problem, although
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the new isolate is capsular and more resistant than the original and the CD 4 count
was 0/mm3 at relapse. Reinfection with a different strain cannot be ruled out.
This case illustrates the importance of culture at 25-30 °C on an appropriate medium
such as 4% malt extract agar in making the diagnosis of cryptococcosis. Standard
48 hour incubation as commonly carried out for more common bacterial pathogens
is insufficient. Culture may be positive even where other parameters such as CSF
cell count are normal. If the diagnosis is still elusive, repeated CSF examination
should be considered. Such procedures should be carried out, particularly in
immunosuppressed patients, even when antigen tests are negative.
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Chapter 8
Conclusions and Further Work
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8.1 Conclusions
These studies confirm that Cryptococcus neoformans is a significant pathogen in
PNG. C. neoformans var. gattii causes disease frequently amongst apparently
immunocompetent individuals. The increase in reported cases over the past two
decades probably reflects increased clinical awareness and improved detection by
latex antigen testing for cryptococcal capsular polysaccharide. The first cases of
cryptococcal meningitis in HIV positive patients in PNG are reported - HIV will
lead to a rise in cryptococcal meningitis in immunocompromised individuals. In
PNG and elsewhere in the tropics cryptococcal meningitis is accompanied by
significant morbidity and mortality. Frequent sequlae include blindness, deafness,
cranial nerve palsies and death. This is perhaps due to late presentation as well as
the effects of raised intracranial pressure.
The environmental source of Cryptococcus neoformans var. gattii has until recently
been unclear. The finding of an association outwith PNG with Eucalyptus
camaldulensis, lead to an investigation as to the likely source(s) of C. neoformans in
PNG. It was found that of the species associated with C. neoformans var. gattii so
far (E. camaldulensis, E. tereticornis, E. grandis, E. rudis and E. b/akelyi), only E.
tereticornis is endemic to PNG and few E. camaldulensis survive plantation trials.
E. camaldulensis cannot be the main source of C. neoformans var. gattii in PNG.
The known association of C. neoformans var. gattii with koalas and C. neoformans
var. neoformans with avian guano lead to a search for possible mammalian and
avian sources. Potential eucalypt, mammalian (particularly marsupial) and avian
sources of C. neoformans were identified.
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Many of these were sampled using similar methodology to that used by Ellis and
Pfeiffer in their Australian eucalypt studies. Despite examination of 1100 samples,
no source of C. neoformans was identified, suggesting that release is of very short
duration, possibly from other as yet unexamined niches, as has been suggested in
studies elsewhere in the tropics. More sensitive methods may be required to detect
C. neoformans in this enivronment.
The epidemiology of cryptococcal meningitis in PNG was studied and a relatively
high incidence of 33 cases /million population in Central Province and the National
Capital District confirmed. Cases did occur amongst children, but the most frequent
incidence was amongst immunocompetent males in their third decade of life.
Clustering of cases appeared in the Rigo subprovince of Central Province. This
suggests the focus for probable source or predisposition in this area. No seasonal
correlation with rainfall could be identified.
Whether var. gatHi meningitis in immunocompetent individuals is due to exposure
to large amounts of var. gattii, virulence of var. gattii or occult immunodeficiency is
unclear. No evidence in support of the latter hypothesis was found, and there is
conflicting evidence for a difference in virulence between the two varieties. It is
most likely that individuals are exposed to var. gattii, sometimes in large quantities,
resulting in clinical disease.
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Laboratory studies confirmed increased mucosity and capsule sizes of C.
neoformans var. gattii as compared with var. neoformans on subculture.
Investigation of human neutrophil-cryptococcal interactions did not demonstrate
consistent differences between the two varieties.
A case of cryptococcal meningitis in Edinburgh illustrated the importance of
extended culture in diagnosing cryptococcal meningitis where microscopy,
including India ink staining, and antigen testing were negative. In PNG, where
outwith Port Moresby not all CSF samples are cultured, undoubtedly cases may be
missed. Initially it was thought that the isolate from this case was acapsulate, but
neutrophil-cryptococcal studies in conjunction with serotyping and culture in CSF
demonstrated the presence of capsule in all isolates from this patient. The
availability of diagnostic and therapeutic options in Edinburgh may be contrasted
with those in the Papua New Guinean setting.
8.2 Further research
Further study of cryptococcosis in PNG is possible. This includes typing of CSF
isolates, full clinical and epidemiological documentation on prospectively studied
patients. This information can be combined with well documented recent cases to
highlight particular features of var. gattii meningitis such as prognostic indicators,
visual loss and the effects of interventions such as corticosteroid use. Studies of cell
mediated immunity, sero-epidemiology and HLA types are all feasible. Following
extensive discussions some of these have been subsequently carried out by Dr
Andrew Seaton, as alluded to in earlier chapters.
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Environmental sampling could be extended to other potential sources and sampling
intensified. More sensitive molecular techniques might be developed to detect C.
neoformans in the environment. Typing of clinical isolates using established
molecular techniques could be carried out to see whether clustering of cases is
correlated with similar var. gattii isolates. These could also be compared with
clinical and environmental isolates from elsewhere, particularly nearby Australia.
Laboratory studies comparing sensitivities of var. gattii and var. neoformans and
their susceptibility to garlic may reveal therapeutically useful adjuncts to current
treatment.
Further studies of C. neoformans var. neoformans and cellular deficiencies in
particular are being carried out in laboratories worldwide, especially in North
America and Australia. Fewer studies to date have attempted to compare and
explain the apparent differences in host predispostition between var. gattii and var.
neoformans.
In PNG currency fluctuations and cash shortages conspire with logistical and
administrative difficulties to obstruct the supply of many basic drugs. In Africa HIV
infection and AIDS have escalated rapidly; this pattern is likely to follow in PNG.
The supply of cryptococcal latex antigen kits, amphotericin B and flucytosine is
becoming increasingly irregular. Liposomal preparations, triazoles and
antiretroviral drugs are not even generally available. Treatment of cryptococcal
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meningitis is therefore becoming more difficult, despite improvements in therapy
elsewhere.
Priority locally should be given to locate the environmental source(s) of C.
neoformans, with the aim of reducing exposure and reducing the incidence of
infection. There is substantial evidence that garlic may be of benefit as an adjunct
in the treatment of cryptococcal meningitis. Garlic is widely available and cheap in
the tropics and should be investigated clinically in this setting. For those who are
infected, there is evidence that corticosteroid therapy reduces visual morbidity. It's
use too should now be investigated to define the optimal dose.
Even these projects may well need some external support if they are to be carried
out. Tuberculosis, malaria, HIV and childhood diseases such as diarrhoea,
meningitis and respiratory tract infections are all high priorities. Among the adult
population cardiovascular disease, diabetes mellitus and chronic obstructive
pulmonary disease are emerging as significant problems. The overall burden of
cryptococcal meningitis against this background is relatively low.
Answers to the issues raised here could result in effective low cost interventions to
deal with cryptococcosis in PNG. C. neoformans var. galtii infection in
immunocompetent individuals is of low priority outwith the tropics in the developed
world (with the possible exception of Australia), yet cure of such patients is still a
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